




I

PATIENT
SURVIVAL





I.1 . 290
Incident patient counts: ESRD patients
by age, gender, race, ethnicity, & primary diagnosis

I.2 . 294
90-day survival probabilities: incident ESRD patients
by age, gender, race, ethnicity, & primary diagnosis

I.3 . 296
One-year survival probabilities: incident ESRD patients
*from day 91 to one year + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.4 . 298
Two-year survival probabilities: incident ESRD patients
*from day 91 to two years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.5 . 299
Three-year survival probabilities: incident ESRD patients
*from day 91 to three years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.6 . 300
Five-year survival probabilities: incident ESRD patients
*from day 91 to five years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.7 . 301
Ten-year survival probabilities: incident ESRD patients
*from day 91 to ten years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.8 . 302
Incident patient counts: dialysis patients, unknowns dropped
*patients alive on day 91,
by age, gender, race, ethnicity, & primary diagnosis*

I.9 . 303
90-day survival probabilities: incident dialysis patients
*censored at transplant,
by age, gender, race, ethnicity, & primary diagnosis*

I.10 . 306
One-year survival probabilities: incident dialysis patients
*censored at transplant, from day 91 to one year + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.11 . 308
Two-year survival probabilities: incident dialysis patients
*censored at transplant, from day 91 to two years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.12 . 310
Three-year survival probabilities: incident dialysis patients
*censored at transplant, from day 91 to three years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.13 . 312
Five-year survival probabilities: incident dialysis patients
*censored at transplant, from day 91 to five years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.14 . 313
Ten-year survival probabilities: incident dialysis patients
*censored at transplant, from day 91 to ten years + 90 days,
by age, gender, race, & primary diagnosis*

I.15 . 314
Incident patient counts: hemodialysis patients, unknowns dropped
*patients alive on day 91,
by age, gender, race, ethnicity, & primary diagnosis*

I.16 . 316
90-day survival probabilities: incident hemodialysis patients
censored at transplant, by age, gender, race, ethnicity, & primary diagnosis

I.17 . 318
One-year survival probabilities: incident hemodialysis patients
*censored at transplant, from day 91 to one year + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.18 . 320
Two-year survival probabilities: incident hemodialysis patients
*censored at transplant, from day 91 to two years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.19 . 322
Three-year survival probabilities: incident hemodialysis patients
*censored at transplant, from day 91 to three years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.20 . 324
Five-year survival probabilities: incident hemodialysis patients
*censored at transplant, from day 91 to five years + 90 days,
by age, gender, race, ethnicity, & primary diagnosis*

I.21 . 325
Ten-year survival probabilities: incident hemodialysis patients
*censored at transplant, from day 91 to ten years + 90 days,
by age, gender, race, & primary diagnosis*

I.22 . 326
 Incident patient counts: CAPD/CCPD patients, unknowns dropped
*patients alive on day 91,
 by age, gender, race, ethnicity, & primary diagnosis*

I.23 . 328
 90-day survival probabilities: incident CAPD/CCPD patients
censored at transplant, by age, gender, race, ethnicity, & primary diagnosis

I.24 . 330
 One-year survival probabilities: incident CAPD/CCPD patients
*censored at transplant, from day 91 to one year + 90 days,
 by age, gender, race, ethnicity, & primary diagnosis*

I.25 . 332
 Two-year survival probabilities: incident CAPD/CCPD patients
*censored at transplant, from day 91 to two years + 90 days,
 by age, gender, race, ethnicity, & primary diagnosis*

I.26 . 334
 Three-year survival probabilities: incident CAPD/CCPD patients
*censored at transplant, from day 91 to three years + 90 days,
 by age, gender, race, ethnicity, & primary diagnosis*

I.27 . 336
 Five-year survival probabilities: incident CAPD/CCPD patients
*censored at transplant, from day 91 to five years + 90 days,
 by age, gender, race, ethnicity, & primary diagnosis*

I.28 . 337
 Ten-year survival probabilities: incident CAPD/CCPD patients
*censored at transplant, from day 91 to ten years + 90 days,
 by age, gender, race, & primary diagnosis*

I.29 . 338
 90-day patient survival probabilities: first transplants, deceased donors
by age, gender, race, ethnicity, & primary diagnosis

I.30 . 340
 One-year patient survival probabilities: first transplants, deceased donors
by age, gender, race, ethnicity, & primary diagnosis

I.31 . 342
 Two-year patient survival probabilities: first transplants, deceased donors
by age, gender, race, ethnicity, & primary diagnosis

I.32 . 344
 Three-year patient survival probabilities: first transplants, deceased donors
by age, gender, race, ethnicity, & primary diagnosis

I.33 . 346
 Five-year patient survival probabilities: first transplants, deceased donors
by age, gender, race, ethnicity, & primary diagnosis

I.34 . 347
 Ten-year patient survival probabilities: first transplants, deceased donors
by age, gender, race, ethnicity, & primary diagnosis

I.35 . 348
 90-day patient survival probabilities: first transplants, living donors
by age, gender, race, ethnicity, & primary diagnosis

I.36 . 350
 One-year patient survival probabilities: first transplants, living donors
by age, gender, race, ethnicity, & primary diagnosis

I.37 . 352
 Two-year patient survival probabilities: first transplants, living donors
by age, gender, race, ethnicity, & primary diagnosis

I.38 . 354
 Three-year patient survival probabilities: first transplants, living donors
by age, gender, race, ethnicity, & primary diagnosis

I.39 . 356
 Five-year patient survival probabilities: first transplants, living donors
by age, gender, race, ethnicity, & primary diagnosis

I.40 . 357
 Ten-year patient survival probabilities: first transplants, living donors
by age, gender, race, ethnicity, & primary diagnosis

Table I.1

Incident patient counts: ESRD patients

by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	46	66	98	105	107	134	131	135	134	144	126
5-9	93	94	105	88	108	101	121	112	99	121	136
10-14	178	186	222	211	221	212	204	217	222	197	220
15-19	425	468	455	437	424	433	454	467	497	514	491
20-29	1,506	1,664	1,870	1,808	1,963	2,052	2,114	2,131	2,329	2,505	2,562
30-39	2,172	2,431	2,702	2,793	3,001	3,225	3,573	3,720	4,157	4,507	4,700
40-49	2,387	2,670	2,812	3,143	3,302	3,597	3,884	4,374	4,868	5,514	6,032
50-59	3,623	4,230	4,515	4,651	4,943	5,266	5,575	6,036	6,893	7,416	7,984
60-64	2,012	2,318	2,625	3,031	3,349	3,705	3,866	4,381	4,764	5,207	5,739
65-69	1,970	2,064	2,338	3,044	3,153	3,539	4,076	4,653	5,219	6,005	6,666
70-79	2,192	2,424	2,974	4,142	4,320	5,046	5,797	6,645	7,325	8,665	9,665
80+	365	410	548	844	916	1,142	1,406	1,622	1,961	2,433	2,813
Unknown	*	*	*	*	*	14	*	*	*	*	*
Male	9,445	10,501	11,675	13,304	14,239	15,409	16,990	18,622	20,574	23,243	25,237
Female	7,524	8,526	9,593	10,998	11,575	13,057	14,219	15,876	17,896	19,992	21,900
Unknown	*	*	*	*	*	*	*	*	*	*	*
White	11,806	13,186	14,705	16,379	17,450	19,193	21,124	23,074	25,338	28,380	31,036
Black	4,680	5,295	5,984	7,203	7,555	8,343	8,986	10,176	11,624	13,324	14,232
Other race	422	486	560	700	785	907	1,050	1,218	1,458	1,493	1,816
Unknown	61	60	19	21	25	23	49	30	50	38	53
†Hispanic											
†Non-Hispanic											
Diabetes	2,589	3,857	5,024	5,859	7,106	8,203	9,516	10,844	12,349	14,875	17,047
Hypertension	3,016	4,297	5,460	5,946	6,673	7,627	8,293	9,566	11,082	12,840	14,035
Glomerulonephritis	2,743	3,562	4,160	4,372	4,665	4,925	5,146	5,616	6,029	6,321	6,724
Cystic kidney	764	932	1,068	1,089	1,125	1,206	1,294	1,349	1,370	1,403	1,546
Other urologic	454	655	813	920	932	1,104	1,139	1,244	1,272	1,299	1,211
Other cause	1,739	2,093	2,630	2,872	3,047	3,286	3,397	3,416	3,693	4,281	4,395
Missing cause	4,158	2,081	828	1,942	929	732	771	649	828	551	439
Unknown cause	1,506	1,550	1,285	1,303	1,338	1,383	1,653	1,814	1,847	1,665	1,740
All	16,969	19,027	21,268	24,303	25,815	28,466	31,209	34,498	38,470	43,235	47,137

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.1 (continued)

Incident patient counts: ESRD patients*by age, gender, race, ethnicity, & primary diagnosis*

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	171	146	177	138	162	177	170	166	167	191	197	176	188
5-9	120	125	131	158	144	140	130	134	152	153	149	177	144
10-14	240	245	240	251	273	269	279	270	298	307	307	340	328
15-19	479	526	523	518	565	576	527	537	598	571	571	576	599
20-29	2,579	2,717	2,768	2,741	2,627	2,658	2,602	2,698	2,611	2,643	2,672	2,550	2,491
30-39	5,001	5,345	5,420	5,709	5,642	5,700	5,653	5,684	5,829	5,667	5,621	5,682	5,598
40-49	6,791	7,319	7,759	8,178	8,731	9,385	9,381	10,183	10,376	10,645	10,662	10,973	11,237
50-59	8,650	9,613	10,117	11,316	11,551	12,203	13,282	14,413	15,513	16,070	16,856	17,504	18,200
60-64	6,296	6,616	6,960	7,322	7,612	7,996	8,413	8,879	9,125	9,413	9,732	10,004	10,601
65-69	7,376	7,982	8,331	8,902	8,915	9,696	10,001	10,282	10,402	10,504	10,771	11,040	11,343
70-79	11,344	12,701	13,355	14,880	15,273	17,205	18,391	19,404	20,604	21,057	21,177	22,284	22,136
80+	3,282	3,872	4,191	4,724	5,115	6,084	6,938	7,607	8,578	9,261	9,651	11,208	11,451
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*
Male	27,873	30,150	31,917	34,246	35,112	38,441	40,355	42,681	45,060	46,335	47,523	50,323	51,106
Female	24,457	27,058	28,056	30,594	31,499	33,648	35,412	37,576	39,191	40,146	40,843	42,192	43,207
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*
White	34,319	37,277	38,597	41,529	41,927	45,748	48,394	50,926	54,132	55,841	56,862	59,399	60,281
Black	15,929	17,507	18,630	20,140	20,780	21,970	22,874	24,410	24,889	25,058	25,853	27,129	27,737
Other race	2,026	2,338	2,648	3,015	3,775	4,302	4,455	4,867	5,176	5,524	5,609	5,936	6,228
Unknown	56	86	98	156	132	69	44	54	56	59	42	51	70
†Hispanic						8,415	8,623	9,184	10,139	11,701	10,973	11,884	12,539
†Non-Hispanic						63,674	67,144	71,073	74,114	74,781	77,393	80,631	81,777
Diabetes	19,549	21,735	23,179	25,787	28,060	31,371	33,635	35,769	37,600	39,123	40,209	41,667	42,459
Hypertension	15,666	17,568	18,199	19,639	17,620	18,716	19,903	20,967	22,193	22,593	23,324	24,799	25,828
Glomerulonephritis	6,983	7,187	7,419	7,959	8,079	8,421	8,348	8,484	8,513	8,283	8,155	8,382	8,059
Cystic kidney	1,605	1,696	1,767	1,816	1,903	1,852	1,942	2,128	2,145	2,153	2,200	2,203	2,259
Other urologic	1,410	1,473	1,308	1,340	1,908	2,126	2,176	2,180	2,574	2,411	2,465	2,655	2,547
Other cause	4,815	5,222	5,556	5,910	6,500	6,712	6,851	7,497	7,756	8,064	8,168	8,836	8,941
Missing cause	386	341	403	256	239	228	200	290	391	444	315	344	536
Unknown cause	1,916	1,986	2,142	2,133	2,305	2,663	2,712	2,942	3,081	3,411	3,530	3,629	3,687
All	52,330	57,208	59,973	64,840	66,614	72,089	75,767	80,257	84,253	86,482	88,366	92,515	94,316

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.1 (continued)

Incident patient counts: ESRD patients, unknowns dropped

by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	41	58	88	103	102	131	119	127	126	138	122	163
5-9	82	82	99	83	104	93	113	104	97	118	132	117
10-14	162	165	207	198	209	201	191	206	209	181	202	227
15-19	384	432	422	429	405	413	425	443	469	486	469	450
20-29	1,386	1,552	1,771	1,720	1,894	1,945	2,025	2,020	2,191	2,404	2,445	2,456
30-39	2,019	2,293	2,576	2,678	2,888	3,091	3,393	3,568	3,964	4,316	4,516	4,779
40-49	2,212	2,506	2,689	3,015	3,171	3,473	3,731	4,196	4,715	5,344	5,825	6,577
50-59	3,290	3,933	4,301	4,441	4,723	5,067	5,319	5,779	6,636	7,190	7,728	8,394
60-64	1,817	2,122	2,467	2,872	3,167	3,526	3,672	4,169	4,560	5,033	5,552	6,107
65-69	1,745	1,842	2,146	2,822	2,957	3,356	3,854	4,377	4,951	5,778	6,423	7,121
70-79	1,923	2,088	2,691	3,820	3,991	4,680	5,365	6,182	6,822	8,242	9,247	10,861
80+	319	339	492	770	816	1,039	1,270	1,449	1,798	2,266	2,643	3,064
Male	8,544	9,600	10,886	12,552	13,461	14,568	16,018	17,569	19,478	22,271	24,160	26,700
Female	6,836	7,812	9,063	10,399	10,966	12,447	13,459	15,051	17,060	19,225	21,144	23,616
White	10,693	11,997	13,747	15,441	16,460	18,167	19,929	21,767	24,069	27,259	29,840	32,977
Black	4,308	4,962	5,680	6,857	7,234	7,993	8,561	9,713	11,091	12,820	13,717	15,406
Other race	379	453	522	653	733	855	987	1,140	1,378	1,417	1,747	1,933
†Hispanic												
†Non-Hispanic												
Diabetes	2,578	3,847	5,016	5,849	7,094	8,178	9,492	10,827	12,321	14,855	17,015	19,515
Hypertension	3,000	4,277	5,454	5,932	6,661	7,612	8,280	9,546	11,061	12,816	14,008	15,636
Glomerulonephritis	2,736	3,557	4,157	4,368	4,658	4,915	5,138	5,609	6,016	6,311	6,713	6,971
Cystic kidney	762	930	1,067	1,088	1,124	1,204	1,293	1,349	1,370	1,402	1,545	1,604
Other urologic	451	653	813	920	929	1,104	1,137	1,243	1,267	1,296	1,211	1,403
Other cause	1,735	2,087	2,628	2,865	3,045	3,279	3,389	3,407	3,688	4,270	4,380	4,803
Missing cause	4,118	2,061	814	1,929	916	723	748	639	815	546	432	384
All	15,380	17,412	19,949	22,951	24,427	27,015	29,477	32,620	36,538	41,496	45,304	50,316

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.1 (continued)

Incident patient counts: ESRD patients, unknowns dropped*by age, gender, race, ethnicity, & primary diagnosis*

	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	141	166	128	157	172	162	161	160	184	192	166	178
5-9	114	116	143	138	136	127	125	142	138	140	164	130
10-14	228	217	236	258	257	252	245	272	281	263	306	291
15-19	498	495	475	530	532	501	494	551	519	516	507	532
20-29	2,578	2,612	2,590	2,505	2,498	2,448	2,533	2,454	2,472	2,471	2,353	2,327
30-39	5,140	5,180	5,469	5,416	5,472	5,434	5,426	5,598	5,395	5,364	5,410	5,340
40-49	7,082	7,492	7,912	8,482	9,066	9,083	9,832	10,024	10,285	10,254	10,549	10,818
50-59	9,326	9,829	11,016	11,230	11,866	12,961	14,016	15,099	15,614	16,361	16,996	17,619
60-64	6,405	6,735	7,127	7,399	7,729	8,188	8,656	8,877	9,132	9,467	9,721	10,283
65-69	7,754	8,051	8,633	8,601	9,416	9,693	9,975	10,103	10,157	10,429	10,698	10,955
70-79	12,191	12,844	14,308	14,616	16,469	17,637	18,653	19,752	20,147	20,270	21,364	21,249
80+	3,643	3,968	4,481	4,792	5,690	6,454	7,074	8,008	8,608	8,980	10,486	10,741
Male	28,912	30,631	32,907	33,684	36,881	38,716	40,927	43,219	44,248	45,430	48,150	48,881
Female	26,188	27,074	29,611	30,440	32,422	34,224	36,263	37,821	38,684	39,277	40,570	41,582
White	35,884	37,163	40,044	40,317	43,873	46,383	48,830	51,827	53,351	54,289	56,737	57,603
Black	16,973	18,016	19,569	20,176	21,297	22,257	23,684	24,213	24,284	25,062	26,286	26,896
Other race	2,243	2,526	2,905	3,631	4,133	4,300	4,676	5,000	5,297	5,356	5,697	5,964
†Hispanic					8,068	8,305	8,822	9,738	11,243	10,544	11,416	12,043
†Non-Hispanic					61,235	64,635	68,368	71,302	71,689	74,163	77,304	78,420
Diabetes	21,680	23,136	25,713	27,976	31,313	33,585	35,721	37,542	39,060	40,153	41,597	42,398
Hypertension	17,538	18,163	19,596	17,575	18,683	19,868	20,933	22,157	22,553	23,293	24,758	25,782
Glomerulonephritis	7,172	7,409	7,929	8,061	8,411	8,340	8,467	8,502	8,278	8,147	8,365	8,049
Cystic kidney	1,694	1,765	1,814	1,901	1,851	1,941	2,128	2,145	2,153	2,199	2,202	2,259
Other urologic	1,468	1,302	1,335	1,895	2,122	2,171	2,173	2,569	2,409	2,463	2,648	2,544
Other cause	5,210	5,536	5,878	6,482	6,701	6,836	7,483	7,739	8,048	8,142	8,818	8,920
Missing cause	338	394	253	234	222	199	285	386	431	310	332	511
All	55,100	57,705	62,518	64,124	69,303	72,940	77,190	81,040	82,932	84,707	88,720	90,463

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.2

90-day survival probabilities: incident ESRD patients

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	97.9	98.5	98.0	100.0	98.2	100.0	97.0	96.4	97.1	96.6	85.7	96.6
5-9	100.0	98.9	100.0	98.9	99.1	99.0	100.0	100.0	97.1	97.6	90.7	98.4
10-14	99.4	100.0	100.0	100.0	98.7	100.0	98.6	100.0	100.0	99.0	90.2	97.2
15-19	99.5	99.4	100.0	99.5	99.8	99.8	99.8	100.0	99.2	98.8	92.3	99.0
20-29	99.2	99.1	99.3	98.7	98.7	99.2	99.2	98.8	98.9	98.5	98.0	98.4
30-39	98.2	98.7	98.5	98.8	98.6	98.4	98.0	98.1	98.3	98.2	97.3	97.7
40-49	98.4	97.9	98.2	97.6	98.2	98.0	98.1	97.9	98.2	97.8	97.2	97.9
50-59	97.2	97.1	96.8	96.3	97.1	96.3	96.7	96.9	96.7	96.8	96.3	96.7
60-64	94.8	95.1	94.7	94.9	95.1	94.2	93.8	95.0	94.5	94.8	94.1	94.5
65-69	90.5	91.1	90.0	91.5	89.8	90.3	91.6	91.2	92.2	92.0	92.1	92.1
70-79	87.1	88.3	87.6	88.4	87.7	87.2	87.9	89.3	88.2	88.6	89.0	89.5
80+	83.9	84.7	84.7	83.0	83.7	82.6	84.4	83.6	85.7	83.8	83.8	84.9
Male	94.8	95.0	94.5	94.1	94.2	93.4	93.6	93.8	93.7	93.6	92.9	93.5
Female	95.0	95.5	95.0	94.5	94.2	93.8	94.1	94.3	94.3	93.9	93.5	93.9
White	94.3	94.7	93.9	93.2	93.3	92.6	92.8	93.0	92.9	92.5	92.1	92.6
Black	96.3	96.5	96.8	96.7	96.1	95.9	95.9	96.1	96.1	96.1	95.3	95.7
Other race	94.5	97.0	96.0	95.4	96.7	95.4	96.7	97.5	96.1	96.3	96.0	96.6
†Hispanic												
†Non-Hispanic												
Diabetes	96.5	95.6	95.0	94.4	94.8	94.4	94.6	94.7	94.8	94.7	94.4	94.7
Hypertension	95.9	95.0	93.5	93.4	93.0	92.6	92.7	92.4	92.7	92.2	91.5	91.9
Glomerulonephritis	98.3	97.7	97.1	97.2	96.7	96.7	96.1	96.1	96.6	95.8	95.2	96.1
Other cause	93.0	94.1	94.1	93.2	93.1	91.9	92.6	93.8	92.8	92.8	92.2	92.9
All	94.9	95.2	94.7	94.3	94.2	93.6	93.8	94.0	94.0	93.7	93.2	93.7
ADJUSTED												
0-19	99.0	98.9	99.6	99.3	98.5	99.6	98.4	99.0	97.9	97.0	83.6	96.4
20-44	98.8	98.8	98.7	98.7	98.7	98.6	98.4	98.3	98.5	98.3	97.6	98.0
45-64	97.1	96.9	96.6	96.1	96.6	95.9	96.0	96.4	96.2	96.3	95.6	96.1
65-74	90.9	91.1	89.9	91.4	89.8	89.8	90.9	91.3	91.3	91.5	91.4	91.5
75+	87.6	88.1	87.7	87.1	87.2	86.3	86.9	87.3	87.4	86.5	87.0	87.8
Male	94.1	94.0	93.3	93.5	93.4	92.7	93.0	93.3	93.2	93.2	92.6	93.3
Female	94.3	94.5	94.0	93.9	93.5	93.2	93.7	94.0	94.0	93.7	93.3	93.8
White	93.4	93.5	92.6	92.6	92.6	92.0	92.4	92.8	92.8	92.5	92.2	92.8
Black	96.0	95.5	95.8	96.2	95.2	95.0	95.0	95.2	95.2	95.3	94.3	94.8
Other race	94.0	96.4	94.8	94.5	95.8	94.2	95.9	96.9	95.2	95.5	95.2	96.0
Diabetes	94.8	93.6	93.0	92.4	93.1	92.7	93.2	93.4	93.7	93.8	93.6	94.0
Hypertension	94.9	94.2	93.0	93.3	92.9	92.8	93.2	93.1	93.3	93.1	92.6	93.1
Glomerulonephritis	97.0	96.1	95.3	95.6	95.2	95.2	94.6	94.6	95.3	94.5	93.8	95.1
Other cause	91.7	92.5	92.5	92.6	92.1	90.9	91.7	93.1	91.9	92.0	91.3	92.0
All	94.2	94.2	93.6	93.7	93.5	93.0	93.3	93.6	93.6	93.4	92.9	93.5

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.2 (continued)

90-day survival probabilities: incident ESRD patients*by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	97.3	97.3	95.8	97.0	96.7	97.1	96.5	94.4	97.4	96.6	97.8	96.9
5-9	100.0	99.2	98.8	98.6	97.9	99.2	100.0	98.7	99.4	98.7	98.9	100.0
10-14	100.0	99.6	98.4	99.6	99.6	99.3	100.0	99.7	99.4	99.4	99.7	100.0
15-19	99.6	99.4	98.9	99.8	99.3	99.4	99.4	98.8	99.3	98.6	99.1	98.0
20-29	98.0	98.4	97.8	97.4	98.4	98.2	98.7	98.6	98.4	98.8	98.3	98.5
30-39	97.6	97.3	97.1	97.6	97.2	97.7	97.7	97.9	97.6	97.9	97.9	97.9
40-49	97.6	97.3	97.0	96.8	96.8	96.7	96.9	96.7	97.0	96.9	96.7	96.9
50-59	96.9	96.0	95.7	95.8	95.8	96.0	95.7	95.3	95.7	95.3	95.8	95.3
60-64	94.5	94.4	93.7	93.8	93.8	93.7	93.4	93.8	93.7	93.4	93.9	94.0
65-69	92.4	92.8	92.5	92.6	92.8	92.1	92.3	92.5	91.9	92.3	92.5	92.6
70-79	89.6	89.0	89.5	89.2	89.0	88.5	88.7	88.8	88.2	88.7	88.7	88.5
80+	85.3	84.6	83.9	83.7	84.3	82.9	82.3	82.4	82.7	82.3	83.0	82.6
Male	93.3	93.2	92.8	92.9	92.7	92.3	92.1	92.1	92.3	91.8	92.2	91.9
Female	94.1	93.4	93.2	92.9	92.9	92.3	92.4	92.1	92.0	91.9	91.8	92.0
White	92.7	92.2	92.0	91.8	91.7	91.1	91.1	91.0	91.1	90.8	90.8	90.7
Black	95.6	95.3	94.9	95.0	94.8	94.6	94.4	94.3	94.1	93.8	94.1	93.9
Other race	95.9	95.6	95.3	94.3	94.1	94.1	94.1	93.7	94.4	94.2	95.0	94.7
†Hispanic					94.8	94.3	94.2	94.5	94.0	93.8	94.5	94.2
†Non-Hispanic					92.5	92.0	92.0	91.8	91.9	91.6	91.7	91.6
Diabetes	94.8	94.2	94.2	93.8	93.8	93.5	93.2	93.1	93.0	92.9	93.2	93.2
Hypertension	92.0	92.0	91.6	91.6	91.9	90.9	90.9	90.7	90.8	90.4	90.7	90.8
Glomerulonephritis	96.3	95.9	95.5	96.2	95.7	95.5	95.1	95.3	95.9	95.7	96.0	95.8
Other cause	92.5	91.9	91.2	91.0	90.1	89.8	90.3	90.1	90.3	89.7	89.6	89.0
All	93.7	93.3	93.0	92.9	92.8	92.3	92.2	92.1	92.1	91.9	92.0	91.9
ADJUSTED												
0-19	98.9	98.3	96.9	98.5	97.8	98.2	98.5	97.0	98.2	97.2	98.3	97.4
20-44	97.9	97.8	97.5	97.5	97.6	97.8	97.9	97.9	97.9	98.0	97.9	98.0
45-64	96.1	95.6	95.2	95.3	95.3	95.3	95.1	95.1	95.3	95.0	95.3	95.1
65-74	91.8	91.8	91.9	91.6	91.6	91.1	91.3	91.3	91.1	91.0	91.3	91.5
75+	87.7	86.9	86.7	86.7	86.8	85.8	85.5	85.7	85.9	85.4	85.9	85.5
Male	93.2	93.1	92.8	92.9	92.9	92.7	92.5	92.7	92.9	92.4	92.9	92.6
Female	94.0	93.5	93.3	93.1	93.2	92.7	92.8	92.7	92.7	92.7	92.7	92.8
White	93.0	92.7	92.5	92.5	92.6	92.2	92.2	92.3	92.4	92.2	92.3	92.3
Black	94.7	94.4	93.9	94.0	93.9	93.8	93.6	93.5	93.4	93.1	93.5	93.3
Other race	95.2	94.9	94.6	93.8	93.6	93.6	93.7	93.4	94.1	93.8	94.9	94.5
Diabetes	94.3	93.7	93.8	93.4	93.6	93.4	93.2	93.2	93.2	93.1	93.5	93.5
Hypertension	93.2	93.2	92.9	93.0	93.4	92.7	92.7	92.7	92.8	92.5	92.8	92.9
Glomerulonephritis	95.2	94.8	94.6	95.3	94.9	94.6	94.2	94.6	95.2	94.7	95.2	94.9
Other cause	91.7	91.0	90.3	90.3	89.6	89.4	90.0	89.9	90.1	89.6	89.6	89.0
All	93.6	93.3	93.0	93.0	93.0	92.7	92.7	92.7	92.8	92.5	92.8	92.7

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.3

One-year survival probabilities: incident ESRD patients

from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	93.5	92.4	89.8	89.5	86.9	89.6	90.8	89.6	82.7	84.7	84.9	81.9
5-9	93.5	94.7	95.2	97.7	95.4	95.0	98.3	99.1	99.0	96.7	97.1	98.3
10-14	97.7	97.8	98.6	98.1	97.3	97.6	99.0	98.6	95.9	95.9	96.8	97.9
15-19	96.5	95.9	96.5	95.0	96.7	95.8	96.0	96.6	98.0	98.4	97.6	96.0
20-29	91.8	93.3	93.6	93.6	93.5	92.3	94.3	92.5	93.0	92.7	92.6	93.1
30-39	89.5	89.0	89.0	90.2	88.7	89.4	89.5	89.0	89.7	89.4	90.2	89.6
40-49	87.9	87.5	86.8	87.7	88.2	88.0	87.5	88.0	88.7	88.5	89.0	88.0
50-59	83.7	83.4	84.0	81.8	81.9	82.2	82.7	83.5	83.7	83.5	84.3	84.3
60-64	78.5	77.8	78.2	77.7	76.0	76.5	77.2	76.4	77.2	77.9	78.3	79.2
65-69	72.7	73.6	73.7	72.2	73.0	71.3	73.0	73.1	73.4	74.1	75.5	75.2
70-79	67.1	67.7	68.7	65.3	66.6	66.9	66.1	65.3	66.1	67.4	68.5	68.2
80+	57.5	53.2	62.3	55.3	56.2	58.0	58.6	55.2	55.4	58.0	59.5	59.2
Male	81.4	81.9	81.7	79.3	79.2	78.8	78.6	78.5	78.3	78.7	79.5	79.0
Female	82.1	81.5	81.9	79.6	79.9	79.4	79.8	78.4	79.5	79.2	79.5	78.9
White	80.3	80.2	80.3	77.6	77.4	77.1	77.1	76.0	76.3	76.6	77.1	76.4
Black	85.2	85.5	85.2	83.2	84.0	83.1	83.1	83.4	83.6	83.1	83.8	83.4
Other race	82.2	81.7	85.8	83.5	83.2	83.5	86.0	83.0	84.9	85.3	86.7	87.6
†Hispanic												
†Non-Hispanic												
Diabetes	76.0	74.8	74.1	74.7	74.8	74.3	75.5	75.3	76.7	77.2	77.1	77.6
Hypertension	84.5	82.4	81.1	79.1	78.2	79.0	77.9	76.8	77.0	77.2	78.1	77.2
Glomerulonephritis	91.5	89.8	89.3	88.5	87.9	88.1	86.7	86.6	87.2	86.8	87.4	86.1
Other cause	79.3	80.9	83.5	78.2	79.8	78.5	79.9	79.0	78.5	78.7	80.2	79.4
All	81.7	81.7	81.8	79.4	79.5	79.1	79.2	78.4	78.9	78.9	79.5	79.0
ADJUSTED												
0-19	93.1	92.6	92.9	91.6	91.8	91.5	93.4	93.5	92.1	92.6	92.5	90.1
20-44	88.1	88.5	88.8	89.4	89.0	89.0	89.3	88.8	89.6	89.2	89.8	89.4
45-64	80.3	80.2	80.9	80.0	79.9	80.3	81.1	81.3	81.9	82.6	83.1	83.5
65-74	70.0	70.6	72.2	69.2	70.3	69.3	70.3	70.4	71.2	72.0	73.4	73.1
75+	61.1	61.7	62.4	59.0	61.0	62.2	61.9	59.4	60.0	62.5	63.4	63.4
Male	73.8	74.4	74.8	73.3	73.4	73.7	74.1	74.2	74.4	75.5	76.8	76.8
Female	75.4	75.1	76.6	75.3	75.9	75.9	76.9	76.1	77.3	77.8	78.4	78.4
White	71.7	71.9	73.1	71.6	71.9	72.3	73.0	72.6	73.5	74.8	75.7	75.6
Black	80.7	80.4	80.4	79.2	79.7	79.0	79.5	79.9	80.1	79.7	80.8	80.8
Other race	74.0	75.0	78.2	77.3	77.1	78.8	82.2	78.8	81.4	82.4	84.6	85.8
Diabetes	69.4	68.4	68.3	69.4	70.0	69.8	71.7	71.9	73.8	74.7	75.1	76.0
Hypertension	81.4	80.2	79.6	78.4	77.7	79.2	78.9	78.1	78.3	79.0	80.1	79.6
Glomerulonephritis	84.6	82.7	82.6	82.1	81.8	82.9	81.1	81.1	82.0	82.3	83.0	81.9
Other cause	75.1	75.5	78.6	75.5	76.4	74.7	76.5	75.8	75.1	75.5	76.9	76.2
All	74.5	74.7	75.7	74.2	74.6	74.7	75.4	75.1	75.8	76.6	77.6	77.6

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.3 (continued)

One-year survival probabilities: incident ESRD patients

from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	89.7	87.0	89.1	88.3	92.1	89.9	88.6	87.4	84.3	88.8	90.3	91.2
5-9	97.6	95.4	100.0	97.2	95.7	96.2	100.0	96.7	96.1	98.0	94.4	97.2
10-14	94.7	95.8	99.2	97.4	97.0	97.8	97.8	98.0	97.7	98.0	96.8	98.2
15-19	96.6	96.9	95.9	97.5	96.7	98.3	96.5	98.0	97.9	97.9	97.7	98.3
20-29	93.9	93.2	92.8	92.7	94.3	95.4	95.1	95.5	93.9	95.0	94.1	94.0
30-39	90.0	89.3	89.9	88.7	90.3	91.2	91.2	91.0	91.1	91.5	91.6	91.8
40-49	88.2	88.9	88.5	89.2	89.6	90.2	89.1	89.6	89.7	89.1	88.9	89.0
50-59	85.3	85.1	85.9	85.8	85.4	85.9	85.6	86.0	85.6	86.0	85.8	85.5
60-64	79.4	81.0	80.7	80.1	81.7	81.9	80.2	81.2	80.9	81.7	81.0	82.0
65-69	75.6	77.2	76.4	77.1	78.0	76.9	76.5	76.6	77.2	76.9	76.8	77.5
70-79	68.5	70.0	70.0	70.3	70.9	69.8	70.0	69.6	69.5	69.8	69.6	69.9
80+	58.4	60.9	61.0	60.4	60.2	59.5	57.5	58.5	57.9	57.9	58.9	59.2
Male	78.9	80.1	79.8	79.6	80.1	79.7	79.2	79.4	79.0	79.3	78.7	79.0
Female	79.3	79.6	79.6	79.6	79.6	78.9	78.1	78.0	77.8	77.8	77.5	77.8
White	76.4	77.5	77.4	77.4	77.6	76.7	76.4	76.6	76.3	76.1	75.9	76.3
Black	83.9	83.8	83.5	83.1	83.9	84.0	82.7	82.6	82.0	82.6	81.9	81.6
Other race	86.3	87.3	86.2	84.4	83.3	84.4	83.0	83.3	84.0	85.1	84.1	85.3
†Hispanic					83.8	83.2	83.4	82.9	83.7	83.9	83.0	83.6
†Non-Hispanic					79.3	78.9	78.1	78.2	77.6	77.8	77.4	77.7
Diabetes	77.7	79.2	79.0	78.8	79.0	78.4	77.7	78.3	78.2	78.4	78.0	78.6
Hypertension	77.5	77.7	77.9	78.7	78.6	77.6	77.1	76.8	76.7	76.7	76.6	76.5
Glomerulonephritis	87.4	88.7	87.1	87.7	88.3	88.5	88.5	87.7	88.1	88.3	88.0	88.5
Other cause	79.1	79.0	79.2	77.7	78.2	78.7	77.9	77.9	76.6	77.1	75.9	76.5
	79.1	79.9	79.7	79.6	79.8	79.4	78.7	78.8	78.4	78.6	78.2	78.5
All												
ADJUSTED												
0-19	91.9	91.2	93.7	93.2	93.0	94.3	93.2	93.8	92.2	93.9	93.0	94.9
20-44	89.5	89.2	89.7	89.2	90.6	91.3	90.9	91.0	90.8	91.1	90.8	91.2
45-64	84.2	84.9	85.2	85.2	85.6	86.1	85.2	85.9	85.6	85.9	85.6	85.6
65-74	73.7	75.6	74.7	75.5	76.3	75.4	75.3	75.5	75.6	75.5	75.2	75.9
75+	62.9	64.2	65.0	64.6	64.9	64.0	63.3	63.4	63.2	63.4	63.8	64.0
Male	77.0	78.5	78.5	78.4	79.5	79.6	79.2	79.7	79.4	79.7	79.5	79.9
Female	79.0	79.5	79.8	80.0	80.3	80.0	79.3	79.4	79.4	79.6	79.5	79.8
White	76.1	77.5	77.8	78.1	78.8	78.4	78.2	78.6	78.6	78.6	78.6	79.1
Black	81.3	81.3	81.1	80.9	82.0	82.3	81.1	80.9	80.5	81.2	80.6	80.3
Other race	84.8	86.0	85.2	84.0	83.4	84.6	83.0	83.7	84.2	85.2	84.5	85.6
Diabetes	76.4	78.2	78.2	78.2	78.8	78.5	77.8	78.6	78.7	78.9	78.8	79.4
Hypertension	79.8	80.3	80.6	81.3	81.6	81.0	80.7	80.6	80.6	80.5	80.9	80.6
Glomerulonephritis	83.5	85.0	83.7	84.1	85.4	85.5	85.5	84.9	85.2	85.0	85.2	85.5
Other cause	76.1	75.7	76.1	75.2	75.9	76.8	75.9	76.0	74.9	75.4	74.5	75.1
All	78.0	79.0	79.1	79.2	79.9	79.8	79.3	79.6	79.5	79.7	79.5	79.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.4

Two-year survival probabilities: incident ESRD patients

from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	87.0	90.9	85.7	82.9	85.0	82.8	85.4	85.2	78.2	80.6	80.2	79.5	87.0	81.9	83.3	84.0	88.1	86.4	84.9	85.0	79.1	85.3	84.0
5-9	92.5	91.5	93.3	94.3	93.5	94.1	94.2	97.3	97.0	95.9	94.1	97.5	97.6	91.6	97.5	95.8	95.0	95.4	97.8	94.7	95.4	96.6	92.6
10-14	95.5	95.2	96.8	97.2	95.5	95.3	96.1	98.2	94.1	93.4	94.5	96.7	92.7	94.2	98.4	95.6	95.9	96.1	96.3	97.3	96.7	96.1	95.0
15-19	95.1	92.9	93.6	92.7	94.1	93.8	93.4	94.6	95.2	96.7	95.5	93.3	95.2	94.5	94.6	95.6	93.2	95.3	94.6	95.5	94.7	95.8	96.0
20-29	86.4	87.6	88.8	87.6	88.0	86.7	88.9	86.2	88.3	88.3	87.6	87.8	88.8	89.1	88.7	88.1	90.2	90.9	91.4	91.5	89.4	90.5	89.4
30-39	80.6	81.4	80.5	82.5	80.1	80.6	80.9	81.0	82.4	82.0	82.3	81.3	82.1	82.2	81.9	82.1	83.1	84.5	84.3	84.7	84.9	85.3	85.7
40-49	77.1	77.0	76.7	76.4	77.7	78.1	77.2	78.0	78.9	78.2	80.0	77.7	79.2	79.0	79.4	80.3	80.3	81.5	80.7	80.8	80.9	80.8	80.6
50-59	70.8	70.6	70.9	68.4	67.7	68.0	68.5	69.2	69.5	70.7	70.7	71.2	72.4	72.6	73.8	73.3	73.6	74.0	73.2	74.3	74.2	74.5	74.9
60-64	63.8	62.0	61.8	61.9	59.1	59.1	60.9	59.9	61.1	61.8	62.2	63.0	63.3	65.5	65.7	64.9	66.9	67.0	65.5	67.1	67.2	68.0	67.6
65-69	54.9	55.9	55.5	52.4	55.4	53.0	53.9	55.3	56.1	56.2	56.7	56.9	58.2	60.1	59.0	59.8	61.0	59.5	59.5	60.0	61.3	62.5	61.5
70-79	46.9	48.5	49.5	44.4	46.6	46.9	46.4	45.7	46.7	47.7	48.0	48.3	49.1	50.0	50.3	50.8	51.8	50.0	51.1	51.1	50.8	51.9	51.7
80+	30.4	32.8	38.0	30.8	36.6	35.5	35.1	32.7	33.2	37.7	37.0	36.0	36.9	37.6	38.6	38.4	38.3	37.1	37.1	37.4	37.3	37.6	38.5
Male	67.9	69.1	68.6	65.0	65.3	63.9	64.4	63.7	64.3	64.6	64.7	64.2	64.6	65.9	65.6	65.8	65.9	65.4	65.3	65.5	65.5	65.9	65.3
Female	69.8	69.0	68.9	65.3	65.9	65.7	64.9	64.4	65.2	65.1	64.7	64.0	64.9	64.9	65.0	64.8	65.1	64.0	63.6	63.7	63.3	64.2	63.6
White	66.9	67.2	66.8	62.7	62.9	62.3	61.9	61.1	61.1	61.5	61.2	60.4	60.9	61.6	61.6	61.7	61.8	60.7	60.9	61.3	61.2	61.5	61.1
Black	73.2	73.8	73.1	69.9	71.2	69.9	70.1	69.8	71.7	70.9	71.1	70.3	71.5	71.6	71.6	71.3	72.3	71.7	70.5	70.3	70.1	70.9	70.1
Other race	71.2	68.5	74.2	72.3	71.6	69.7	72.3	71.0	72.5	74.2	75.3	77.1	75.2	76.5	74.2	72.0	70.9	72.0	71.0	72.1	72.2	74.7	72.9
†Hispanic																	70.7	70.1	70.6	70.9	72.1	72.3	71.8
†Non-Hispanic																	64.9	64.0	63.7	63.8	63.3	64.1	63.4
Diabetes	58.8	57.7	56.0	57.7	56.0	56.2	57.1	57.4	59.0	60.0	59.2	59.9	60.6	62.1	61.9	61.9	62.4	61.5	61.2	62.2	62.3	63.1	62.6
Hypertension	72.4	69.6	68.0	64.3	65.0	64.1	63.0	61.7	62.7	62.7	62.4	61.8	62.8	62.5	63.3	64.1	64.1	62.5	62.4	62.2	62.1	62.5	62.3
Glomerulonephritis	83.4	81.5	80.9	79.3	79.0	77.6	76.6	76.8	77.9	76.9	78.0	75.7	77.7	79.1	77.7	78.3	79.0	79.2	79.9	78.8	79.5	80.3	79.7
Other cause	65.8	68.7	71.4	63.6	66.9	66.3	67.6	66.7	66.3	67.3	68.9	67.6	67.7	67.7	67.7	66.2	66.6	66.9	66.4	66.5	65.3	66.2	64.9
All	68.7	69.1	68.7	65.2	65.6	64.7	64.6	64.0	64.7	64.8	64.7	64.1	64.7	65.4	65.3	65.3	65.5	64.7	64.5	64.7	64.5	65.1	64.5
ADJUSTED																							
0-19	89.8	87.7	88.3	87.1	88.0	86.9	87.8	90.2	87.6	89.1	88.2	86.7	89.4	86.6	90.4	89.6	88.7	90.1	89.8	90.5	87.9	90.2	89.1
20-44	78.0	79.8	80.1	80.6	80.2	80.1	80.8	80.2	81.8	81.6	82.1	80.9	81.7	81.6	82.0	82.1	83.3	84.6	84.0	84.3	84.2	84.3	84.2
45-64	66.0	65.5	66.3	65.3	64.6	65.1	66.2	66.5	67.5	68.9	69.5	69.9	71.1	72.2	72.9	72.8	73.6	74.1	73.3	74.3	74.3	74.8	74.8
65-74	50.5	52.2	53.5	48.7	51.7	50.3	51.0	51.9	53.2	53.6	54.2	54.6	55.9	57.2	56.7	58.0	58.8	57.5	58.1	58.6	59.0	60.3	59.5
75+	38.7	41.2	40.5	36.3	40.3	40.8	40.1	38.1	38.8	42.1	41.7	41.7	42.2	43.1	43.9	43.4	44.5	42.8	43.5	43.6	43.5	44.1	44.4
Male	56.8	58.2	58.4	56.3	57.1	56.6	57.9	57.6	58.8	60.2	60.8	60.9	61.9	63.6	63.7	64.1	65.1	65.1	65.3	66.0	66.2	66.6	66.5
Female	60.0	59.8	61.0	59.0	60.3	60.7	60.7	61.1	62.1	63.1	63.3	63.4	64.6	64.8	65.4	65.5	66.4	65.8	65.5	65.8	65.9	66.9	66.7
White	54.8	55.7	56.6	54.4	55.4	55.7	56.2	56.4	57.2	59.1	59.3	59.5	60.6	61.8	62.4	62.9	63.8	63.3	63.8	64.5	64.7	65.2	65.3
Black	65.9	65.6	65.4	63.6	64.5	63.6	64.7	64.4	66.2	65.7	66.6	66.2	67.5	67.8	68.0	68.0	69.3	69.2	68.1	67.9	68.0	68.9	68.3
Other race	59.5	58.7	61.9	62.4	62.4	62.3	65.7	64.4	66.8	69.7	71.8	74.1	72.7	74.3	72.4	71.4	71.1	72.3	71.1	72.8	72.6	74.8	73.4
Diabetes	50.2	49.5	48.7	50.8	49.9	50.5	52.0	53.0	55.1	56.8	56.6	57.8	59.0	60.8	60.9	61.2	62.2	61.8	61.7	62.9	63.3	64.1	64.0
Hypertension	67.5	66.2	65.8	63.3	64.3	64.5	64.4	63.7	64.6	65.4	65.6	65.5	66.3	66.6	67.4	68.2	68.7	67.7	67.8	67.8	67.9	68.2	68.6
Glomerulonephritis	71.0	70.0	69.8	68.8	69.4	68.8	67.8	68.1	69.7	69.5	70.8	69.0	71.3	72.8	72.1	72.5	74.1	74.0	74.8	74.3	74.7	75.1	75.1
Other cause	59.8	61.0	64.1	59.6	61.8	61.0	62.8	62.1	61.5	63.0	64.1	63.0	63.4	63.2	63.4	62.8	63.4	64.1	63.5	63.9	62.8	63.8	62.9
All	58.3	59.0	59.7	57.6	58.6	58.5	59.3	59.3	60.4	61.6	62.0	62.1	63.2	64.2	64.6	64.8	65.8	65.5	65.4	66.0	66.1	66.8	66.6

298

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.5
Three-year survival probabilities: incident ESRD patients
from day 91 to three years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	84.8	89.4	84.7	80.0	82.2	82.1	81.5	81.5	75.9	78.5	79.4	77.8	84.2	78.5	82.6	82.7	84.7	83.4	84.3	83.2	75.4	84.2
5-9	92.5	90.4	92.4	92.0	91.7	92.1	94.2	95.5	96.0	95.9	92.6	97.5	96.8	90.1	96.2	95.1	90.7	95.4	97.0	94.1	93.5	94.6
10-14	94.4	90.3	93.7	94.8	93.7	93.4	94.6	96.3	92.8	92.9	94.1	94.6	90.6	92.1	95.6	94.9	94.4	95.0	96.3	96.6	95.8	95.1
15-19	92.7	90.8	92.3	91.8	92.5	91.2	91.2	92.7	93.4	94.0	93.7	92.3	93.7	92.5	93.2	93.1	91.5	92.6	92.2	92.8	93.2	93.4
20-29	82.3	83.4	84.6	83.7	83.6	82.7	84.5	82.5	85.1	84.7	83.6	84.3	85.2	85.4	85.1	84.4	87.0	87.8	88.2	87.4	85.7	86.6
30-39	75.7	75.4	73.0	75.9	74.0	74.4	75.2	74.5	76.7	76.3	76.6	75.5	75.7	76.5	76.4	76.5	78.0	79.0	79.2	79.3	79.9	79.9
40-49	68.8	69.2	68.7	67.8	69.4	69.9	68.9	70.3	71.1	70.1	71.5	69.7	71.0	71.0	71.6	72.4	72.6	73.8	72.8	73.3	73.1	73.6
50-59	60.3	59.7	59.2	57.2	56.8	56.1	57.0	58.5	58.7	59.5	59.9	60.2	60.6	61.6	62.5	62.6	62.7	63.8	63.3	64.2	64.5	65.0
60-64	51.7	50.0	48.5	49.2	46.5	46.5	47.0	47.2	49.1	49.1	49.3	50.3	50.2	52.2	53.0	52.4	53.8	55.1	53.8	54.7	55.5	55.9
65-69	40.4	42.9	42.1	38.3	41.6	39.8	40.1	41.5	42.7	42.0	42.3	42.8	43.8	45.7	45.2	46.3	46.6	46.2	46.4	46.9	48.5	49.3
70-79	33.5	33.8	34.9	30.0	32.3	32.5	31.8	32.0	33.0	33.8	33.3	34.2	34.1	35.7	35.4	36.0	37.0	35.8	36.6	36.9	37.4	38.5
80+	18.4	20.3	19.0	18.2	21.2	21.6	20.8	21.2	20.0	22.9	22.2	21.9	22.8	23.0	23.3	23.3	24.4	23.1	22.4	23.1	23.8	23.8
Male	58.5	59.2	58.3	54.4	55.0	53.1	53.3	53.4	54.0	54.1	53.7	53.4	53.0	54.6	54.3	54.9	54.8	54.3	54.4	54.5	54.8	55.1
Female	60.0	59.3	58.0	54.7	55.1	55.2	54.1	53.7	54.9	53.7	53.2	52.5	53.2	53.3	53.2	53.0	53.2	52.8	52.2	52.3	52.5	53.3
White	57.2	57.2	56.3	52.0	52.5	51.6	50.9	50.4	50.3	50.2	49.5	48.9	48.7	49.7	49.4	49.8	49.6	49.1	49.4	49.5	49.8	50.1
Black	63.6	64.6	62.0	59.3	60.4	59.1	59.2	59.7	62.1	60.5	60.7	60.0	60.7	61.1	61.2	61.1	62.0	61.6	60.1	60.2	60.4	60.9
Other race	62.3	57.5	64.7	63.2	60.7	59.9	61.9	61.6	63.2	64.9	66.1	67.6	65.2	66.1	64.6	61.0	60.3	61.1	60.9	62.1	62.8	65.1
†Hispanic																	59.6	59.8	60.4	60.4	62.7	62.4
†Non-Hispanic																	53.3	52.8	52.4	52.5	52.3	53.1
Diabetes	46.4	45.8	43.2	44.2	43.4	43.5	44.3	44.9	46.3	46.6	46.0	46.5	47.0	48.3	48.6	48.4	48.9	48.6	48.3	49.1	49.7	50.8
Hypertension	63.0	59.4	56.3	53.5	53.1	53.0	51.3	50.5	52.0	51.6	50.9	50.3	50.7	50.9	51.1	52.5	52.5	51.1	51.0	50.8	51.1	51.0
Glomerulonephritis	77.2	74.4	73.3	72.4	71.3	68.6	68.3	68.9	70.4	68.7	69.6	68.1	69.3	71.3	70.0	70.5	70.7	72.0	72.2	70.8	72.4	73.2
Other cause	55.9	59.0	61.6	53.1	57.7	57.0	57.7	57.8	57.7	58.8	59.5	59.2	58.4	59.3	59.0	57.9	57.8	58.3	58.0	58.2	57.3	57.9
All	59.1	59.3	58.2	54.5	55.0	54.0	53.7	53.5	54.4	53.9	53.5	53.0	53.1	54.0	53.8	54.0	54.0	53.6	53.3	53.5	53.7	54.3
ADJUSTED																						
0-19	86.9	83.5	85.6	84.4	85.1	83.7	84.7	86.7	85.0	86.2	86.2	84.8	86.7	83.4	87.9	87.0	85.2	87.1	87.8	87.7	85.2	87.5
20-44	71.9	73.1	72.7	73.8	73.8	73.6	74.5	73.9	75.8	75.7	75.9	75.0	75.4	75.6	76.1	76.1	77.8	78.8	78.4	78.3	78.4	78.5
45-64	54.4	54.0	54.1	53.3	52.9	53.2	54.1	55.4	56.6	57.6	58.2	58.8	59.5	61.0	62.1	62.2	62.8	64.1	63.4	64.3	64.7	65.2
65-74	36.5	38.4	38.8	34.2	38.0	36.7	36.5	38.0	39.7	39.5	39.8	40.4	41.4	43.0	42.4	44.0	44.7	43.8	44.6	45.3	46.2	47.5
75+	25.2	27.1	25.8	22.9	24.9	26.1	26.3	25.5	25.2	28.0	26.8	27.8	27.3	28.7	28.9	28.4	29.8	28.8	28.9	29.3	30.0	30.2
Male	45.9	46.7	46.5	44.5	45.7	44.9	45.9	46.5	47.7	49.1	49.3	49.8	49.9	52.0	52.2	52.9	53.9	54.1	54.4	55.1	55.6	56.0
Female	48.6	48.8	48.8	47.5	48.7	49.5	49.4	50.1	51.3	51.5	51.7	51.9	53.0	53.4	53.9	54.1	54.9	55.0	54.6	55.0	55.7	56.6
White	43.7	44.3	44.8	42.8	44.2	44.3	44.6	45.3	46.1	47.6	47.4	48.0	48.6	50.1	50.6	51.3	52.2	52.3	52.8	53.4	54.0	54.6
Black	54.7	54.8	52.6	51.7	52.4	51.7	52.8	53.4	55.6	54.5	55.2	55.2	55.9	56.6	56.9	57.1	58.4	58.5	57.2	57.3	58.0	58.6
Other race	48.8	46.4	49.5	51.2	49.2	51.0	53.5	53.5	56.1	59.3	61.5	63.6	62.1	63.2	62.5	60.4	60.4	61.6	61.0	63.0	63.4	65.3
Diabetes	37.8	37.6	36.0	37.4	37.5	38.1	39.3	40.7	42.4	43.4	43.6	44.6	45.5	47.2	47.9	48.1	49.1	49.3	49.3	50.3	51.2	52.4
Hypertension	57.1	55.4	53.8	52.5	52.6	53.6	53.1	52.9	54.2	54.9	54.7	54.8	55.0	55.8	56.1	57.3	58.1	57.2	57.4	57.5	58.0	57.7
Glomerulonephritis	61.5	59.7	59.3	59.5	57.3	57.4	58.2	60.4	59.5	60.4	59.9	61.0	63.1	62.9	63.1	64.2	65.3	65.4	64.8	66.3	66.3	66.3
Other cause	49.2	50.3	52.9	48.4	51.7	50.8	52.0	52.4	52.2	53.7	53.8	53.7	53.4	54.0	54.0	53.8	54.0	55.0	54.5	55.0	54.4	54.9
All	47.2	47.7	47.6	46.0	47.2	47.1	47.6	48.2	49.4	50.3	50.4	50.9	51.4	52.7	53.1	53.5	54.4	54.5	54.5	55.1	55.7	56.3

Reference cohort is 1996 incident ESRD patients.
 Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.
 The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.
 The age of the incident patient is determined as of the date of ESRD initiation.
 U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.
 †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.6

Five-year survival probabilities: incident ESRD patients

from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	80.4	80.3	80.6	77.1	76.6	79.9	76.9	77.0	75.2	77.1	76.2	76.6	82.2	76.3	80.4	79.0	82.5	81.1	80.7	82.0
5-9	88.2	88.3	86.7	89.8	89.8	90.1	90.9	95.5	93.9	91.7	90.4	95.0	93.6	87.8	94.9	93.8	90.0	95.4	95.5	92.8
10-14	88.1	85.5	91.0	91.5	91.0	90.6	92.2	95.4	90.1	88.8	89.5	92.1	87.8	90.0	92.8	93.4	92.9	92.5	92.2	93.5
15-19	89.6	87.8	88.6	89.0	87.0	85.0	87.7	88.4	88.5	89.5	89.8	87.7	91.1	88.9	90.2	90.4	88.0	89.6	88.1	88.4
20-29	77.6	76.2	78.7	76.0	76.2	75.7	78.6	77.0	78.7	77.8	77.6	78.6	78.8	79.7	79.8	78.9	81.4	82.0	81.8	82.9
30-39	65.0	65.9	64.1	65.5	65.1	64.5	66.0	63.8	67.5	67.9	67.4	66.2	66.5	67.7	67.3	67.8	68.6	70.2	70.1	70.6
40-49	55.7	55.4	55.5	53.7	56.8	56.5	57.0	58.2	58.5	57.3	58.1	56.9	58.5	58.5	58.5	59.9	59.2	60.7	60.0	60.7
50-59	42.1	42.9	41.8	40.5	40.0	39.7	41.6	43.0	41.9	42.1	42.1	43.6	43.3	44.8	45.4	45.5	45.4	46.9	46.7	47.8
60-64	31.9	32.1	30.2	30.1	27.8	28.4	30.1	29.0	31.1	30.6	31.2	31.0	31.9	33.2	33.7	33.2	34.6	36.0	35.6	36.4
65-69	23.5	25.1	24.2	20.8	22.6	22.7	22.1	23.4	23.6	23.8	23.6	22.9	24.6	25.2	26.0	25.9	26.6	26.0	27.2	27.7
70-79	16.0	16.0	17.3	14.0	15.3	15.7	15.0	15.7	15.8	16.4	15.9	16.3	16.0	16.8	16.7	17.5	18.2	17.5	18.4	18.6
80+	7.4	6.4	6.2	6.4	7.4	7.8	7.6	7.6	6.9	9.0	8.9	7.8	7.7	8.1	8.4	8.9	8.7	8.3	8.4	8.4
Male	44.5	44.4	44.0	40.0	40.3	39.3	40.0	39.5	39.8	39.7	39.1	38.4	38.2	39.4	38.9	39.7	39.1	38.7	39.0	39.2
Female	44.8	45.5	43.8	39.8	40.5	39.9	39.4	38.9	39.3	38.0	37.2	36.4	36.9	36.8	36.8	36.4	36.2	36.2	36.0	36.1
White	43.3	42.8	42.4	38.0	38.3	37.8	37.6	36.5	36.0	35.7	34.7	33.9	33.8	34.3	33.9	34.0	33.6	33.2	33.8	33.9
Black	47.9	50.0	46.7	43.2	44.5	42.8	43.4	43.8	45.9	44.3	44.4	43.4	44.1	44.4	44.5	45.2	45.3	45.1	43.9	44.3
Other race	46.2	46.9	53.8	51.7	47.5	47.5	50.2	50.9	50.2	51.9	49.8	51.3	49.0	50.2	48.9	44.4	43.8	46.0	45.5	47.5
†Hispanic																	43.4	43.5	44.5	44.4
†Non-Hispanic																	37.0	36.8	36.7	36.9
Diabetes	32.1	29.8	27.3	27.8	27.3	27.3	29.2	28.4	29.6	29.4	28.5	28.8	29.3	29.9	30.3	29.9	30.0	30.0	30.2	31.1
Hypertension	48.7	43.7	41.0	37.9	37.8	37.2	35.9	35.2	36.6	35.6	35.4	34.0	34.7	34.5	34.6	36.2	35.7	34.9	34.7	34.9
Glomerulonephritis	66.2	63.7	62.0	59.4	58.2	55.9	56.7	57.1	58.0	57.4	57.4	55.9	56.9	58.9	57.6	58.5	58.3	59.4	60.2	59.2
Other cause	40.1	44.5	47.6	39.7	44.2	44.4	45.0	45.6	44.5	46.2	46.5	46.8	46.2	47.4	47.1	46.0	45.7	46.4	46.6	46.2
All	44.6	44.9	43.9	39.9	40.4	39.6	39.7	39.2	39.6	38.9	38.3	37.5	37.6	38.1	37.9	38.1	37.7	37.5	37.6	37.8
ADJUSTED																				
0-19	80.7	77.9	79.9	80.2	78.7	77.3	79.7	82.3	80.0	80.6	80.8	82.9	79.3	84.0	83.6	81.7	83.6	82.4	83.0	83.0
20-44	61.5	62.4	62.7	62.3	63.9	63.4	65.2	64.0	65.8	66.5	66.5	65.6	66.0	66.6	67.0	67.0	67.9	69.1	68.6	69.2
45-64	36.0	36.7	36.7	36.0	35.8	36.2	38.4	39.1	40.1	40.4	40.6	41.8	42.7	44.1	44.9	45.4	45.8	47.5	47.2	48.3
65-74	19.3	20.6	20.9	17.4	19.3	19.7	19.1	20.6	21.1	21.5	21.6	21.2	22.6	23.1	23.6	24.1	24.9	24.3	25.6	26.3
75+	10.7	10.8	10.8	8.9	10.4	11.0	10.9	10.7	10.3	12.1	11.1	11.6	10.7	11.6	11.4	12.3	12.7	12.2	12.8	12.8
Male	31.3	31.2	31.7	29.8	30.8	31.0	32.3	32.4	33.2	34.5	34.3	34.6	34.9	36.5	36.7	37.5	38.1	38.3	38.9	39.9
Female	32.8	34.3	34.0	32.5	33.8	34.0	34.6	35.1	35.5	35.7	35.7	35.9	36.8	37.0	37.7	37.8	38.3	38.8	38.9	39.2
White	29.5	29.6	30.5	28.7	29.9	30.4	31.1	31.3	31.7	33.1	32.6	33.0	33.7	34.7	35.2	35.7	36.4	36.6	37.5	38.1
Black	37.5	38.7	36.2	34.7	35.8	34.9	36.4	37.0	38.4	37.5	38.3	38.2	38.7	39.4	39.7	40.7	41.1	41.5	40.7	41.1
Other race	31.7	35.3	36.8	38.1	34.8	37.6	40.4	41.5	41.9	45.2	43.7	46.5	45.3	46.6	46.2	43.9	44.1	46.7	45.9	48.7
Diabetes	24.7	22.9	21.7	22.5	22.7	23.2	25.1	25.3	26.6	27.0	26.9	27.7	28.6	29.7	30.4	30.4	31.1	31.4	32.0	33.1
Hypertension	42.2	39.5	38.7	37.2	37.5	38.1	37.9	38.2	39.0	39.2	39.5	38.9	39.2	39.7	40.0	41.4	41.8	41.6	41.7	42.0
Glomerulonephritis	46.4	45.8	44.9	43.6	43.7	42.4	43.8	44.3	45.6	46.1	45.8	46.0	46.5	48.4	48.3	49.0	49.7	50.3	51.1	51.2
Other cause	33.3	35.4	37.9	34.2	37.4	37.5	38.6	39.2	38.2	40.3	39.8	40.3	40.3	41.2	41.3	41.0	41.2	42.2	42.3	42.1
All	32.0	32.7	32.8	31.1	32.2	32.4	33.4	33.7	34.3	35.1	35.0	35.3	35.8	36.8	37.2	37.7	38.2	38.6	39.0	39.6

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.7

Ten-year survival probabilities: incident ESRD patients

from day 91 to ten years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	76.1	69.7	76.5	72.4	72.9	73.9	75.4	75.6	66.9	74.3	71.4	72.5	76.7	74.6	76.1
5-9	80.6	80.9	80.0	83.0	86.1	83.2	86.8	83.9	89.9	85.1	86.0	90.0	90.4	80.2	89.2
10-14	79.1	77.4	77.5	82.5	82.8	82.5	85.8	89.4	81.5	80.7	81.4	86.7	81.6	83.8	82.4
15-19	80.0	79.7	80.0	81.0	78.8	76.7	78.9	78.8	80.7	83.5	82.7	79.1	80.8	80.1	82.6
20-29	64.5	62.1	65.3	63.6	63.8	64.1	65.7	65.1	67.0	64.6	65.8	64.8	66.1	69.0	68.7
30-39	47.1	47.6	47.9	49.2	48.9	47.4	49.4	47.7	49.5	50.0	50.6	49.6	50.5	50.9	50.5
40-49	33.5	32.6	33.7	33.9	36.0	35.7	36.3	36.3	36.6	34.7	36.2	34.9	37.2	37.4	37.4
50-59	16.6	17.9	18.3	16.6	17.3	18.1	18.9	19.9	18.2	18.4	18.5	19.6	19.5	19.8	21.3
60-64	8.7	8.7	7.2	8.8	8.6	9.5	9.1	8.9	9.5	9.0	9.0	9.4	10.0	10.4	11.0
65-69	4.8	5.7	4.5	4.9	5.6	6.3	5.2	4.9	5.3	5.0	5.4	4.8	5.1	5.8	5.7
70-79	2.8	2.4	2.9	2.4	2.9	2.9	2.4	2.8	2.6	2.3	2.1	2.0	2.2	2.5	2.3
80+	1.9	1.0	1.6	0.2	1.4	0.8	0.9	0.7	0.6	0.7	0.5	0.6	0.6	0.7	0.7
Male	25.4	25.4	25.9	23.5	24.0	23.4	23.8	22.9	22.4	21.8	22.0	20.7	21.2	21.6	21.1
Female	25.6	25.5	24.6	22.1	22.8	22.3	21.3	20.6	20.9	19.4	18.6	18.2	18.3	18.2	18.3
White	26.0	25.4	25.5	22.9	23.3	22.8	22.4	21.6	20.6	19.6	19.4	18.4	18.5	18.7	18.3
Black	24.1	25.2	23.6	21.6	22.6	22.1	22.0	21.2	21.9	21.1	20.6	21.4	21.2	21.7	21.7
Other race	27.3	29.3	37.2	34.3	34.0	31.8	33.6	31.1	32.0	30.4	31.1	30.1	28.1	29.3	27.5
Diabetes	14.2	12.8	12.2	11.8	12.1	12.4	12.7	12.1	11.9	11.6	10.8	10.6	10.9	11.2	11.5
Hypertension	26.4	22.0	19.9	18.7	18.8	17.7	17.5	15.8	17.1	16.1	16.2	15.5	16.4	15.9	16.1
Glomerulonephritis	47.7	43.8	42.7	40.9	40.6	39.9	40.0	39.3	39.9	39.0	39.3	37.3	39.7	40.6	39.5
Other cause	21.5	25.2	28.7	24.3	27.7	28.2	28.5	29.4	28.7	29.2	30.6	31.0	30.1	31.2	30.9
All	25.5	25.4	25.3	22.9	23.5	22.9	22.7	21.8	21.7	20.7	20.4	19.6	19.8	20.0	19.8
ADJUSTED															
0-19	68.1	66.5	66.9	69.2	68.9	66.7	70.4	71.1	69.5	72.3	71.6	70.8	71.9	69.9	73.2
20-44	43.7	43.4	45.2	45.7	46.9	46.7	47.9	46.8	48.2	48.5	49.0	48.1	49.2	49.9	50.2
45-64	13.3	13.9	14.6	14.4	15.2	15.9	17.0	17.4	17.3	17.4	17.6	18.5	19.6	20.2	21.5
65-74	3.7	4.0	3.7	3.6	4.4	4.9	4.1	4.2	4.3	4.2	4.5	4.0	4.5	4.9	4.9
75+	2.0	1.7	1.9	1.0	1.8	1.5	1.4	1.6	1.5	1.4	0.9	1.2	1.1	1.4	1.3
Male	14.9	14.8	15.7	15.2	16.0	16.6	17.1	16.9	16.8	17.1	17.6	17.3	18.1	18.8	18.9
Female	16.1	16.7	16.7	16.3	17.4	17.5	17.3	17.5	17.8	17.5	17.3	17.7	18.1	18.5	19.0
White	15.0	14.8	15.7	15.3	16.2	16.6	16.7	17.0	16.8	17.0	17.2	17.3	18.0	18.7	19.0
Black	15.4	16.0	15.3	14.9	15.7	15.9	16.2	15.9	16.6	16.2	16.1	16.3	16.8	17.0	17.6
Other race	15.5	18.9	20.8	20.8	21.5	21.5	23.0	21.6	23.2	23.2	24.4	24.6	24.3	25.1	24.3
Diabetes	10.2	9.5	9.5	9.4	10.0	10.5	10.8	10.9	10.8	10.7	10.6	10.8	11.3	12.0	12.5
Hypertension	21.2	19.2	18.7	18.7	18.8	18.8	19.0	18.5	19.0	18.9	19.1	18.9	19.6	19.7	20.2
Glomerulonephritis	26.0	24.8	24.5	24.3	25.4	25.6	26.1	25.5	26.3	26.3	26.0	26.2	27.7	28.3	28.2
Other cause	16.2	17.6	19.8	18.7	20.9	21.2	21.4	22.3	21.8	22.6	23.2	23.6	23.3	24.2	24.2
All	15.5	15.7	16.1	15.7	16.7	17.0	17.2	17.2	17.3	17.3	17.4	17.5	18.1	18.6	19.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age > 110, are excluded.

Table I.8

Incident patient counts: dialysis patients, unknowns dropped

dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	27	44	59	81	80	104	98	95	97	111	94
5-9	61	56	69	65	76	55	79	75	67	78	91
10-14	130	135	173	159	149	148	127	133	139	118	148
15-19	331	371	351	369	337	343	326	337	388	408	377
20-29	1,218	1,383	1,579	1,540	1,700	1,729	1,790	1,773	1,922	2,098	2,175
30-39	1,868	2,096	2,375	2,459	2,661	2,840	3,025	3,200	3,586	3,953	4,130
40-49	2,109	2,409	2,573	2,891	3,021	3,307	3,502	3,927	4,422	5,055	5,472
50-59	3,242	3,890	4,229	4,379	4,647	4,993	5,193	5,612	6,471	7,048	7,538
60-64	1,814	2,113	2,463	2,860	3,160	3,511	3,650	4,132	4,532	4,993	5,515
65-69	1,743	1,841	2,146	2,821	2,952	3,347	3,848	4,366	4,943	5,764	6,405
70-79	1,923	2,087	2,691	3,818	3,984	4,676	5,359	6,176	6,812	8,235	9,238
80+	318	339	492	770	815	1,037	1,268	1,448	1,798	2,266	2,641
Male	8,168	9,179	10,416	12,079	12,951	14,021	15,260	16,750	18,655	21,450	23,293
Female	6,616	7,585	8,784	10,133	10,631	12,069	13,005	14,524	16,522	18,677	20,531
White	10,186	11,448	13,125	14,827	15,751	17,379	18,881	20,639	22,920	26,082	28,559
Black	4,238	4,881	5,584	6,772	7,135	7,895	8,439	9,561	10,931	12,672	13,577
Other race	360	435	491	613	696	816	945	1,074	1,326	1,373	1,688
†Hispanic											
†Non-Hispanic											
Diabetes	2,472	3,685	4,820	5,657	6,865	7,930	9,138	10,449	11,951	14,461	16,607
Hypertension	2,953	4,220	5,378	5,877	6,594	7,537	8,173	9,429	10,917	12,713	13,889
Glomerulonephritis	2,591	3,403	3,940	4,152	4,431	4,644	4,853	5,263	5,694	5,963	6,341
Cystic kidney	748	897	1,041	1,051	1,076	1,149	1,188	1,238	1,255	1,286	1,381
Other urologic	419	612	780	886	876	1,055	1,062	1,173	1,202	1,220	1,146
Other cause	1,632	1,991	2,514	2,754	2,910	3,133	3,215	3,208	3,502	4,056	4,170
Missing cause	3,969	1,956	727	1,835	830	642	636	514	656	428	290
All	14,784	16,764	19,200	22,212	23,582	26,090	28,265	31,274	35,177	40,127	43,824

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.8 (continued)

Incident patient counts: dialysis patients, unknowns dropped*patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis*

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	132	113	126	107	127	128	128	136	122	150	153	142	147
5-9	67	66	72	107	91	91	85	87	103	98	97	106	84
10-14	163	174	165	182	179	192	189	176	200	205	197	239	234
15-19	367	433	409	368	422	432	413	421	447	431	418	411	433
20-29	2,202	2,351	2,359	2,373	2,286	2,308	2,255	2,315	2,220	2,268	2,247	2,180	2,129
30-39	4,355	4,713	4,769	5,055	4,974	5,067	5,049	4,975	5,227	5,002	4,983	4,980	4,995
40-49	6,190	6,692	7,166	7,539	8,063	8,601	8,649	9,334	9,499	9,714	9,673	9,970	10,245
50-59	8,203	9,091	9,617	10,792	10,959	11,559	12,620	13,634	14,706	15,117	15,807	16,430	17,027
60-64	6,060	6,349	6,674	7,069	7,328	7,648	8,093	8,564	8,770	8,991	9,307	9,523	10,093
65-69	7,101	7,731	8,018	8,608	8,565	9,377	9,635	9,914	10,036	10,072	10,333	10,579	10,815
70-79	10,856	12,181	12,832	14,295	14,600	16,459	17,624	18,643	19,721	20,107	20,213	21,305	21,192
80+	3,062	3,643	3,968	4,481	4,792	5,690	6,454	7,072	8,007	8,607	8,978	10,486	10,738
Male	25,788	28,039	29,731	32,039	32,669	35,804	37,672	39,834	42,059	43,010	44,090	46,773	47,535
Female	22,970	25,498	26,444	28,937	29,717	31,748	33,522	35,437	36,999	37,752	38,316	39,578	40,597
White	31,623	34,533	35,820	38,762	38,939	42,446	44,867	47,129	50,083	51,486	52,270	54,706	55,603
Black	15,256	16,805	17,880	19,358	19,882	21,049	22,090	23,536	24,039	24,093	24,880	26,056	26,671
Other race	1,879	2,199	2,475	2,856	3,565	4,057	4,237	4,606	4,936	5,183	5,256	5,589	5,858
†Hispanic						7,969	8,214	8,690	9,624	11,086	10,408	11,235	11,875
†Non-Hispanic						59,583	62,980	66,581	69,434	69,676	71,998	75,116	76,257
Diabetes	19,061	21,289	22,722	25,292	27,530	30,809	33,129	35,265	37,091	38,598	39,631	41,050	41,915
Hypertension	15,502	17,358	18,039	19,468	17,441	18,568	19,738	20,794	22,024	22,397	23,090	24,522	25,563
Glomerulonephritis	6,626	6,791	7,031	7,565	7,632	8,012	7,933	8,010	8,019	7,798	7,646	7,839	7,515
Cystic kidney	1,443	1,523	1,605	1,676	1,700	1,654	1,754	1,851	1,907	1,862	1,862	1,852	1,854
Other urologic	1,317	1,404	1,211	1,249	1,767	2,013	2,038	2,065	2,472	2,278	2,323	2,484	2,394
Other cause	4,553	4,977	5,274	5,621	6,215	6,417	6,536	7,208	7,441	7,726	7,762	8,429	8,533
Missing cause	256	195	293	105	101	79	66	78	104	103	92	175	358
All	48,758	53,537	56,175	60,976	62,386	67,552	71,194	75,271	79,058	80,762	82,406	86,351	88,132

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.9

90-day survival probabilities: incident dialysis patients

censored at transplant, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	97.4	100.0	100.0	100.0	97.8	100.0	96.6	95.6	97.3	96.0	85.1
5-9	100.0	98.6	100.0	98.6	98.9	98.7	100.0	100.0	96.2	97.8	92.9
10-14	100.0	100.0	100.0	100.0	98.9	100.0	100.0	100.0	100.0	99.3	91.0
15-19	99.7	99.5	100.0	99.5	99.7	99.7	100.0	99.1	99.1	99.1	93.4
20-29	99.3	99.2	99.5	98.9	98.7	99.3	99.2	99.0	98.9	98.7	98.0
30-39	98.3	98.8	98.7	99.0	98.6	98.5	97.9	98.0	98.2	98.1	97.4
40-49	98.5	98.0	98.4	97.7	98.2	98.0	98.1	97.8	98.1	97.8	97.2
50-59	97.3	97.2	96.7	96.3	97.1	96.3	96.6	96.8	96.7	96.8	96.3
60-64	94.8	95.1	94.7	94.8	95.1	94.2	93.8	95.0	94.5	94.8	94.1
65-69	90.5	91.1	90.0	91.5	89.8	90.2	91.6	91.2	92.2	92.0	92.1
70-79	87.1	88.3	87.6	88.4	87.7	87.2	87.9	89.3	88.2	88.6	89.0
80+	84.1	84.9	84.8	83.0	83.6	82.6	84.4	83.6	85.7	83.8	83.8
Male	94.8	95.0	94.4	94.0	94.0	93.3	93.4	93.6	93.5	93.4	92.9
Female	95.0	95.5	95.0	94.4	94.1	93.8	94.0	94.2	94.2	93.8	93.5
White	94.3	94.6	93.8	93.1	93.1	92.4	92.6	92.8	92.7	92.3	92.0
Black	96.3	96.5	96.8	96.6	96.1	95.9	95.9	96.0	96.1	96.1	95.4
Other race	94.5	96.9	95.8	95.2	96.5	95.5	96.6	97.4	96.1	96.4	96.0
†Hispanic											
†Non-Hispanic											
Diabetes	96.5	95.5	95.0	94.4	94.8	94.4	94.5	94.6	94.7	94.6	94.4
Hypertension	95.8	94.9	93.5	93.4	92.9	92.6	92.7	92.4	92.6	92.2	91.5
Glomerulonephritis	98.3	97.7	97.1	97.1	96.7	96.6	96.0	95.9	96.5	95.7	95.2
Other cause	93.0	94.1	94.0	93.2	92.8	91.7	92.3	93.5	92.5	92.5	92.1
All	94.9	95.2	94.7	94.2	94.1	93.5	93.7	93.9	93.9	93.6	93.2
ADJUSTED											
0-19	98.8	99.2	99.5	99.2	98.4	99.5	98.6	98.6	97.5	97.1	83.9
20-44	98.8	98.8	98.8	98.8	98.7	98.6	98.4	98.2	98.5	98.2	97.6
45-64	97.2	97.0	96.6	96.1	96.6	95.9	95.9	96.4	96.1	96.2	95.6
65-74	90.9	91.1	89.9	91.4	89.8	89.7	90.9	91.3	91.3	91.5	91.4
75+	87.6	88.2	87.8	87.1	87.2	86.3	86.9	87.3	87.4	86.5	87.0
Male	94.2	94.1	93.3	93.5	93.4	92.7	93.0	93.3	93.2	93.2	92.7
Female	94.4	94.6	94.0	94.0	93.5	93.2	93.7	93.9	93.9	93.6	93.3
White	93.5	93.6	92.6	92.6	92.5	91.9	92.4	92.7	92.8	92.5	92.3
Black	96.0	95.6	95.8	96.2	95.1	95.0	95.0	95.2	95.2	95.2	94.3
Other race	93.9	96.3	94.7	94.5	95.7	94.3	95.8	96.8	95.3	95.6	95.2
Diabetes	94.8	93.5	93.0	92.4	93.1	92.7	93.1	93.4	93.7	93.7	93.6
Hypertension	94.9	94.2	93.0	93.2	92.9	92.8	93.2	93.0	93.3	93.1	92.6
Glomerulonephritis	96.9	96.1	95.3	95.6	95.2	95.3	94.6	94.5	95.3	94.5	94.0
Other cause	91.8	92.7	92.6	92.6	92.1	90.8	91.7	93.0	91.9	92.0	91.5
All	94.3	94.3	93.6	93.7	93.4	92.9	93.3	93.6	93.6	93.4	93.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.9 (continued)

90-day survival probabilities: incident dialysis patients*censored at transplant, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	97.3	96.7	97.2	96.8	96.5	97.8	97.1	96.0	93.5	96.9	96.4	97.4	96.3
5-9	98.8	100.0	100.0	99.2	99.1	98.0	100.0	100.0	98.2	99.1	98.2	98.4	100.0
10-14	97.4	100.0	99.5	98.1	99.5	100.0	99.1	100.0	99.6	99.1	99.6	99.6	100.0
15-19	98.8	99.8	99.3	98.6	99.8	99.2	99.3	99.4	98.6	99.2	98.3	99.2	97.9
20-29	98.3	97.9	98.4	97.7	97.2	98.3	98.1	98.6	98.4	98.3	98.7	98.2	98.5
30-39	97.7	97.5	97.2	97.0	97.4	97.2	97.6	97.6	97.8	97.5	97.8	97.7	97.7
40-49	97.9	97.6	97.2	96.9	96.7	96.7	96.6	96.8	96.6	96.9	96.8	96.6	96.8
50-59	96.7	96.9	96.0	95.7	95.8	95.8	96.0	95.6	95.2	95.7	95.2	95.7	95.2
60-64	94.5	94.5	94.4	93.7	93.8	93.8	93.6	93.4	93.8	93.7	93.4	93.8	93.9
65-69	92.1	92.4	92.8	92.5	92.6	92.8	92.0	92.2	92.4	91.9	92.3	92.5	92.6
70-79	89.5	89.6	89.0	89.5	89.1	89.0	88.5	88.7	88.7	88.8	88.2	88.7	88.5
80+	84.9	85.3	84.6	83.9	83.7	84.3	82.9	82.3	82.4	82.7	82.3	83.0	82.6
Male	93.3	93.2	93.1	92.7	92.8	92.6	92.2	92.0	92.0	92.2	91.7	92.1	91.7
Female	93.8	94.0	93.3	93.1	92.8	92.8	92.2	92.2	92.0	91.8	91.8	91.7	91.8
White	92.4	92.5	92.0	91.8	91.6	91.5	90.9	90.9	90.8	90.9	90.5	90.6	90.5
Black	95.7	95.6	95.3	94.9	94.9	94.8	94.5	94.3	94.3	94.0	93.8	94.1	93.9
Other race	96.5	95.9	95.5	95.2	94.3	94.0	94.1	94.1	93.6	94.3	94.1	95.0	94.6
†Hispanic						94.7	94.3	94.1	94.4	93.9	93.8	94.5	94.2
†Non-Hispanic						92.4	91.9	91.9	91.6	91.7	91.4	91.5	91.4
Diabetes	94.6	94.8	94.2	94.2	93.7	93.7	93.4	93.2	93.1	92.9	92.8	93.1	93.1
Hypertension	91.9	92.0	91.9	91.5	91.6	91.8	90.8	90.8	90.7	90.8	90.4	90.6	90.8
Glomerulonephritis	96.0	96.1	95.8	95.4	96.0	95.5	95.3	94.9	95.1	95.8	95.4	95.8	95.6
Other cause	92.6	92.1	91.6	90.8	90.5	89.8	89.3	89.9	89.6	89.8	89.2	89.1	88.4
All	93.6	93.5	93.2	92.9	92.8	92.7	92.2	92.1	92.0	92.0	91.7	91.9	91.8
ADJUSTED													
0-19	96.5	98.8	98.2	96.2	98.2	98.1	98.0	98.0	96.3	97.7	96.7	98.0	96.9
20-44	98.0	97.8	97.7	97.3	97.4	97.5	97.7	97.8	97.8	97.8	97.9	97.8	97.9
45-64	96.1	96.1	95.6	95.1	95.2	95.2	95.2	95.0	94.9	95.2	94.8	95.2	95.0
65-74	91.5	91.8	91.8	91.9	91.5	91.6	91.0	91.3	91.3	91.1	90.9	91.3	91.5
75+	87.8	87.7	86.9	86.7	86.7	86.8	85.8	85.5	85.7	85.9	85.4	85.9	85.4
Male	93.2	93.1	93.0	92.7	92.8	92.8	92.6	92.5	92.6	92.8	92.3	92.8	92.5
Female	93.8	94.0	93.4	93.2	93.0	93.1	92.7	92.8	92.6	92.6	92.6	92.6	92.7
White	92.8	93.0	92.6	92.5	92.4	92.5	92.1	92.1	92.2	92.3	92.1	92.2	92.2
Black	94.8	94.6	94.4	93.9	94.0	93.9	93.7	93.5	93.5	93.3	93.0	93.5	93.3
Other race	95.9	95.2	94.9	94.6	93.8	93.5	93.6	93.6	93.3	94.0	93.8	94.8	94.5
Diabetes	94.0	94.2	93.7	93.8	93.4	93.5	93.4	93.2	93.2	93.1	93.1	93.5	93.4
Hypertension	93.1	93.1	93.2	92.9	93.0	93.3	92.7	92.7	92.7	92.8	92.5	92.8	92.8
Glomerulonephritis	95.1	95.2	94.8	94.5	95.3	94.8	94.5	94.1	94.5	95.1	94.6	95.1	94.8
Other cause	92.0	91.6	90.9	90.1	90.1	89.5	89.3	89.8	89.7	89.9	89.3	89.3	88.7
All	93.5	93.5	93.2	93.0	92.9	93.0	92.6	92.6	92.6	92.7	92.4	92.7	92.6

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.10

One-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	96.2	92.7	89.4	89.8	85.3	85.2	89.0	90.8	79.4	83.6	79.3
5-9	92.9	92.3	95.9	98.1	90.2	89.9	100.0	100.0	98.4	98.6	93.6
10-14	96.4	98.5	97.8	98.4	96.8	97.7	98.9	99.0	95.6	97.1	95.5
15-19	96.0	94.6	95.4	94.6	96.8	93.5	94.5	95.6	97.8	98.4	97.1
20-29	90.8	92.5	92.3	92.6	92.4	90.8	93.2	90.7	91.8	91.1	91.1
30-39	89.1	89.0	88.1	89.4	87.1	88.0	87.9	87.4	88.2	87.8	88.8
40-49	87.7	87.4	86.4	87.3	87.4	87.0	86.4	86.9	87.7	87.7	88.3
50-59	83.7	83.6	83.9	81.5	81.7	82.0	82.1	83.1	83.4	83.1	83.9
60-64	78.5	77.7	78.3	77.7	75.9	76.3	76.9	76.1	77.0	77.6	78.1
65-69	72.7	73.6	73.7	72.1	73.0	71.2	73.0	73.0	73.4	74.0	75.5
70-79	67.1	67.7	68.7	65.3	66.6	66.8	66.1	65.3	66.1	67.4	68.4
80+	57.7	53.2	62.3	55.3	56.3	57.9	58.6	55.2	55.4	58.0	59.5
Male	80.3	80.8	80.4	77.7	77.6	77.1	76.7	76.8	76.7	77.4	78.3
Female	81.3	80.8	81.0	78.7	78.8	78.2	78.6	77.1	78.5	78.2	78.5
White	78.9	78.9	78.7	75.8	75.5	75.1	74.9	73.9	74.4	74.9	75.4
Black	84.9	85.2	84.8	82.9	83.5	82.7	82.6	82.9	83.2	82.7	83.5
Other race	81.7	81.0	84.4	81.6	82.2	81.8	84.8	81.2	84.1	84.2	86.0
†Hispanic											
†Non-Hispanic											
Diabetes	74.6	73.9	72.9	73.2	73.3	72.9	73.9	74.0	75.6	76.2	76.3
Hypertension	83.9	82.0	80.6	78.6	77.8	78.5	77.3	76.1	76.4	76.8	77.6
Glomerulonephritis	90.6	88.7	87.9	87.2	86.7	86.7	85.0	84.9	85.8	85.3	86.1
Other cause	78.4	80.0	82.4	76.9	78.1	76.5	77.9	76.8	76.5	76.8	78.2
All	80.7	80.8	80.7	78.2	78.2	77.6	77.6	76.9	77.6	77.7	78.4
ADJUSTED											
0-19	92.3	91.0	91.6	91.0	89.8	87.1	91.1	92.8	90.2	92.7	89.2
20-44	87.6	88.6	88.2	88.6	87.7	87.7	87.9	87.3	88.2	87.6	88.5
45-64	81.1	80.7	81.2	80.1	79.7	80.0	80.5	80.7	81.4	82.0	82.6
65-74	70.3	70.8	72.4	69.3	70.4	69.4	70.3	70.4	71.1	71.9	73.4
75+	61.2	61.7	62.4	59.0	61.1	62.2	61.9	59.4	60.0	62.5	63.4
Male	75.1	75.7	75.8	73.8	73.8	73.9	74.0	74.2	74.3	75.5	76.7
Female	76.4	76.1	77.1	75.6	76.1	75.8	76.8	75.7	77.1	77.4	78.1
White	73.0	73.3	74.0	72.0	72.1	72.3	72.8	72.2	73.0	74.3	75.1
Black	81.2	80.9	80.8	79.5	79.9	79.2	79.5	79.8	80.1	79.7	80.8
Other race	75.9	76.1	78.8	77.3	77.7	78.5	82.3	78.3	81.7	82.2	84.6
Diabetes	70.2	69.5	69.0	69.5	69.9	69.7	71.3	71.5	73.4	74.3	74.7
Hypertension	81.3	80.2	79.4	78.1	77.4	78.8	78.3	77.5	77.7	78.5	79.6
Glomerulonephritis	86.1	84.2	83.6	83.1	82.9	83.6	81.8	81.6	82.6	82.7	83.5
Other cause	75.8	76.5	79.5	75.6	76.4	74.6	76.4	75.5	74.9	75.4	76.6
All	75.7	75.9	76.4	74.7	74.9	74.8	75.3	74.9	75.6	76.4	77.3

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.10 (continued)

One-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	77.7	86.2	82.8	85.7	84.9	87.4	86.0	85.4	81.9	79.7	85.1	88.4	89.2
5-9	95.7	94.1	92.2	100.0	97.8	91.8	97.4	100.0	96.9	94.6	96.9	91.2	96.6
10-14	97.1	92.1	94.3	98.7	97.4	95.9	96.3	97.2	96.7	96.3	97.6	94.8	98.6
15-19	95.6	96.6	96.3	95.3	97.2	96.3	97.8	95.5	97.3	97.3	96.9	96.8	97.6
20-29	92.0	92.7	91.8	91.7	91.5	93.3	94.8	94.2	94.7	92.9	94.2	93.2	93.0
30-39	88.0	88.6	87.9	88.7	87.2	89.2	90.1	90.1	90.0	90.1	90.4	90.6	90.9
40-49	86.8	87.2	88.0	87.7	88.5	88.8	89.4	88.2	88.9	88.8	88.3	88.0	88.2
50-59	83.7	84.8	84.7	85.6	85.3	85.0	85.3	85.0	85.5	85.0	85.3	85.2	84.9
60-64	79.0	79.1	80.8	80.6	79.8	81.4	81.6	79.8	80.9	80.5	81.3	80.5	81.6
65-69	75.1	75.5	77.1	76.3	76.9	77.8	76.7	76.3	76.4	76.9	76.6	76.5	77.2
70-79	68.2	68.5	69.9	70.0	70.2	70.9	69.8	69.9	69.6	69.5	69.7	69.5	69.8
80+	59.2	58.4	60.9	61.0	60.4	60.2	59.5	57.5	58.5	57.9	57.9	58.9	59.2
Male	77.8	77.8	79.1	78.9	78.6	79.2	78.8	78.3	78.5	78.1	78.4	77.8	78.2
Female	78.0	78.4	78.8	78.8	78.8	78.9	78.2	77.3	77.3	77.0	77.0	76.7	77.1
White	74.7	74.8	76.0	76.1	76.1	76.4	75.4	75.0	75.3	75.0	74.8	74.6	75.1
Black	83.1	83.6	83.6	83.2	82.8	83.6	83.7	82.5	82.4	81.7	82.4	81.6	81.4
Other race	86.9	85.8	86.8	85.7	83.9	82.8	84.0	82.6	82.8	83.4	84.7	83.7	84.8
†Hispanic						83.5	82.7	83.0	82.5	83.2	83.5	82.6	83.2
†Non-Hispanic						78.4	78.0	77.2	77.3	76.7	76.9	76.5	76.8
Diabetes	76.8	77.0	78.7	78.4	78.3	78.5	77.9	77.2	77.8	77.7	77.9	77.6	78.2
Hypertension	76.8	77.0	77.3	77.6	78.3	78.3	77.3	76.7	76.5	76.4	76.3	76.3	76.2
Glomerulonephritis	84.6	86.1	87.5	85.9	86.3	87.2	87.3	87.4	86.5	87.0	87.0	86.8	87.2
Other cause	77.2	77.1	77.0	77.3	75.7	76.5	76.8	75.8	75.8	74.4	74.8	73.7	74.4
All	77.9	78.1	79.0	78.9	78.7	79.0	78.5	77.8	77.9	77.6	77.7	77.3	77.7
ADJUSTED													
0-19	87.1	89.2	88.2	91.5	91.4	90.3	92.2	90.5	91.2	89.1	91.3	90.3	93.7
20-44	87.8	88.1	87.6	88.2	87.7	89.4	90.1	89.6	89.9	89.7	89.8	89.6	90.0
45-64	82.7	83.5	84.3	84.6	84.4	84.9	85.4	84.4	85.2	84.8	85.1	84.8	84.9
65-74	73.1	73.6	75.5	74.6	75.3	76.2	75.2	75.1	75.3	75.4	75.2	74.9	75.6
75+	63.4	62.9	64.2	65.0	64.6	64.9	64.0	63.2	63.4	63.2	63.4	63.8	64.0
Male	76.5	76.8	78.3	78.3	78.1	79.2	79.2	78.7	79.3	79.0	79.2	79.0	79.3
Female	77.9	78.5	78.9	79.2	79.4	79.7	79.4	78.6	78.7	78.7	78.8	78.7	79.0
White	74.9	75.3	76.8	77.1	77.3	78.0	77.5	77.2	77.7	77.6	77.5	77.5	78.0
Black	80.7	81.3	81.2	81.0	80.7	81.8	82.2	81.0	80.8	80.4	81.0	80.4	80.2
Other race	85.6	84.7	85.9	84.9	83.7	83.0	84.3	82.7	83.3	83.8	84.9	84.1	85.3
Diabetes	75.5	75.9	77.7	77.7	77.5	78.1	77.8	77.1	77.9	78.0	78.2	78.0	78.7
Hypertension	79.1	79.2	79.8	80.1	80.8	81.1	80.4	80.1	80.0	80.0	79.9	80.2	80.0
Glomerulonephritis	82.1	83.7	85.2	83.9	84.2	85.6	85.5	85.5	85.0	85.2	85.0	85.1	85.4
Other cause	75.7	75.7	75.3	75.8	74.6	75.6	76.2	75.2	75.3	74.1	74.5	73.6	74.1
All	77.2	77.6	78.6	78.7	78.7	79.5	79.3	78.7	79.0	78.8	79.0	78.9	79.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.11

Two-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	84.5	90.0	86.2	82.5	83.2	77.7	79.5	80.3	71.3	77.0	71.1
5-9	89.2	92.3	91.1	89.2	85.7	89.9	86.2	100.0	98.4	95.5	86.3
10-14	95.0	94.8	94.3	96.9	90.8	94.9	95.6	99.0	90.2	95.9	90.8
15-19	94.2	90.2	91.8	90.1	93.6	90.7	90.0	93.7	94.0	95.9	94.1
20-29	82.7	84.6	84.6	83.4	84.0	80.7	84.9	81.7	85.2	84.5	83.7
30-39	78.6	79.7	77.4	80.0	75.7	75.6	75.5	76.5	78.4	77.9	78.5
40-49	76.3	75.7	75.4	74.8	75.1	75.1	74.0	74.2	76.0	75.6	78.0
50-59	70.6	70.3	70.4	67.6	66.6	66.6	66.7	67.3	67.9	69.2	69.3
60-64	64.0	61.8	61.7	61.7	58.8	58.6	60.3	59.2	60.4	60.9	61.3
65-69	55.0	55.9	55.6	52.3	55.3	52.9	53.7	55.1	55.9	55.9	56.4
70-79	46.9	48.5	49.5	44.4	46.5	46.9	46.3	45.6	46.6	47.7	47.9
80+	30.5	33.0	38.0	30.8	36.7	35.6	35.1	32.7	33.2	37.7	37.0
Male	65.0	65.9	65.0	61.2	61.2	59.3	59.8	59.4	60.5	61.2	61.4
Female	67.7	66.9	66.4	62.8	63.0	62.7	61.8	61.3	62.6	62.5	62.4
White	63.5	63.5	62.7	58.4	58.2	57.1	56.5	56.0	56.4	57.1	57.0
Black	72.3	72.8	71.9	68.8	69.7	68.5	68.7	68.3	70.5	69.8	70.3
Other race	68.8	66.5	70.3	67.4	68.0	65.0	68.9	67.2	69.9	71.2	73.4
†Hispanic											
†Non-Hispanic											
Diabetes	56.2	54.6	52.7	54.5	52.1	52.2	53.0	53.9	56.1	57.3	57.0
Hypertension	70.8	68.3	66.5	62.9	63.5	62.3	61.2	59.9	61.2	61.4	61.1
Glomerulonephritis	80.4	78.2	76.9	75.3	75.2	72.7	71.9	72.1	73.8	72.6	74.3
Other cause	63.4	66.1	68.6	60.1	62.8	62.1	63.1	62.1	62.0	63.2	64.6
All	66.2	66.4	65.7	61.9	62.1	60.9	60.7	60.3	61.5	61.8	61.9
ADJUSTED											
0-19	88.0	84.5	85.4	83.1	83.3	81.7	81.1	88.5	83.1	87.9	81.9
20-44	75.6	78.2	77.1	77.7	75.7	74.9	75.9	75.7	77.8	77.4	78.5
45-64	67.1	65.8	66.2	64.9	63.7	63.8	64.6	64.5	65.8	67.2	67.8
65-74	51.1	52.5	53.8	48.9	51.9	50.4	51.0	51.9	53.1	53.5	54.0
75+	39.0	41.5	40.6	36.5	40.4	40.9	40.2	38.1	38.9	42.1	41.7
Male	58.0	59.1	58.7	56.1	56.6	55.5	56.8	56.3	57.6	59.1	59.7
Female	61.0	60.5	61.2	58.9	59.7	59.9	59.7	59.9	61.0	61.9	62.1
White	55.7	56.3	56.6	53.8	54.4	54.3	54.5	54.6	55.5	57.3	57.4
Black	66.7	66.2	65.7	63.8	64.3	63.4	64.3	63.9	65.9	65.4	66.3
Other race	60.6	59.9	61.9	61.1	61.8	60.7	65.1	63.4	66.4	68.6	71.3
Diabetes	50.7	49.3	48.0	50.0	48.3	48.6	49.9	51.1	53.4	55.1	55.1
Hypertension	67.1	65.9	65.2	62.5	63.5	63.4	63.3	62.4	63.5	64.3	64.4
Glomerulonephritis	72.7	71.2	70.5	69.3	69.9	68.4	67.6	67.8	69.5	68.9	70.6
Other cause	60.1	61.7	64.5	58.9	60.9	60.1	61.6	60.7	60.2	61.8	62.8
All	59.4	59.8	59.9	57.4	58.0	57.6	58.2	58.0	59.3	60.4	60.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.11 (continued)

Two-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	75.0	83.0	76.6	77.5	79.4	82.4	80.3	80.2	80.7	69.9	77.4	79.0
5-9	95.7	94.1	85.8	96.0	95.3	89.8	97.4	93.9	92.8	94.6	93.5	85.8
10-14	96.0	87.7	90.5	96.6	94.3	93.0	92.2	93.4	96.7	94.7	93.1	92.0
15-19	91.6	94.6	91.7	93.0	93.9	90.3	92.7	92.2	92.7	91.5	93.4	94.7
20-29	84.3	85.8	85.9	86.0	85.3	87.5	88.7	89.4	89.4	87.2	88.5	87.3
30-39	77.1	78.6	78.8	78.5	78.8	80.1	81.9	81.3	82.2	82.4	82.9	83.4
40-49	74.4	76.6	76.3	77.1	78.3	78.2	79.4	78.5	78.8	78.8	78.7	78.6
50-59	69.5	70.8	71.2	72.5	71.8	72.3	72.4	71.5	72.8	72.6	72.9	73.3
60-64	62.2	62.5	64.9	65.0	64.0	66.1	66.1	64.5	66.3	66.2	67.0	66.3
65-69	56.5	58.0	59.8	58.7	59.4	60.6	58.9	59.1	59.3	60.7	61.7	60.7
70-79	48.3	49.0	50.0	50.3	50.7	51.7	49.9	51.0	51.0	50.6	51.7	51.5
80+	36.0	36.9	37.6	38.6	38.4	38.3	37.1	37.1	37.3	37.3	37.5	38.5
Male	61.0	61.8	63.1	63.1	63.2	63.6	63.0	63.0	63.4	63.4	63.7	63.2
Female	61.5	62.7	62.8	63.0	62.8	63.4	62.1	61.7	61.9	61.4	62.5	61.9
White	56.3	57.2	58.0	58.3	58.4	58.8	57.5	57.8	58.5	58.3	58.6	58.3
Black	69.3	70.6	70.8	70.7	70.4	71.5	71.1	69.9	69.7	69.4	70.4	69.4
Other race	74.9	73.7	74.9	72.7	70.6	69.6	70.8	69.8	71.0	70.9	73.6	71.7
†Hispanic						69.3	68.6	69.2	69.8	70.9	71.1	70.6
†Non-Hispanic						62.7	61.8	61.5	61.7	61.1	62.0	61.4
Diabetes	57.7	58.6	60.4	60.2	60.3	60.9	60.1	59.9	61.0	61.2	61.9	61.4
Hypertension	60.6	61.6	61.4	62.4	63.1	63.2	61.5	61.6	61.4	61.2	61.7	61.4
Glomerulonephritis	71.6	74.1	75.6	74.5	75.1	75.9	76.0	76.8	75.7	76.4	77.4	76.7
Other cause	63.0	63.6	63.6	63.8	62.2	63.0	63.0	62.4	62.6	61.0	62.1	61.0
All	61.2	62.2	62.9	63.1	63.0	63.5	62.6	62.4	62.7	62.5	63.1	62.6
ADJUSTED												
0-19	82.4	85.3	80.4	85.9	85.4	82.3	84.5	84.0	86.1	81.1	84.2	84.5
20-44	76.6	78.0	77.6	78.4	78.6	80.0	81.7	80.9	81.6	81.5	81.5	81.5
45-64	67.9	69.2	70.5	71.3	70.9	71.9	72.3	71.3	72.5	72.6	73.0	73.0
65-74	54.4	55.7	57.0	56.4	57.6	58.5	57.0	57.7	58.1	58.4	59.7	58.8
75+	41.7	42.2	43.1	43.9	43.3	44.5	42.8	43.4	43.6	43.5	44.0	44.3
Male	59.7	60.7	62.4	62.6	62.9	64.0	63.8	64.0	64.9	65.0	65.2	65.1
Female	61.9	63.2	63.4	64.0	64.1	65.0	64.2	63.9	64.3	64.2	65.3	65.1
White	57.4	58.7	59.8	60.5	60.9	61.8	61.1	61.6	62.5	62.6	62.9	63.1
Black	65.8	67.1	67.4	67.5	67.5	68.9	68.8	67.6	67.4	67.5	68.5	67.8
Other race	73.2	72.2	73.7	71.7	70.6	70.2	71.5	70.3	72.0	71.7	74.0	72.7
Diabetes	56.1	57.3	59.2	59.3	59.5	60.5	60.1	60.0	61.3	61.8	62.5	62.3
Hypertension	64.3	65.1	65.4	66.3	67.0	67.6	66.5	66.7	66.7	66.7	67.0	67.3
Glomerulonephritis	68.3	70.8	72.2	71.8	72.0	73.5	73.3	74.1	73.6	73.8	74.3	74.3
Other cause	61.4	62.1	61.7	62.1	61.2	62.1	62.5	61.8	62.2	60.9	61.9	61.1
All	60.7	61.9	62.9	63.3	63.5	64.5	64.0	64.0	64.6	64.6	65.3	65.1

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.12

Three-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to three years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	84.5	85.9	86.2	75.1	73.9	77.7	76.8	69.7	65.9	70.5	68.6
5-9	89.2	92.3	91.1	80.3	85.7	83.5	86.2	89.5	91.4	95.5	78.8
10-14	95.0	86.1	94.3	92.8	90.8	90.3	89.3	90.2	87.9	94.0	89.3
15-19	90.0	86.8	91.0	88.7	91.9	86.7	83.8	90.1	90.8	89.6	90.6
20-29	77.2	79.2	78.5	77.3	76.2	73.2	76.9	75.8	79.5	78.4	77.0
30-39	72.8	72.0	66.6	71.5	67.0	66.3	66.2	66.9	70.3	69.4	70.0
40-49	67.1	66.6	65.8	63.9	64.3	64.7	63.2	64.0	66.0	64.7	67.1
50-59	59.6	58.9	57.9	55.5	54.6	53.3	53.6	55.2	55.6	56.6	57.0
60-64	51.7	49.6	48.2	48.6	45.7	45.4	46.0	45.9	47.7	47.6	47.9
65-69	40.4	42.8	42.1	38.3	41.3	39.5	39.8	41.1	42.4	41.5	41.7
70-79	33.5	33.8	34.9	30.0	32.2	32.4	31.8	31.8	32.9	33.7	33.1
80+	18.3	20.4	19.0	18.2	21.3	21.6	20.7	21.1	20.0	22.9	22.2
Male	53.7	53.9	52.2	48.1	48.3	45.5	45.8	46.7	47.8	48.3	48.2
Female	56.6	55.8	53.8	50.5	50.3	50.4	49.0	48.7	50.5	49.3	49.2
White	51.9	51.2	49.7	45.2	45.0	43.3	42.3	42.5	42.9	43.1	42.6
Black	61.9	63.0	59.7	56.9	57.6	56.6	56.7	57.1	60.0	58.4	59.0
Other race	58.2	53.2	58.2	56.6	54.7	52.4	55.1	55.4	58.5	59.6	62.2
†Hispanic											
†Non-Hispanic											
Diabetes	42.1	41.3	38.1	39.2	37.5	37.3	38.3	39.7	41.6	42.0	42.2
Hypertension	60.3	57.1	53.4	51.0	50.1	49.9	48.2	47.6	49.3	49.3	48.5
Glomerulonephritis	72.2	68.3	66.5	65.8	64.7	59.6	59.9	60.9	63.3	60.9	62.7
Other cause	52.1	54.6	56.6	47.4	51.3	50.4	50.2	50.7	51.1	52.2	52.6
All	55.0	54.8	52.9	49.3	49.2	47.8	47.3	47.6	49.1	48.8	48.7
ADJUSTED											
0-19	83.4	77.5	84.6	78.2	80.1	75.8	73.6	79.1	77.5	80.2	76.7
20-44	68.4	69.8	67.1	68.7	66.3	64.8	66.2	66.3	69.2	68.6	69.4
45-64	55.3	53.9	53.3	52.0	50.9	50.6	51.0	52.0	53.4	54.3	55.1
65-74	37.2	38.7	39.2	34.5	38.1	36.8	36.5	37.9	39.5	39.3	39.3
75+	25.5	27.4	26.0	23.1	25.0	26.2	26.3	25.6	25.3	28.1	26.8
Male	46.3	46.7	45.8	43.1	43.9	42.3	43.3	44.0	45.2	46.6	46.8
Female	49.3	49.0	48.3	46.6	47.2	47.8	47.3	47.8	49.2	49.2	49.4
White	43.7	43.8	43.6	41.0	41.9	41.3	41.3	42.0	42.8	44.2	44.0
Black	55.4	55.3	52.6	51.2	51.6	51.0	51.9	52.3	54.8	53.6	54.4
Other race	49.4	46.7	48.7	49.7	47.9	48.1	51.2	51.3	54.7	57.1	60.0
Diabetes	36.8	36.2	33.8	35.0	34.3	34.4	35.6	37.3	39.2	40.2	40.6
Hypertension	56.2	54.7	52.6	51.0	50.8	51.8	51.2	51.0	52.3	53.0	52.8
Glomerulonephritis	62.8	60.1	59.3	59.1	59.0	55.2	55.6	56.4	58.7	57.1	58.6
Other cause	48.7	50.1	52.3	46.5	49.7	48.8	49.2	49.7	49.7	51.2	51.0
All	47.7	47.8	47.0	44.8	45.4	44.9	45.2	45.8	47.1	47.9	48.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.12 (continued)

Three-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to three years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	69.9	78.8	69.7	75.7	77.5	74.3	74.3	80.2	78.0	65.8	73.2
5-9	95.7	90.2	77.4	90.7	95.3	86.6	97.4	91.2	89.6	92.2	90.0
10-14	89.3	82.9	84.6	87.9	91.1	89.2	89.3	93.4	95.2	93.4	91.7
15-19	89.4	92.8	88.3	90.9	89.9	87.6	90.2	88.2	88.1	88.6	88.6
20-29	78.8	79.7	80.2	80.2	80.4	82.7	84.0	84.3	83.9	82.2	82.8
30-39	68.6	69.2	70.8	70.9	71.0	73.3	74.4	74.4	75.2	75.9	75.9
40-49	64.0	65.8	66.2	67.4	68.5	68.8	70.0	68.9	69.6	69.3	69.9
50-59	57.1	57.5	58.8	59.7	59.8	60.1	60.8	60.4	61.5	61.7	62.2
60-64	48.7	48.7	50.7	51.7	50.6	52.1	53.4	52.2	53.1	53.5	54.0
65-69	42.2	43.3	45.1	44.6	45.5	45.8	45.3	45.5	45.7	47.3	47.9
70-79	34.1	34.0	35.6	35.2	35.8	36.9	35.6	36.4	36.7	37.1	38.2
80+	21.9	22.8	23.0	23.3	23.3	24.4	23.1	22.4	23.1	23.8	23.8
Male	48.1	48.0	49.9	50.0	50.5	50.7	50.4	50.6	51.0	51.3	51.5
Female	48.5	49.4	49.8	49.8	49.7	50.2	49.7	49.1	49.3	49.5	50.5
White	42.3	42.5	43.8	43.9	44.3	44.6	43.9	44.3	44.8	45.2	45.5
Black	58.1	58.9	59.5	59.5	59.4	60.5	60.4	58.8	59.0	59.2	59.8
Other race	63.4	62.1	63.0	61.9	58.3	57.9	58.9	58.6	60.1	60.4	63.0
†Hispanic						57.0	57.1	57.8	58.3	60.5	60.2
†Non-Hispanic						49.6	49.2	48.8	49.1	48.8	49.7
Diabetes	42.8	43.4	45.2	45.6	45.6	46.2	46.2	45.9	47.0	47.7	48.8
Hypertension	48.1	48.5	48.8	49.2	50.6	50.8	49.4	49.5	49.4	49.5	49.4
Glomerulonephritis	61.2	62.6	65.1	64.3	64.7	65.2	66.5	66.6	65.2	67.3	67.8
Other cause	52.0	52.0	53.0	52.9	51.8	52.2	52.4	52.0	52.4	51.2	51.9
All	48.3	48.7	49.8	49.9	50.1	50.5	50.1	49.9	50.2	50.4	51.0
ADJUSTED											
0-19	77.4	80.9	73.4	79.9	79.8	77.0	80.1	79.6	80.4	77.0	78.1
20-44	67.9	68.7	69.0	70.0	70.4	72.4	73.8	73.3	73.8	73.8	73.9
45-64	55.4	55.9	57.8	58.9	58.9	59.6	60.8	60.1	61.2	61.6	62.0
65-74	40.0	41.0	42.5	41.9	43.3	44.1	43.1	43.8	44.4	45.2	46.5
75+	27.8	27.4	28.7	28.9	28.4	29.8	28.8	28.9	29.2	29.9	30.1
Male	47.4	47.4	49.6	49.9	50.5	51.6	51.7	52.0	53.0	53.4	53.6
Female	49.4	50.5	51.0	51.4	51.7	52.6	52.5	52.1	52.5	53.1	54.1
White	44.4	45.0	46.7	47.2	47.9	48.8	48.7	49.3	50.0	50.6	51.1
Black	54.2	54.9	55.6	55.8	56.1	57.4	57.7	56.3	56.4	57.0	57.7
Other race	61.8	60.7	61.8	61.0	58.6	58.8	60.1	59.4	61.5	61.7	63.7
Diabetes	41.6	42.5	44.4	45.0	45.1	46.2	46.5	46.4	47.7	48.6	49.8
Hypertension	52.9	53.1	53.8	54.2	55.5	56.4	55.4	55.7	55.7	56.1	55.9
Glomerulonephritis	57.9	59.0	61.3	61.3	61.2	62.4	63.4	63.3	62.8	64.3	64.2
Other cause	50.7	50.7	51.4	51.4	50.9	51.6	52.2	51.6	52.2	51.4	51.8
All	48.3	48.9	50.3	50.6	51.1	52.1	52.1	52.1	52.7	53.3	53.9

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.13

Five-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	84.5	79.3	86.2	75.1	66.5	67.7	72.0	69.7	65.9	70.5	58.8	63.6	68.2	63.6	66.9	70.8	66.7	72.0	71.9	78.0
5-9	89.2	92.3	69.4	80.3	85.7	74.2	80.8	89.5	91.4	76.4	78.8	95.7	78.2	71.9	88.0	79.2	86.6	97.4	87.0	85.5
10-14	82.3	76.9	88.1	92.8	84.5	90.3	79.4	86.6	73.4	85.3	84.5	83.3	78.5	77.7	80.6	86.0	86.4	86.9	82.8	81.3
15-19	87.0	81.8	79.9	85.4	84.3	73.1	75.5	83.6	79.3	79.7	84.2	82.1	87.0	79.3	83.3	85.7	81.5	84.2	79.1	78.7
20-29	73.3	67.9	68.9	65.3	62.7	60.3	66.2	64.7	68.4	65.1	66.1	67.2	69.1	70.5	71.1	71.9	73.9	74.4	74.2	76.9
30-39	59.7	59.5	52.9	56.0	54.1	52.3	51.6	50.2	55.9	56.5	55.0	54.6	55.9	58.1	57.6	58.2	59.7	61.8	61.2	62.7
40-49	52.9	50.4	49.8	46.7	48.7	47.7	47.1	48.1	49.4	47.1	48.6	47.3	48.7	49.1	50.3	52.0	51.5	52.9	51.9	53.3
50-59	40.5	40.5	39.4	37.0	35.6	34.7	36.1	37.2	36.3	36.2	36.1	37.7	37.6	39.2	39.7	40.0	39.9	40.9	40.9	42.2
60-64	31.8	31.4	29.5	29.2	26.4	26.7	28.2	26.6	28.7	28.0	28.6	28.4	29.1	30.5	31.0	29.8	31.4	32.6	32.2	33.3
65-69	23.5	25.0	24.2	20.6	22.3	22.2	21.7	22.8	22.8	22.8	22.7	21.7	23.7	24.0	24.8	24.4	25.0	24.3	25.7	25.6
70-79	16.0	16.0	17.3	13.9	15.2	15.6	14.9	15.6	15.7	16.3	15.7	16.1	15.9	16.7	16.5	17.2	17.9	17.2	18.1	18.1
80+	7.5	6.4	6.2	6.4	7.4	7.8	7.4	7.6	6.9	9.0	8.9	7.8	7.7	8.1	8.4	8.9	8.7	8.3	8.3	8.4
Male	37.1	35.4	34.0	30.1	29.6	28.2	28.7	29.0	29.9	30.0	29.7	29.6	29.7	31.1	31.4	32.1	31.9	31.7	32.3	32.9
Female	39.0	39.4	36.5	32.9	32.6	32.0	31.2	30.9	31.8	30.5	30.4	29.6	30.3	30.6	30.8	30.6	30.8	30.7	30.6	30.8
White	35.1	33.0	31.6	27.4	26.7	25.7	25.1	24.7	24.6	24.5	23.9	23.5	23.8	24.6	24.9	25.0	25.0	24.5	25.3	25.7
Black	44.5	46.4	42.3	38.6	39.2	38.1	38.7	39.0	41.5	39.8	40.5	39.6	40.1	40.7	40.8	41.6	42.0	42.2	41.1	41.6
Other race	37.5	39.5	44.9	42.4	37.6	35.9	39.4	41.5	41.4	42.7	41.3	42.7	42.6	43.7	43.0	39.1	38.8	41.3	41.3	43.3
†Hispanic																	38.2	37.7	38.9	39.4
†Non-Hispanic																	30.5	30.4	30.5	30.8
Diabetes	26.4	23.4	19.9	20.9	19.3	18.8	20.8	20.9	22.7	22.1	22.1	22.8	23.4	24.5	25.1	25.0	25.3	25.5	26.0	27.1
Hypertension	44.3	39.4	36.1	33.5	32.4	32.3	30.6	30.3	31.8	31.1	31.0	29.9	30.5	30.5	31.0	32.6	32.5	31.7	31.6	31.9
Glomerulonephritis	56.7	52.9	49.7	46.1	45.0	40.9	42.1	43.3	44.3	43.7	44.5	43.9	44.4	47.1	46.2	47.8	47.8	48.4	49.6	48.5
Other cause	34.1	36.9	38.8	30.9	33.9	34.2	34.0	34.3	33.7	35.5	35.4	35.2	35.7	37.2	37.3	36.2	36.4	37.1	36.9	36.8
All	38.0	37.3	35.2	31.5	31.0	30.0	29.9	29.9	30.8	30.3	30.0	29.6	30.0	30.8	31.1	31.4	31.4	31.2	31.5	31.9
ADJUSTED																				
0-19	75.8	69.2	69.4	75.1	70.3	61.4	63.1	72.3	64.4	67.4	68.6	68.1	71.5	62.5	69.5	72.1	69.4	73.6	66.7	68.1
20-44	56.7	55.7	52.7	52.1	52.0	49.8	51.9	51.1	53.8	54.0	54.2	53.2	54.6	55.3	56.4	57.0	58.0	59.5	59.1	60.7
45-64	36.2	35.4	34.8	33.2	31.8	31.7	33.3	33.3	34.3	34.2	34.6	35.8	36.2	38.1	38.8	39.1	39.6	41.1	40.8	42.3
65-74	20.1	21.1	21.3	17.6	19.4	19.7	19.0	20.3	20.7	20.9	21.0	20.4	21.9	22.2	22.7	22.9	23.8	23.0	24.3	24.6
75+	11.1	11.1	11.1	9.2	10.7	11.1	11.0	10.8	10.4	12.2	11.1	11.7	10.7	11.6	11.4	12.2	12.7	12.2	12.7	12.7
Male	30.5	29.3	29.0	26.5	26.7	26.7	27.6	27.8	28.5	29.7	29.4	30.0	30.1	31.8	32.1	32.8	33.6	33.7	34.4	35.6
Female	32.4	33.1	32.0	30.1	30.6	30.5	30.7	31.1	31.6	31.4	31.5	31.5	32.5	32.7	33.4	33.5	34.1	34.4	34.6	34.8
White	28.1	27.0	27.2	24.9	25.3	25.5	25.6	25.8	26.1	27.2	26.7	27.0	27.7	28.8	29.4	29.7	30.6	30.5	31.5	32.2
Black	37.6	38.4	35.2	33.3	33.8	33.0	34.4	34.8	36.4	35.2	36.2	36.1	36.4	37.1	37.4	38.5	39.0	39.5	38.7	39.1
Other race	29.9	33.8	35.6	35.9	31.7	32.8	36.2	37.9	38.1	40.9	39.8	42.4	42.3	43.2	42.9	40.3	40.7	43.3	43.0	45.5
Diabetes	22.4	19.9	17.5	18.4	17.8	17.8	19.5	19.8	21.4	21.5	21.6	22.6	23.4	24.6	25.3	25.4	26.1	26.5	27.1	28.4
Hypertension	40.5	37.5	36.4	34.6	34.2	35.2	34.7	35.0	35.7	35.9	36.2	35.7	36.0	36.4	36.8	38.2	38.8	38.4	38.7	39.0
Glomerulonephritis	46.1	44.2	42.7	40.1	40.2	37.8	38.8	39.6	40.8	40.8	40.9	41.6	41.5	43.6	43.6	44.3	45.1	45.2	46.3	46.1
Other cause	31.5	33.2	35.3	30.7	33.3	33.4	34.0	34.2	33.1	35.4	34.6	34.7	35.2	36.2	36.4	35.8	36.3	37.3	37.0	37.0
All	31.4	31.1	30.4	28.2	28.6	28.5	29.1	29.4	30.0	30.5	30.4	30.7	31.3	32.2	32.7	33.1	33.8	34.0	34.5	35.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.14

Ten-year survival probabilities: incident dialysis patients*censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	72.4	68.0	69.0	62.6	58.2	37.0	72.0	62.0	42.8	70.5	44.8	58.7	59.1	57.0	61.8
5-9	89.2	71.2	52.1	80.3	85.7	59.4	80.8	78.3	91.4	66.9	67.5	28.7	70.3	35.9	75.7
10-14	61.4	57.8	63.0	83.0	66.0	82.1	61.3	86.6	54.5	64.5	58.0	72.2	64.2	71.7	57.1
15-19	78.3	63.9	64.6	73.8	64.8	59.0	58.8	58.6	68.5	68.2	65.0	67.5	63.9	65.3	72.9
20-29	54.1	47.2	47.8	46.2	44.5	43.5	45.8	45.1	46.7	44.1	45.9	44.9	48.0	52.3	52.0
30-39	38.5	36.2	31.5	33.8	33.0	30.8	29.4	29.2	30.8	33.4	32.3	32.3	33.1	34.2	32.7
40-49	26.5	23.7	23.4	22.7	24.8	22.2	21.2	22.3	24.0	20.3	21.7	20.1	22.2	22.1	23.0
50-59	13.7	14.1	14.3	11.9	11.7	12.6	11.8	12.0	11.3	11.1	10.9	11.8	11.5	11.3	12.7
60-64	8.3	8.0	6.5	7.6	7.1	7.7	7.3	6.6	7.2	6.3	6.3	6.6	6.7	7.4	7.7
65-69	4.7	5.5	4.3	4.7	5.2	5.8	4.7	4.3	4.5	4.2	4.6	3.9	4.3	4.8	4.5
70-79	2.8	2.4	2.9	2.4	2.9	2.8	2.3	2.7	2.5	2.2	2.0	1.9	2.1	2.3	2.1
80+	1.9	1.0	1.6	0.2	1.3	0.8	0.8	0.7	0.6	0.7	0.4	0.6	0.6	0.7	0.7
Male	14.4	12.8	12.0	10.8	11.0	10.5	10.3	10.2	10.1	9.7	10.1	9.5	10.1	10.3	10.5
Female	16.3	15.6	13.5	12.3	12.0	11.7	10.3	9.9	10.8	9.8	9.1	9.0	9.1	9.5	9.5
White	14.1	11.8	10.9	9.4	9.4	8.8	7.8	7.8	7.4	6.6	6.7	6.3	6.6	6.8	6.9
Black	17.9	18.8	16.0	15.1	15.0	15.2	14.5	13.8	15.5	15.0	14.2	14.1	14.5	14.6	14.7
Other race	16.0	18.3	20.3	18.5	19.1	15.0	18.0	16.6	16.7	15.8	16.7	15.8	15.6	17.4	16.3
Diabetes	8.3	6.0	5.0	4.9	4.9	4.8	4.6	4.9	5.1	4.3	4.5	4.5	4.5	4.8	5.3
Hypertension	18.6	15.3	12.1	12.2	11.6	11.1	10.3	9.4	10.5	10.2	9.6	9.6	10.0	10.0	10.4
Glomerulonephritis	31.3	25.3	21.3	20.0	20.4	19.3	18.9	18.6	18.6	18.5	19.2	17.9	20.3	21.4	19.8
Other cause	12.3	13.6	15.3	12.4	13.5	14.0	13.2	13.9	14.4	14.3	14.8	14.9	15.1	16.2	16.1
All	15.3	14.2	12.7	11.5	11.5	11.1	10.3	10.0	10.4	9.7	9.6	9.3	9.6	9.9	10.0
ADJUSTED															
0-19	59.6	46.7	45.4	60.3	49.6	44.9	47.4	51.2	49.9	52.7	47.1	50.4	48.9	47.8	52.9
20-44	35.3	31.7	29.3	30.3	30.6	28.9	28.8	28.6	29.6	30.2	30.2	29.6	30.8	31.6	31.6
45-64	11.6	11.1	11.1	10.1	10.2	10.6	10.5	10.4	10.7	10.0	10.3	10.9	11.2	11.5	12.7
65-74	4.0	4.2	3.8	3.7	4.3	4.8	3.9	3.9	3.9	3.7	3.9	3.4	3.9	4.2	4.0
75+	2.1	1.8	2.0	1.1	1.8	1.5	1.4	1.6	1.5	1.4	0.9	1.2	1.1	1.3	1.2
Male	11.8	10.6	10.7	10.0	10.7	11.2	11.0	10.8	10.5	10.6	10.9	10.8	11.3	11.7	11.8
Female	13.2	13.0	12.3	11.8	12.3	12.2	11.2	11.5	12.1	11.6	11.1	11.4	11.7	12.1	12.3
White	11.2	10.0	10.2	9.4	10.1	10.4	9.8	10.0	9.7	9.6	9.7	9.6	10.2	10.6	10.9
Black	13.9	14.1	12.6	12.5	12.7	12.9	12.4	12.3	13.2	12.6	12.4	12.6	12.7	13.0	13.2
Other race	11.9	15.2	15.8	15.3	15.7	14.0	16.9	15.6	15.5	16.5	16.5	17.5	17.3	18.6	17.7
Diabetes	7.0	5.4	4.8	4.7	5.1	5.3	4.9	5.2	5.4	4.7	5.0	5.1	5.3	5.8	6.2
Hypertension	17.5	15.7	14.4	14.6	14.5	14.8	14.4	14.1	14.3	14.4	14.0	14.1	14.6	14.7	15.2
Glomerulonephritis	22.6	19.6	18.2	17.1	18.7	18.7	18.0	17.4	17.9	17.8	17.6	17.7	19.0	19.6	18.8
Other cause	12.1	12.7	14.4	12.9	14.3	14.8	14.2	14.8	14.7	15.1	15.1	15.4	15.5	16.2	15.8
All	12.4	11.8	11.5	10.9	11.4	11.7	11.1	11.1	11.2	11.0	11.0	11.1	11.4	11.9	12.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

Table I.15

Incident patient counts: hemodialysis patients, unknowns dropped

patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	14	13	11	14	*	19	24	16	16	26	23
5-9	36	34	33	21	20	11	18	26	16	20	32
10-14	104	96	91	83	61	77	59	61	61	58	62
15-19	304	326	270	276	248	243	224	228	284	288	252
20-29	1,093	1,185	1,310	1,244	1,320	1,374	1,371	1,337	1,429	1,605	1,623
30-39	1,597	1,752	1,887	1,890	2,075	2,147	2,273	2,405	2,729	2,943	3,031
40-49	1,847	2,087	2,057	2,302	2,378	2,549	2,673	3,019	3,447	3,852	4,196
50-59	2,825	3,322	3,493	3,556	3,723	3,965	4,129	4,465	5,256	5,638	5,925
60-64	1,631	1,790	2,051	2,356	2,612	2,830	2,961	3,314	3,701	4,107	4,460
65-69	1,545	1,578	1,836	2,416	2,418	2,617	3,036	3,464	4,017	4,744	5,232
70-79	1,682	1,826	2,296	3,260	3,372	3,789	4,386	5,016	5,654	6,973	7,751
80+	276	290	417	657	677	829	1,045	1,232	1,535	1,966	2,312
Male	7,222	7,928	8,637	9,900	10,379	11,024	11,998	13,149	14,943	17,159	18,530
Female	5,732	6,371	7,115	8,175	8,534	9,426	10,201	11,434	13,202	15,061	16,369
White	8,818	9,582	10,583	11,790	12,318	13,138	14,403	15,715	17,737	20,260	21,963
Black	3,820	4,314	4,740	5,752	6,028	6,607	7,004	7,954	9,263	10,796	11,481
Other race	316	403	429	533	567	705	792	914	1,145	1,164	1,455
†Hispanic											
†Non-Hispanic											
Diabetes	2,019	2,981	3,743	4,358	5,331	6,084	7,050	8,077	9,474	11,530	13,153
Hypertension	2,588	3,663	4,527	4,913	5,515	6,139	6,662	7,760	9,078	10,593	11,472
Glomerulonephritis	2,237	2,916	3,231	3,348	3,510	3,594	3,742	4,024	4,359	4,547	4,809
Cystic kidney	668	752	871	878	843	903	920	945	973	981	1,017
Other urologic	366	530	650	741	719	842	875	981	1,008	1,046	947
Other cause	1,418	1,713	2,089	2,211	2,321	2,418	2,497	2,439	2,776	3,199	3,275
Missing cause	3,658	1,744	641	1,626	674	470	453	357	477	324	226
All	12,954	14,299	15,752	18,075	18,913	20,450	22,199	24,583	28,145	32,220	34,899

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.15 (continued)

Incident patient counts: hemodialysis patients, unknowns dropped*patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis*

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	18	17	25	18	27	12	32	20	26	31	35	28	27
5-9	19	17	20	34	34	27	28	35	40	35	39	47	29
10-14	53	81	75	82	77	77	89	87	102	107	109	135	121
15-19	260	282	272	240	287	304	292	312	350	322	323	328	344
20-29	1,626	1,744	1,758	1,775	1,779	1,816	1,838	1,936	1,902	1,939	1,950	1,905	1,885
30-39	3,117	3,432	3,482	3,710	3,786	4,034	4,135	4,159	4,401	4,295	4,312	4,317	4,369
40-49	4,557	5,057	5,423	5,774	6,282	6,949	7,223	8,009	8,196	8,471	8,536	8,914	9,132
50-59	6,447	7,066	7,625	8,538	8,855	9,555	10,686	11,792	12,890	13,400	14,024	14,717	15,335
60-64	4,865	5,068	5,425	5,727	6,028	6,521	7,078	7,601	7,790	8,040	8,421	8,641	9,218
65-69	5,653	6,229	6,435	6,953	7,021	7,917	8,349	8,728	8,862	8,928	9,312	9,541	9,788
70-79	8,871	9,955	10,689	11,617	12,418	14,122	15,576	16,728	17,694	18,141	18,551	19,619	19,574
80+	2,636	3,127	3,438	3,813	4,222	5,065	5,844	6,538	7,402	7,968	8,407	9,880	10,134
Male	19,986	21,933	23,574	25,301	26,483	29,837	32,381	34,933	37,105	38,244	39,670	42,290	43,149
Female	18,136	20,142	21,093	22,980	24,333	26,562	28,789	31,012	32,550	33,433	34,349	35,782	36,807
White	23,736	26,036	27,439	29,568	30,651	34,222	37,421	40,327	43,146	44,825	46,174	48,770	49,765
Black	12,823	14,222	15,166	16,382	17,232	18,750	20,078	21,590	22,106	22,267	23,151	24,317	24,907
Other race	1,563	1,817	2,062	2,331	2,933	3,427	3,671	4,028	4,403	4,585	4,694	4,985	5,284
†Hispanic						6,766	7,179	7,712	8,610	9,969	9,519	10,213	10,882
†Non-Hispanic						49,633	53,991	58,233	61,045	61,708	64,500	67,859	69,074
Diabetes	14,825	16,580	18,048	20,005	22,378	25,669	28,493	30,931	32,737	34,367	35,815	37,223	38,261
Hypertension	12,660	14,333	14,942	16,019	14,762	16,145	17,498	18,717	19,885	20,310	21,190	22,619	23,614
Glomerulonephritis	4,885	4,999	5,269	5,588	5,824	6,230	6,397	6,587	6,720	6,535	6,468	6,734	6,400
Cystic kidney	1,026	1,072	1,141	1,193	1,246	1,227	1,338	1,491	1,511	1,502	1,486	1,515	1,482
Other urologic	1,081	1,126	969	1,008	1,446	1,726	1,758	1,848	2,204	2,013	2,083	2,242	2,178
Other cause	3,456	3,833	4,092	4,403	5,081	5,346	5,635	6,308	6,523	6,866	6,904	7,613	7,712
Missing cause	189	132	206	65	79	56	51	63	75	84	73	126	309
All	38,122	42,075	44,667	48,281	50,816	56,399	61,170	65,945	69,655	71,677	74,019	78,072	79,956

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.16

90-day survival probabilities: incident hemodialysis patients

censored at transplant, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	100.0	100.0	100.0	100.0	*	100.0	100.0	100.0	100.0	93.2	96.0
5-9	100.0	100.0	100.0	96.0	100.0	100.0	100.0	100.0	100.0	100.0	97.1
10-14	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
15-19	100.0	99.7	100.0	99.7	100.0	100.0	99.6	100.0	100.0	100.0	99.6
20-29	99.8	99.7	99.9	99.7	99.6	99.8	99.7	99.7	99.4	99.5	99.5
30-39	99.5	99.6	99.2	99.4	99.3	99.2	98.9	98.9	99.3	99.3	98.8
40-49	99.3	98.9	99.4	98.8	99.2	99.2	99.1	98.9	99.0	99.0	98.9
50-59	98.8	98.6	98.5	98.5	98.8	98.3	98.4	98.6	98.8	98.7	98.2
60-64	97.9	97.8	97.8	97.5	98.0	97.7	97.2	97.4	97.6	98.0	97.2
65-69	96.5	96.6	96.6	96.2	95.6	95.9	96.4	96.0	96.9	96.6	96.6
70-79	95.4	95.9	95.6	95.5	94.5	94.4	94.7	95.0	94.2	94.6	95.2
80+	94.8	95.0	94.1	93.1	92.7	91.9	93.0	91.7	93.6	92.4	93.0
Male	98.1	98.1	97.8	97.5	97.4	97.3	97.1	97.1	97.0	97.0	97.0
Female	98.2	98.1	98.1	97.5	97.4	97.1	97.3	97.1	97.4	97.2	97.0
White	98.0	97.9	97.6	97.0	96.9	96.6	96.7	96.5	96.7	96.5	96.4
Black	98.5	98.6	98.7	98.4	98.2	98.2	98.1	98.1	98.1	98.1	97.9
Other race	97.6	98.2	98.2	98.0	98.4	98.5	98.2	98.2	98.3	98.5	98.5
†Hispanic											
†Non-Hispanic											
Diabetes	98.5	97.5	98.0	97.5	97.7	97.5	97.4	97.4	97.5	97.6	97.4
Hypertension	98.4	98.0	97.6	97.0	96.7	96.7	96.8	96.5	96.7	96.3	96.3
Glomerulonephritis	99.2	99.1	98.7	98.7	98.4	98.5	98.2	97.7	98.5	98.0	97.9
Other cause	97.6	98.0	97.8	97.2	97.0	96.6	96.7	96.9	96.7	96.9	96.6
All	98.1	98.1	97.9	97.5	97.4	97.2	97.2	97.1	97.2	97.1	97.0
ADJUSTED											
0-19	100.0	99.5	100.0	98.7	100.0	100.0	99.3	100.0	100.0	97.8	98.1
20-44	99.6	99.6	99.4	99.4	99.4	99.4	99.2	99.2	99.3	99.2	99.1
45-64	98.9	98.5	98.5	98.2	98.6	98.3	98.1	98.2	98.4	98.5	97.9
65-74	96.8	96.7	96.4	96.3	95.5	95.6	96.0	96.1	96.0	96.0	96.2
75+	95.6	95.9	95.5	95.2	94.2	93.7	94.3	93.5	94.1	93.8	94.3
Male	97.9	97.7	97.4	97.3	97.1	97.0	96.9	96.9	96.9	96.9	96.9
Female	98.0	97.7	97.7	97.3	97.1	96.8	97.1	97.0	97.3	97.2	96.9
White	97.7	97.5	97.2	96.9	96.7	96.5	96.6	96.5	96.8	96.6	96.6
Black	98.3	98.2	98.3	98.2	97.8	97.8	97.7	97.7	97.7	97.8	97.4
Other race	97.3	97.8	97.6	97.7	98.1	98.1	97.9	97.8	97.9	98.2	98.2
Diabetes	97.7	96.4	97.2	96.7	97.0	96.8	96.7	96.9	97.0	97.2	97.1
Hypertension	98.0	97.7	97.3	96.9	96.7	96.7	96.9	96.8	96.9	96.7	96.7
Glomerulonephritis	98.6	98.5	98.0	98.1	97.8	97.9	97.5	97.0	98.0	97.5	97.5
Other cause	97.2	97.5	97.2	97.1	96.8	96.2	96.5	96.7	96.5	96.7	96.4
All	97.9	97.7	97.5	97.3	97.1	96.9	97.0	96.9	97.1	97.0	96.9

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.16 (continued)

90-day survival probabilities: incident hemodialysis patients*censored at transplant, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	95.0	94.4	100.0	95.2	100.0	100.0	100.0	95.8	96.4	97.1	97.4	94.0	100.0
5-9	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.7	100.0	100.0	100.0	100.0
10-14	100.0	100.0	100.0	100.0	100.0	100.0	99.0	100.0	100.0	99.2	99.2	99.4	100.0
15-19	100.0	100.0	99.7	99.3	99.7	99.7	100.0	99.7	99.5	99.7	98.9	99.7	99.8
20-29	99.5	98.8	99.3	99.1	99.0	99.3	99.2	99.3	99.2	99.4	99.3	99.0	99.3
30-39	98.7	98.7	98.6	98.6	99.0	98.9	98.9	98.9	99.0	98.8	98.8	99.0	99.0
40-49	99.0	99.1	98.9	98.3	98.5	98.6	98.7	98.5	98.5	98.8	98.7	98.7	98.6
50-59	98.7	98.5	98.3	98.3	98.2	98.2	98.2	98.1	98.1	98.4	98.1	98.1	97.9
60-64	97.7	97.6	97.9	97.3	97.4	97.3	97.3	97.2	97.4	97.3	97.2	97.4	97.4
65-69	96.6	96.7	96.8	96.9	96.6	96.8	96.6	96.5	96.7	96.3	96.6	96.9	96.8
70-79	94.9	95.0	95.3	95.2	95.3	95.1	94.8	95.0	95.0	94.9	94.7	95.0	94.8
80+	92.9	93.8	93.2	93.5	92.6	93.3	92.3	92.5	92.7	92.6	92.6	92.9	92.3
Male	97.0	96.8	97.1	96.8	96.9	96.8	96.6	96.6	96.7	96.7	96.4	96.7	96.5
Female	97.0	97.2	97.0	97.0	96.7	96.8	96.5	96.4	96.4	96.4	96.5	96.4	96.2
White	96.4	96.4	96.4	96.3	96.2	96.1	95.8	95.9	96.0	96.0	95.9	96.0	95.8
Black	98.0	98.0	98.1	97.8	97.8	97.8	97.8	97.5	97.6	97.5	97.3	97.4	97.4
Other race	98.4	97.8	98.0	98.1	97.4	98.1	97.7	97.6	97.3	97.7	97.6	97.7	97.8
†Hispanic						98.0	97.8	97.4	97.5	97.3	97.3	97.6	97.4
†Non-Hispanic						96.6	96.4	96.4	96.4	96.4	96.3	96.4	96.2
Diabetes	97.6	97.5	97.5	97.6	97.2	97.3	97.2	96.9	97.0	96.9	96.9	97.1	96.9
Hypertension	96.3	96.5	96.7	96.4	96.4	96.6	96.0	96.2	96.2	96.2	96.0	96.0	96.2
Glomerulonephritis	98.2	98.1	97.8	97.8	98.4	97.8	97.8	97.6	98.0	97.9	97.9	98.2	97.9
Other cause	96.3	96.2	96.3	95.7	95.5	95.4	95.2	95.6	95.4	95.5	95.3	95.2	94.7
All	97.0	97.0	97.0	96.9	96.8	96.8	96.5	96.5	96.6	96.5	96.4	96.5	96.4
ADJUSTED													
0-19	99.3	99.4	99.4	97.6	99.4	99.5	99.4	99.0	98.3	98.6	97.3	98.4	99.6
20-44	99.0	99.0	99.0	98.7	98.8	99.0	99.1	99.0	99.1	99.1	99.0	99.0	99.1
45-64	98.4	98.2	98.2	97.9	98.0	97.9	97.9	97.8	97.9	98.1	97.9	97.9	97.8
65-74	96.0	96.2	96.3	96.5	96.1	96.0	96.1	96.2	96.1	95.9	96.0	96.2	96.3
75+	94.1	94.4	94.4	94.1	94.2	94.5	93.5	93.6	93.9	93.8	93.7	94.0	93.4
Male	97.0	96.8	97.1	96.8	97.0	96.9	96.8	96.8	97.0	96.9	96.7	97.0	96.8
Female	97.0	97.2	97.0	97.1	96.8	97.0	96.7	96.6	96.6	96.7	96.8	96.7	96.6
White	96.7	96.8	96.8	96.7	96.6	96.7	96.4	96.5	96.6	96.6	96.5	96.7	96.5
Black	97.6	97.6	97.7	97.3	97.4	97.4	97.4	97.2	97.3	97.2	97.0	97.1	97.1
Other race	98.1	97.6	97.8	97.9	97.2	98.0	97.5	97.5	97.2	97.6	97.5	97.7	97.7
Diabetes	97.3	97.3	97.3	97.4	97.1	97.2	97.1	96.8	97.0	97.0	97.0	97.2	97.0
Hypertension	96.8	96.9	97.2	96.9	96.9	97.2	96.8	96.9	97.0	97.0	96.8	96.9	97.0
Glomerulonephritis	97.8	97.7	97.4	97.5	98.1	97.5	97.5	97.3	97.7	97.6	97.5	98.0	97.6
Other cause	96.1	96.0	96.0	95.5	95.4	95.3	95.2	95.6	95.5	95.5	95.4	95.3	94.9
All	97.0	97.0	97.1	96.9	96.9	96.9	96.8	96.7	96.8	96.8	96.7	96.9	96.7

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.17

One-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	100.0	90.0	88.9	91.7	*	94.1	85.5	79.6	55.5	72.4	67.4
5-9	90.9	90.3	100.0	94.4	100.0	100.0	100.0	100.0	92.9	100.0	90.6
10-14	96.9	98.0	98.7	96.9	96.5	96.7	100.0	98.0	94.2	98.4	96.7
15-19	96.0	94.5	96.2	95.0	97.7	93.0	95.3	96.1	97.0	99.1	96.7
20-29	91.0	92.8	92.5	93.1	92.6	90.7	93.0	90.9	91.4	90.7	90.9
30-39	90.3	90.0	88.7	90.2	87.2	89.0	88.3	87.2	88.3	87.5	88.1
40-49	88.3	88.1	87.1	88.2	88.0	87.8	87.1	87.1	87.7	87.4	87.8
50-59	84.4	84.4	84.7	82.0	82.0	83.0	82.7	83.3	83.6	83.2	83.5
60-64	79.9	78.7	79.0	78.7	76.5	76.5	77.5	76.6	77.1	77.7	77.7
65-69	73.6	74.3	74.6	72.7	73.9	71.9	73.5	73.6	73.2	74.4	75.5
70-79	68.7	68.4	69.6	66.1	67.4	67.0	66.7	65.6	66.2	67.3	68.8
80+	57.6	53.4	64.9	56.8	57.7	59.2	59.5	56.1	54.7	58.9	60.0
Male	81.0	81.2	80.5	77.9	77.7	77.3	76.7	76.6	76.3	76.8	77.7
Female	82.3	81.7	82.1	79.2	79.3	78.9	79.0	77.2	78.3	77.9	77.9
White	79.8	79.5	79.2	75.8	75.4	75.0	74.8	73.5	73.5	74.1	74.4
Black	85.7	85.8	85.4	83.7	84.1	83.4	83.1	83.0	83.3	82.7	83.2
Other race	81.9	80.7	84.9	81.0	82.0	81.6	84.6	81.1	83.5	83.2	86.2
†Hispanic											
†Non-Hispanic											
Diabetes	77.0	75.2	74.0	74.2	74.1	74.0	74.6	74.4	75.4	76.0	76.1
Hypertension	85.2	82.9	81.4	79.5	78.6	78.8	77.7	76.3	76.4	76.8	77.3
Glomerulonephritis	91.3	88.7	88.1	87.0	86.7	86.6	84.5	84.2	85.1	84.3	84.9
Other cause	78.8	80.2	82.2	76.4	77.4	76.2	77.7	76.4	75.8	75.9	77.1
All	81.6	81.4	81.2	78.5	78.4	78.0	77.8	76.9	77.2	77.4	77.8
ADJUSTED											
0-19	92.3	90.0	93.7	90.4	94.7	88.7	91.9	92.0	89.8	95.1	90.1
20-44	88.5	89.4	88.7	89.2	87.8	88.2	87.9	87.0	88.1	87.1	87.9
45-64	82.3	81.7	81.9	80.8	80.2	80.6	81.1	80.9	81.4	81.8	82.0
65-74	71.9	71.5	73.5	70.3	71.4	69.7	70.7	70.9	71.0	72.0	73.4
75+	62.2	63.2	63.8	59.9	62.3	63.0	62.8	59.8	59.9	62.9	63.8
Male	76.3	76.4	76.2	74.4	74.3	74.2	74.3	74.3	74.1	75.2	76.4
Female	78.0	77.5	78.8	76.7	77.0	76.8	77.6	76.2	77.2	77.6	77.9
White	74.5	74.5	75.1	72.7	72.7	72.8	73.3	72.5	72.8	74.2	74.8
Black	82.3	81.7	81.6	80.7	80.9	80.1	80.2	80.3	80.5	80.0	80.9
Other race	76.4	75.9	79.8	76.9	78.0	78.7	82.1	78.3	81.2	81.5	85.1
Diabetes	72.8	71.1	70.3	70.8	70.9	70.9	72.1	72.0	73.3	74.3	74.6
Hypertension	82.5	81.0	80.4	79.0	78.2	79.0	78.6	77.7	77.8	78.6	79.4
Glomerulonephritis	87.2	84.4	84.3	83.3	83.5	83.7	81.7	81.3	82.2	82.0	82.8
Other cause	76.3	77.0	79.5	75.7	76.2	74.8	76.5	75.4	74.6	75.1	76.2
All	77.1	77.0	77.4	75.5	75.6	75.5	75.9	75.2	75.6	76.4	77.1

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.17 (continued)

One-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	82.1	83.0	71.6	60.3	70.9	100.0	85.5	82.7	73.6	60.6	72.6	77.7	85.1
5-9	100.0	100.0	85.4	100.0	97.0	82.4	100.0	100.0	93.9	88.9	95.1	81.7	93.9
10-14	98.0	89.1	94.3	97.2	97.4	96.6	93.2	95.1	93.1	97.1	96.6	91.9	97.2
15-19	95.0	96.3	96.3	96.6	97.1	95.3	97.7	95.0	97.2	96.9	96.4	96.3	97.4
20-29	91.8	92.0	91.6	91.5	91.1	93.0	94.0	93.9	94.1	92.6	94.0	92.9	92.6
30-39	87.1	88.2	87.2	88.3	86.4	88.6	89.7	89.5	89.2	89.2	89.7	90.0	90.5
40-49	86.0	87.1	87.8	87.5	87.7	88.3	89.1	87.6	88.4	88.2	87.5	87.6	87.6
50-59	83.5	84.7	84.9	85.6	85.1	84.8	85.0	84.8	85.1	84.6	84.8	84.7	84.5
60-64	78.6	79.1	81.5	81.0	79.8	81.5	81.5	79.9	81.1	80.3	81.2	80.1	81.2
65-69	75.2	75.4	77.1	76.7	77.1	77.8	76.7	75.9	76.3	76.6	76.5	76.2	76.8
70-79	68.3	68.8	70.6	70.5	70.2	70.7	69.8	69.9	69.3	69.2	69.4	69.3	69.6
80+	59.4	59.2	62.3	61.7	60.3	60.0	60.0	57.6	58.4	57.5	58.0	58.9	59.1
Male	77.1	77.5	78.9	78.8	78.1	78.7	78.4	77.9	78.0	77.6	77.8	77.4	77.6
Female	77.4	78.0	78.8	78.8	78.2	78.3	77.8	76.7	76.7	76.3	76.4	76.0	76.5
White	73.5	73.9	75.6	75.7	75.3	75.5	74.7	74.3	74.6	74.2	74.0	73.9	74.4
Black	82.9	83.6	83.7	83.3	82.5	83.3	83.4	82.1	82.0	81.4	82.0	81.1	81.0
Other race	86.3	85.2	86.0	85.4	82.7	82.2	83.6	81.9	82.6	82.8	84.1	83.0	84.4
†Hispanic						83.1	82.4	82.5	81.8	82.8	83.2	82.3	82.9
†Non-Hispanic						77.9	77.5	76.7	76.8	76.1	76.3	75.9	76.2
Diabetes	76.6	77.0	79.0	78.9	78.1	78.4	78.1	77.0	77.6	77.5	77.6	77.4	77.9
Hypertension	76.4	77.0	77.4	77.8	78.2	78.0	77.0	76.6	76.2	75.8	76.0	75.8	75.9
Glomerulonephritis	83.4	85.3	86.7	84.9	85.3	86.3	86.5	86.3	85.5	85.9	86.2	85.8	86.2
Other cause	76.1	75.9	76.3	76.3	74.0	75.1	75.3	74.8	74.8	73.3	73.5	72.5	73.2
All	77.2	77.7	78.9	78.8	78.2	78.5	78.1	77.3	77.4	77.0	77.2	76.7	77.1
ADJUSTED													
0-19	90.9	90.1	88.9	91.5	91.2	90.7	92.8	90.5	91.3	89.1	90.2	88.0	93.7
20-44	86.9	87.6	87.0	87.7	86.9	88.6	89.4	88.9	89.2	88.9	89.1	89.0	89.5
45-64	82.1	83.2	84.4	84.6	84.0	84.6	85.0	84.1	84.8	84.4	84.6	84.2	84.3
65-74	73.1	73.6	75.6	74.8	75.3	75.9	75.1	74.8	75.0	75.0	74.9	74.6	75.2
75+	63.4	63.4	65.2	65.7	64.4	64.7	64.2	63.2	63.2	62.8	63.3	63.6	63.9
Male	76.1	76.6	78.4	78.3	77.8	78.9	78.9	78.5	78.9	78.6	78.8	78.7	78.9
Female	77.7	78.4	79.3	79.4	79.1	79.4	79.2	78.2	78.4	78.2	78.4	78.2	78.6
White	74.4	75.1	76.9	77.1	77.0	77.6	77.2	76.9	77.3	77.1	77.1	77.2	77.6
Black	80.8	81.5	81.7	81.4	80.7	81.7	82.0	80.7	80.6	80.1	80.8	80.1	79.9
Other race	85.3	84.3	85.4	85.0	82.8	82.7	84.1	82.3	83.3	83.4	84.5	83.6	85.0
Diabetes	75.3	76.0	78.2	78.2	77.5	78.0	77.9	76.9	77.7	77.8	77.9	77.9	78.4
Hypertension	78.7	79.1	79.9	80.1	80.7	80.8	80.2	79.9	79.8	79.5	79.6	79.8	79.7
Glomerulonephritis	81.3	83.4	84.8	83.4	83.5	85.0	85.0	84.8	84.2	84.4	84.3	84.3	84.6
Other cause	75.3	75.2	75.3	75.4	73.6	74.7	75.3	74.6	74.7	73.4	73.7	72.9	73.4
All	76.9	77.5	78.8	78.9	78.5	79.1	79.1	78.4	78.7	78.4	78.7	78.5	78.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.18

Two-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	100.0	90.0	88.9	91.7	*	78.4	59.9	59.7	55.5	54.3	56.1	73.0
5-9	90.9	90.3	90.0	94.4	100.0	100.0	87.5	100.0	92.9	88.9	83.6	100.0
10-14	96.9	98.0	94.0	94.0	89.1	94.0	97.0	98.0	86.0	98.4	96.7	98.0
15-19	93.9	89.9	92.8	89.8	95.9	91.2	90.2	94.1	92.6	96.2	93.5	91.1
20-29	83.6	85.4	85.7	83.2	85.0	81.1	84.1	82.5	84.9	84.1	83.5	84.3
30-39	81.0	81.3	77.5	80.6	76.0	76.6	76.0	76.0	78.8	77.8	78.1	76.3
40-49	77.7	77.0	76.9	76.3	76.7	76.5	74.8	74.4	76.0	75.5	77.3	74.0
50-59	71.8	71.2	71.7	68.6	67.1	67.8	67.7	68.3	68.3	69.3	69.1	69.9
60-64	64.8	63.2	63.1	63.5	60.4	59.2	61.7	60.1	61.0	61.5	61.4	62.6
65-69	56.2	56.2	56.7	53.1	56.6	54.3	55.0	56.1	56.0	56.7	56.3	57.2
70-79	48.2	49.7	50.3	45.4	48.1	47.1	47.3	46.1	47.0	48.2	48.4	48.9
80+	31.5	33.5	40.5	31.0	37.8	36.0	36.5	33.6	33.4	38.7	37.0	36.5
Male	66.0	66.5	64.9	61.2	61.8	59.6	60.2	59.3	60.4	60.9	60.9	60.7
Female	69.2	68.2	68.0	63.6	63.8	63.4	62.5	61.7	62.4	62.3	61.6	61.2
White	64.7	64.3	63.2	58.2	58.5	57.1	56.9	55.8	55.6	56.3	55.8	55.4
Black	73.3	73.6	72.7	69.8	70.7	69.2	69.1	68.4	70.7	69.9	69.8	69.2
Other race	68.5	66.8	70.9	67.2	66.7	64.9	68.5	68.2	69.8	70.9	72.7	74.8
†Hispanic												
†Non-Hispanic												
Diabetes	59.3	56.5	54.2	55.7	53.9	54.0	54.1	54.8	56.4	57.8	57.1	58.3
Hypertension	72.8	69.4	67.2	64.1	64.6	62.5	61.8	60.3	61.2	61.6	60.7	60.4
Glomerulonephritis	81.2	78.3	76.9	74.8	75.3	72.8	71.5	71.3	73.7	71.4	72.3	70.5
Other cause	63.9	66.4	68.4	59.5	62.0	61.8	63.5	61.7	61.2	61.8	63.1	61.7
All	67.4	67.3	66.4	62.3	62.7	61.4	61.3	60.5	61.3	61.6	61.2	61.0
ADJUSTED												
0-19	89.7	84.1	86.6	82.5	89.8	84.4	80.5	87.2	82.2	89.0	84.8	85.0
20-44	77.6	79.6	77.8	77.8	76.0	75.5	75.5	75.4	77.8	77.0	77.8	75.7
45-64	68.5	67.1	67.6	66.2	64.8	64.6	65.8	65.2	65.9	67.1	67.4	67.9
65-74	52.9	53.3	55.1	50.0	53.5	51.1	52.1	52.6	53.2	54.0	54.1	54.8
75+	40.2	43.1	41.8	37.1	41.7	41.5	41.5	38.9	39.4	42.9	41.9	42.2
Male	59.4	59.9	59.3	56.8	57.7	56.1	57.6	56.7	57.8	59.2	59.6	59.9
Female	63.2	62.5	63.5	60.3	61.1	61.0	60.9	60.7	61.3	62.3	61.9	62.1
White	57.6	57.8	58.1	54.7	55.8	55.1	55.7	55.3	55.5	57.4	57.2	57.5
Black	68.0	67.3	66.9	65.3	65.8	64.4	65.0	64.4	66.6	66.1	66.4	66.1
Other race	60.9	60.4	63.2	61.2	61.0	61.1	64.9	64.6	66.6	68.8	71.3	73.5
Diabetes	53.7	51.2	49.7	51.3	50.2	50.3	51.1	52.0	53.7	55.8	55.3	56.8
Hypertension	68.8	66.9	66.1	63.7	64.5	63.4	63.8	62.7	63.5	64.5	64.2	64.2
Glomerulonephritis	73.9	71.6	71.3	69.3	70.9	68.9	67.9	67.4	69.8	68.4	69.5	67.9
Other cause	60.8	62.2	64.9	58.9	61.0	60.3	62.4	60.9	60.0	61.3	62.2	61.0
All	61.1	61.1	61.3	58.4	59.3	58.4	59.2	58.7	59.5	60.7	60.7	61.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.18 (continued)

Two-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	62.2	54.8	60.3	70.9	80.0	85.5	69.0	73.6	52.2	57.4	72.1
5-9	100.0	68.4	100.0	97.0	76.9	100.0	95.0	87.2	88.9	95.1	81.7
10-14	86.9	88.0	95.2	95.2	94.7	91.4	88.5	93.1	95.7	92.4	89.5
15-19	94.6	92.1	94.4	93.6	89.2	92.3	92.6	92.0	91.1	92.7	93.7
20-29	85.3	85.7	85.7	84.7	87.1	88.2	89.2	88.8	86.4	88.4	87.0
30-39	78.2	78.0	78.4	78.0	79.4	81.5	80.7	81.5	81.4	82.4	82.4
40-49	76.7	76.6	77.5	77.7	77.7	79.3	78.1	78.4	78.2	77.9	78.2
50-59	71.3	71.9	73.3	72.1	72.6	72.5	71.6	72.4	72.4	72.6	72.8
60-64	63.5	65.8	66.1	64.8	66.7	66.4	64.9	66.6	66.0	67.0	65.8
65-69	58.7	60.6	59.0	60.0	61.0	59.5	59.2	59.6	60.7	61.7	60.6
70-79	49.7	50.8	51.2	51.3	51.9	50.0	51.2	51.1	50.7	51.6	51.6
80+	38.3	39.0	39.5	38.9	38.3	37.5	37.1	37.5	37.2	37.6	38.7
Male	61.8	63.1	63.3	63.2	63.3	62.8	62.8	63.2	63.1	63.3	62.7
Female	62.6	62.9	63.2	62.5	62.9	61.8	61.2	61.4	60.8	61.8	61.3
White	56.6	57.7	58.0	58.0	58.0	56.9	57.3	57.9	57.7	57.8	57.7
Black	70.7	70.9	71.2	70.2	71.3	70.7	69.4	69.2	69.0	69.9	68.9
Other race	73.2	73.9	71.9	69.7	69.1	70.4	69.1	70.8	70.0	73.0	71.0
†Hispanic					69.2	68.5	68.8	69.3	70.4	70.8	70.3
†Non-Hispanic					62.3	61.5	61.2	61.4	60.7	61.4	60.9
Diabetes	59.5	61.3	61.3	61.0	61.3	60.7	60.1	61.1	61.2	61.8	61.4
Hypertension	61.9	61.7	62.8	63.1	63.1	61.4	61.5	61.1	61.0	61.3	61.0
Glomerulonephritis	73.2	74.4	73.6	74.2	74.4	74.9	75.8	74.4	75.0	76.4	75.6
Other cause	62.0	62.4	62.5	60.5	61.4	61.4	61.0	61.5	59.9	60.6	59.8
All	62.2	63.0	63.3	62.9	63.2	62.3	62.1	62.3	62.0	62.6	62.1
ADJUSTED											
0-19	86.5	79.2	88.4	86.1	81.0	85.5	84.4	84.4	80.8	83.1	83.9
20-44	77.4	77.1	78.0	77.8	79.2	81.2	80.2	80.8	80.5	80.8	80.7
45-64	69.4	70.9	71.9	71.0	71.8	72.1	71.2	72.2	72.1	72.5	72.4
65-74	56.2	57.5	56.7	58.1	58.6	57.1	57.7	58.1	58.3	59.4	58.7
75+	43.1	44.1	44.8	43.8	44.4	43.1	43.5	43.7	43.4	44.0	44.4
Male	61.1	62.7	63.1	63.1	63.9	63.8	64.0	64.7	64.8	65.0	64.9
Female	63.7	64.0	64.5	64.2	64.9	64.2	63.8	64.1	63.9	65.0	64.8
White	59.0	60.3	60.9	61.1	61.7	61.1	61.6	62.4	62.3	62.7	62.9
Black	67.7	68.1	68.4	67.6	69.0	68.7	67.4	67.2	67.3	68.2	67.4
Other race	72.3	73.3	71.6	70.2	70.1	71.4	70.0	71.9	71.2	73.7	72.2
Diabetes	58.3	60.2	60.5	60.3	61.0	60.7	60.2	61.5	61.7	62.5	62.2
Hypertension	65.3	65.8	66.5	67.1	67.4	66.3	66.6	66.4	66.5	66.7	66.9
Glomerulonephritis	70.6	71.6	71.6	71.6	72.4	72.7	73.6	72.7	72.8	73.7	73.6
Other cause	61.4	61.6	61.7	60.3	61.3	61.6	61.1	61.6	60.3	61.1	60.5
All	62.4	63.4	63.8	63.7	64.4	64.0	63.9	64.4	64.4	65.0	64.9

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.19

Three-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to three years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	100.0	90.0	88.9	55.0	*	78.4	51.3	39.8	41.6	43.4	56.1
5-9	90.9	90.3	90.0	94.4	100.0	100.0	87.5	81.8	92.9	88.9	83.6
10-14	96.9	91.1	94.0	90.2	89.1	85.3	85.9	91.5	81.2	95.1	93.4
15-19	89.4	87.1	92.8	88.9	95.9	90.0	82.3	89.6	89.1	89.5	90.2
20-29	78.9	80.0	79.9	77.1	76.3	73.3	76.4	76.7	78.8	77.8	77.7
30-39	75.4	73.8	66.6	72.5	66.8	67.6	66.5	66.7	71.4	69.5	69.6
40-49	68.7	67.9	67.9	66.0	65.9	65.4	63.6	64.7	66.5	65.1	67.4
50-59	60.9	59.8	58.9	56.4	55.3	54.2	55.0	56.1	56.0	56.9	57.1
60-64	53.1	50.8	49.6	50.1	47.0	46.0	46.9	47.0	48.9	47.9	48.2
65-69	41.5	42.4	42.7	39.3	42.1	40.9	41.4	42.2	43.1	42.4	42.0
70-79	34.7	34.7	35.5	30.4	33.3	32.5	33.0	32.8	33.4	34.1	33.8
80+	18.8	22.0	20.5	18.3	21.3	22.1	20.8	21.7	20.0	23.4	22.3
Male	54.8	54.3	52.0	48.0	48.7	45.7	46.3	46.8	48.0	47.8	48.0
Female	58.1	56.9	55.0	51.2	50.5	50.9	49.4	49.2	50.4	49.2	48.6
White	53.2	51.9	49.9	45.1	44.9	43.1	42.5	42.5	42.5	42.2	41.7
Black	63.0	63.4	60.4	57.3	58.2	57.2	57.1	57.1	60.0	58.3	58.6
Other race	56.8	52.8	58.0	56.6	52.3	52.8	54.3	56.0	58.4	59.3	61.2
†Hispanic											
†Non-Hispanic											
Diabetes	44.9	42.8	39.5	40.4	38.9	38.8	39.0	40.8	42.1	42.5	42.8
Hypertension	62.3	58.4	54.1	52.1	50.8	49.9	48.8	48.0	49.6	49.4	48.3
Glomerulonephritis	73.5	67.9	66.0	65.2	64.3	59.4	59.7	60.1	63.0	59.8	60.9
Other cause	52.7	54.7	56.0	46.4	50.2	50.3	50.7	50.6	50.8	50.7	51.2
All	56.3	55.5	53.4	49.5	49.5	48.2	47.8	48.0	49.2	48.5	48.3
ADJUSTED											
0-19	83.9	78.4	86.6	77.9	88.2	79.9	68.8	75.7	75.9	79.6	80.1
20-44	70.7	71.3	68.0	68.8	66.2	65.1	65.7	66.2	69.7	68.3	69.1
45-64	57.1	55.2	54.6	53.3	52.0	51.2	52.0	52.7	53.8	54.2	55.0
65-74	38.7	39.2	40.1	35.5	39.2	37.6	37.7	38.9	40.1	39.8	39.8
75+	26.9	28.8	26.7	23.4	25.6	26.4	27.4	26.2	25.7	28.3	27.0
Male	47.7	47.4	46.3	43.6	44.9	42.8	44.2	44.7	45.8	46.7	47.1
Female	51.5	50.7	50.2	47.9	48.0	48.7	48.2	48.7	49.6	49.7	49.5
White	45.7	45.2	44.9	41.9	42.9	41.9	42.3	42.9	43.2	44.4	44.1
Black	56.8	56.0	53.7	52.2	52.6	51.8	52.7	52.9	55.4	54.1	54.8
Other race	48.6	46.4	49.3	49.8	46.1	49.2	50.7	52.3	54.9	57.4	59.9
Diabetes	39.3	37.8	35.4	36.3	35.7	35.6	36.4	38.4	39.7	40.8	41.3
Hypertension	57.7	55.7	53.4	52.0	51.4	51.5	51.7	51.3	52.6	53.2	52.7
Glomerulonephritis	64.5	60.0	59.6	59.1	59.6	55.4	56.1	56.1	59.0	56.8	58.0
Other cause	49.5	50.4	52.3	46.3	49.6	49.2	50.2	50.2	49.9	50.6	50.7
All	49.4	48.9	48.1	45.7	46.4	45.6	46.1	46.6	47.6	48.1	48.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.19 (continued)

Three-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to three years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	60.8	62.2	49.8	60.3	65.0	80.0	78.3	69.0	61.3	39.2	51.6
5-9	100.0	100.0	68.4	94.1	97.0	69.2	100.0	95.0	79.3	88.9	87.1
10-14	86.5	78.5	88.0	87.6	95.2	90.6	88.7	88.5	90.2	95.7	90.1
15-19	88.9	92.6	88.3	92.1	89.8	86.0	90.2	89.6	88.4	89.1	87.2
20-29	79.2	79.5	80.0	80.0	80.1	82.4	83.2	84.0	83.3	81.9	82.8
30-39	68.1	69.4	70.4	71.4	70.2	72.6	73.9	73.9	74.6	74.9	75.1
40-49	64.2	66.8	67.3	67.9	68.2	68.5	70.0	68.7	69.3	69.0	69.1
50-59	58.2	58.0	60.1	60.8	60.5	60.6	61.4	60.7	61.4	61.6	62.1
60-64	49.1	50.1	52.0	53.1	51.9	53.0	53.9	52.7	53.7	53.8	54.2
65-69	43.3	44.2	46.2	45.5	46.5	46.4	46.0	46.0	46.3	47.5	48.4
70-79	35.1	35.0	36.4	36.3	36.4	37.0	35.9	36.6	36.9	37.2	38.3
80+	22.5	23.8	24.0	24.4	23.8	24.5	23.6	22.4	23.3	23.8	23.9
Male	48.2	48.4	50.3	50.7	50.8	50.7	50.5	50.7	50.9	51.3	51.4
Female	48.5	49.4	50.0	50.1	49.4	49.8	49.4	48.5	48.9	48.8	49.9
White	41.7	42.1	43.9	44.0	44.1	44.0	43.5	43.9	44.4	44.7	45.0
Black	58.3	59.1	59.5	60.0	59.2	60.1	60.1	58.5	58.6	58.8	59.3
Other race	63.1	61.1	61.8	60.9	57.5	57.5	58.6	58.2	59.9	59.5	62.5
†Hispanic						57.1	57.0	57.6	58.0	60.0	59.9
†Non-Hispanic						49.3	49.0	48.6	48.8	48.5	49.3
Diabetes	43.9	44.6	46.6	47.1	46.5	46.9	46.8	46.4	47.3	47.8	48.9
Hypertension	48.2	49.2	49.3	49.8	50.9	50.8	49.4	49.3	49.4	49.3	49.3
Glomerulonephritis	60.4	61.3	64.3	63.4	63.5	63.7	65.7	65.8	63.8	66.0	67.2
Other cause	50.8	50.5	51.8	51.8	50.1	50.5	51.0	50.8	51.4	50.4	50.4
All	48.4	48.9	50.2	50.4	50.1	50.3	50.0	49.7	50.0	50.1	50.7
ADJUSTED											
0-19	78.9	81.5	74.1	82.3	80.3	75.5	81.7	80.4	78.2	77.9	75.2
20-44	67.2	68.7	68.9	69.9	69.5	71.7	73.1	72.8	73.1	73.1	73.2
45-64	55.8	56.4	58.7	59.7	59.3	59.7	61.0	60.1	61.0	61.3	61.7
65-74	40.7	41.7	43.3	42.6	43.9	44.3	43.3	44.0	44.6	45.1	46.6
75+	28.7	28.3	29.3	29.9	28.9	29.7	29.2	28.9	29.4	30.0	30.2
Male	47.9	48.0	50.4	50.8	51.0	51.7	52.0	52.2	53.0	53.5	53.6
Female	50.0	51.1	51.7	52.1	51.9	52.5	52.5	51.9	52.3	52.7	53.8
White	44.9	45.6	47.6	47.9	48.4	48.9	48.9	49.4	50.1	50.5	51.0
Black	55.0	55.7	56.3	56.8	56.4	57.5	57.7	56.2	56.2	57.0	57.5
Other race	62.2	60.5	61.4	60.9	58.5	59.0	60.1	59.5	61.6	61.2	63.6
Diabetes	42.7	43.6	45.8	46.4	46.0	46.9	47.1	46.8	47.9	48.7	49.9
Hypertension	53.0	53.6	54.4	54.5	55.8	56.1	55.3	55.4	55.7	55.8	55.7
Glomerulonephritis	57.9	58.6	61.2	61.4	60.8	61.4	63.2	63.2	61.9	63.7	64.0
Other cause	50.5	50.3	51.2	51.2	50.2	50.7	51.5	51.1	51.8	51.1	51.0
All	48.9	49.6	51.1	51.4	51.4	52.1	52.3	52.1	52.7	53.1	53.7

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.20

Five-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	100.0	72.0	88.9	55.0	*	78.4	41.1	39.8	41.6	43.4	28.1	22.8	62.2	49.8	30.2	65.0	40.0	78.3	69.0	61.3
5-9	90.9	90.3	60.0	94.4	100.0	100.0	87.5	81.8	92.9	88.9	83.6	100.0	75.0	45.6	94.1	97.0	69.2	100.0	95.0	69.3
10-14	84.2	81.7	87.8	90.2	89.1	85.3	68.7	91.5	58.2	87.2	93.4	86.5	71.8	83.1	81.1	90.8	84.9	85.0	88.5	75.8
15-19	86.1	82.1	79.8	84.6	92.0	79.6	74.4	83.3	77.4	79.1	86.7	80.7	86.1	76.6	85.2	87.1	80.4	83.1	79.7	78.6
20-29	75.2	69.4	71.1	65.7	63.4	60.0	65.7	65.3	67.5	66.0	67.5	67.2	69.1	70.0	71.3	72.3	73.9	73.3	73.9	76.6
30-39	62.6	61.6	53.4	58.3	54.8	53.2	52.4	50.3	56.8	56.7	55.0	54.8	57.0	58.3	58.3	58.4	59.3	61.5	61.2	62.4
40-49	54.9	52.1	51.8	48.6	50.3	48.6	47.1	49.6	49.9	47.8	49.3	48.3	50.4	50.3	50.8	51.9	51.6	53.3	51.9	53.2
50-59	41.5	40.8	40.2	37.0	36.3	35.9	36.6	37.3	37.0	36.7	37.0	39.1	38.5	40.3	41.0	41.0	40.6	41.6	41.1	42.6
60-64	32.6	32.6	30.3	30.3	27.8	27.8	28.8	27.1	29.7	28.7	29.2	29.3	30.5	31.6	32.1	30.8	32.2	33.2	33.0	33.9
65-69	24.0	25.0	24.7	21.3	22.8	23.2	22.9	23.5	23.5	23.6	23.1	22.7	24.6	24.9	25.8	25.2	25.5	24.9	26.1	26.1
70-79	16.7	16.4	17.8	14.2	16.1	16.0	15.6	16.0	16.2	16.5	16.4	16.8	16.6	17.4	17.4	17.8	18.0	17.5	18.3	18.3
80+	7.8	6.8	6.7	6.3	7.5	8.3	7.6	7.9	6.9	9.1	9.0	8.3	8.0	8.5	8.8	9.0	8.8	8.6	8.4	8.5
Male	38.0	35.8	33.9	29.9	30.1	28.5	28.9	28.9	30.2	29.9	29.9	30.0	30.4	31.4	32.1	32.5	32.2	31.9	32.4	33.0
Female	40.1	40.1	37.1	33.1	32.5	32.8	31.2	31.0	31.7	30.4	30.1	29.7	30.4	30.7	31.0	30.4	30.3	30.5	30.2	30.5
White	36.1	33.5	31.4	27.1	26.5	25.7	24.8	24.3	24.3	24.0	23.6	23.3	23.7	24.6	25.0	24.8	24.7	24.2	25.1	25.6
Black	45.2	46.6	42.9	38.5	39.9	38.8	38.8	38.8	41.4	39.6	40.1	39.7	40.4	40.7	41.2	41.4	41.5	41.9	40.8	41.2
Other race	38.0	38.3	44.5	42.5	35.9	36.1	38.0	41.9	41.8	42.4	40.4	42.3	42.0	42.3	41.7					
†Hispanic																	38.3	37.8	39.1	39.3
†Non-Hispanic																	30.3	30.4	30.4	30.7
Diabetes	28.5	24.2	20.6	21.3	20.1	19.8	21.4	21.7	23.1	22.6	23.2	23.8	24.8	25.6	26.3	25.8	26.0	26.1	26.5	27.5
Hypertension	46.2	40.5	36.2	33.7	33.0	32.6	30.6	30.3	32.0	31.3	30.8	30.2	30.9	30.7	31.8	32.8	32.6	31.9	31.7	32.0
Glomerulonephritis	58.6	53.1	49.4	45.8	44.7	40.8	41.5	42.0	44.6	42.8	43.2	43.4	43.2	46.7	45.6	46.8	46.9	47.6	48.7	47.4
Other cause	34.3	36.8	38.4	30.2	33.1	34.8	34.0	34.0	33.2	34.5	34.3	34.3	34.8	36.2	36.4	35.0	34.8	35.9	35.8	35.9
All	38.9	37.8	35.4	31.4	31.3	30.6	30.0	29.9	30.9	30.1	30.0	29.8	30.4	31.1	31.5	31.5	31.3	31.2	31.4	31.8
ADJUSTED																				
0-19	75.3	68.8	67.4	73.0	80.4	67.7	57.6	69.2	59.7	67.1	73.7	67.3	71.2	60.2	72.1	75.9	67.1	72.5	67.9	64.2
20-44	59.4	57.3	53.7	52.9	52.4	49.8	51.5	50.9	54.1	54.0	54.5	53.1	55.3	55.3	56.5	56.8	57.5	59.1	58.9	60.2
45-64	37.6	36.4	35.7	33.7	32.8	32.7	33.6	33.5	34.7	34.4	35.2	36.6	36.9	38.8	39.6	39.5	39.8	41.3	40.8	42.3
65-74	21.0	21.5	22.0	18.2	20.2	20.3	19.9	20.9	21.3	21.4	21.3	21.1	22.5	22.9	23.5	23.4	24.0	23.3	24.5	24.8
75+	11.8	11.6	11.5	9.4	11.1	11.6	11.4	11.1	10.6	12.3	11.6	12.2	11.2	11.9	11.9	12.5	12.6	12.4	12.7	12.8
Male	31.7	29.9	29.5	26.9	27.8	27.1	28.2	28.1	29.0	30.0	30.1	30.7	30.9	32.4	32.9	33.4	33.9	34.0	34.6	35.7
Female	33.8	34.3	33.1	30.9	31.3	31.6	31.2	31.5	32.0	31.8	31.8	32.1	33.0	33.3	33.9	33.7	33.9	34.4	34.4	34.7
White	29.6	28.1	28.0	25.5	26.1	26.2	26.3	26.2	26.5	27.6	27.3	27.7	28.4	29.5	30.1	30.2	30.7	30.7	31.6	32.3
Black	38.6	38.8	36.2	33.8	34.9	34.0	34.9	35.2	36.9	35.7	36.6	36.8	37.1	37.7	38.2	38.7	38.9	39.6	38.7	38.9
Other race	30.8	32.9	35.9	36.0	30.6	33.6	35.3	38.7	38.7	41.3	39.8	42.7	42.5	42.7	42.6	40.8	41.0	43.3	43.0	45.7
Diabetes	24.0	20.6	18.2	18.8	18.6	18.4	20.2	20.6	21.8	22.0	22.7	23.5	24.6	25.5	26.4	26.1	26.7	26.9	27.4	28.7
Hypertension	41.8	38.3	36.6	34.8	34.7	35.3	34.7	34.9	35.9	36.2	36.1	36.0	36.3	36.8	37.3	38.4	38.6	38.5	38.6	39.0
Glomerulonephritis	48.1	44.5	43.3	40.4	41.0	37.9	39.0	38.9	41.6	40.7	40.9	41.9	41.4	44.0	43.9	44.2	44.7	45.0	46.1	45.5
Other cause	31.9	33.3	35.5	30.6	33.5	34.5	34.4	34.4	33.2	35.3	34.6	34.9	35.3	36.2	36.4	35.4	35.5	36.8	36.6	36.6
All	32.7	32.0	31.2	28.8	29.4	29.3	29.6	29.8	30.4	30.9	30.9	31.4	32.0	32.9	33.4	33.5	33.9	34.2	34.5	35.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.21

Ten-year survival probabilities: incident hemodialysis patients*censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	50.0	72.0	.	36.7	*	.	41.1	19.9	20.8	43.4	28.1	22.8	62.2	49.8	30.2
5-9	90.9	67.8	60.0	94.4	100.0	100.0	87.5	65.5	92.9	88.9	83.6	33.3	75.0	.	70.6
10-14	64.1	59.1	62.7	80.7	59.4	85.3	68.7	91.5	29.1	81.3	76.7	76.8	57.7	72.7	54.6
15-19	76.5	65.8	62.8	71.9	76.8	66.9	58.9	49.3	65.0	68.9	70.3	69.7	65.6	64.5	78.0
20-29	54.7	48.4	49.5	47.7	45.5	43.0	45.7	45.3	46.3	45.1	46.5	45.1	47.5	52.4	51.3
30-39	41.3	38.0	31.6	35.9	33.3	32.0	29.1	29.4	31.8	33.9	32.1	33.0	34.6	33.3	33.2
40-49	27.4	24.8	25.4	23.0	25.2	23.1	21.6	22.6	23.9	20.5	21.8	20.6	22.7	22.1	22.9
50-59	14.0	14.1	14.9	11.8	12.2	12.7	12.0	12.0	11.5	11.5	11.1	12.3	11.6	11.4	12.9
60-64	8.5	7.9	6.8	8.0	7.4	8.3	7.5	6.9	7.5	6.5	6.4	6.9	7.1	7.4	7.8
65-69	5.0	5.5	4.6	5.0	5.1	6.0	5.0	4.7	4.7	4.3	4.8	4.1	4.4	4.9	4.6
70-79	2.8	2.3	3.0	2.4	3.2	2.9	2.3	2.6	2.5	2.1	2.0	1.9	2.1	2.3	2.2
80+	1.6	0.9	1.7	0.3	1.2	0.8	0.8	0.8	0.5	0.7	0.3	0.6	0.6	0.6	0.6
Male	14.5	12.8	11.8	10.5	11.0	10.6	10.1	10.0	10.1	9.6	10.0	9.6	10.1	10.1	10.5
Female	16.7	15.8	13.8	12.2	11.6	11.9	10.1	9.7	10.5	9.5	8.7	8.8	8.8	9.0	9.1
White	14.3	11.8	10.7	9.0	9.0	8.7	7.4	7.4	7.2	6.2	6.3	6.0	6.2	6.4	6.6
Black	18.1	18.8	16.5	15.0	15.0	15.3	14.3	13.6	15.1	14.6	13.9	14.0	14.3	14.1	14.5
Other race	15.9	17.4	20.0	17.4	18.3	15.1	17.4	15.1	16.1	14.5	15.5	14.7	14.2	15.1	15.3
Diabetes	8.6	6.4	5.4	4.8	4.9	5.1	4.7	4.9	5.0	4.4	4.7	4.7	4.8	5.0	5.5
Hypertension	19.7	15.4	11.9	12.2	11.8	11.4	10.2	9.2	10.4	10.2	9.6	9.5	10.2	9.7	10.5
Glomerulonephritis	32.4	26.0	20.7	19.8	19.5	19.2	18.2	17.6	18.5	18.0	18.4	17.8	19.5	20.5	18.9
Other cause	12.1	13.1	15.3	11.7	13.1	13.9	12.9	13.6	14.1	13.4	13.7	14.2	14.0	15.1	15.2
All	15.5	14.2	12.8	11.3	11.3	11.2	10.1	9.8	10.3	9.5	9.3	9.2	9.4	9.6	9.8
ADJUSTED															
0-19	57.8	46.9	42.2	56.6	56.1	53.2	44.5	39.6	44.2	55.1	55.4	51.1	48.9	47.9	55.0
20-44	37.0	32.5	30.3	31.0	30.5	29.1	28.4	28.1	29.6	30.4	30.0	29.9	31.2	30.8	31.3
45-64	12.0	11.3	11.6	10.1	10.5	11.0	10.6	10.4	10.6	10.0	10.3	11.0	11.0	11.4	12.6
65-74	4.3	4.2	4.0	3.9	4.4	4.9	4.0	4.0	3.9	3.7	3.9	3.4	3.9	4.2	4.0
75+	1.9	1.8	2.1	1.1	2.0	1.4	1.3	1.6	1.5	1.3	0.8	1.1	1.0	1.2	1.2
Male	12.0	10.7	11.0	10.0	11.1	11.4	11.2	10.9	10.6	10.6	11.0	11.0	11.3	11.6	11.9
Female	13.7	13.4	12.8	12.1	12.4	12.5	11.3	11.5	11.9	11.4	11.0	11.3	11.5	11.8	12.0
White	11.6	10.3	10.5	9.6	10.5	10.7	9.9	10.1	9.9	9.6	9.8	9.8	10.3	10.6	10.9
Black	14.2	14.3	13.1	12.7	12.9	13.3	12.6	12.5	13.1	12.7	12.5	12.8	12.8	13.0	13.3
Other race	11.9	14.3	16.4	14.0	15.4	14.5	16.6	14.6	15.2	15.8	16.1	16.9	16.5	16.7	17.4
Diabetes	7.0	5.6	5.1	4.6	5.0	5.4	5.0	5.1	5.1	4.7	5.2	5.3	5.4	5.7	6.3
Hypertension	17.9	15.6	14.2	14.5	14.6	14.9	14.4	13.9	14.1	14.4	14.0	14.0	14.6	14.4	14.9
Glomerulonephritis	23.6	19.9	18.4	17.2	18.6	18.8	17.8	17.2	18.3	17.7	17.5	17.9	18.8	19.3	18.5
Other cause	12.0	12.4	14.8	12.8	14.6	15.0	14.2	14.8	14.8	14.6	14.6	15.3	15.0	15.7	15.7
All	12.8	11.9	11.9	11.0	11.7	11.9	11.2	11.2	11.2	11.0	11.0	11.1	11.4	11.7	12.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

*Values for cells with ten or fewer patients are suppressed.

." Zero values in this cell.

Table I.22

Incident patient counts: CAPD/CCPD patients, unknowns dropped

patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	*	23	36	51	54	74	62	57	64	59	51	77
5-9	*	14	28	33	48	32	44	36	33	41	39	30
10-14	*	20	51	60	73	51	53	57	51	46	65	67
15-19	*	22	53	65	64	70	64	75	65	88	85	68
20-29	54	107	175	199	236	223	268	263	307	300	367	325
30-39	108	192	326	398	389	445	460	500	574	656	710	783
40-49	114	183	361	412	438	487	541	565	624	775	888	1,040
50-59	159	332	504	560	626	648	656	703	751	921	1,008	1,052
60-64	59	195	282	349	343	422	397	450	484	532	643	658
65-69	48	144	237	219	230	278	299	345	348	424	543	509
70-79	44	130	311	271	269	339	290	389	402	489	596	617
80+	*	25	60	53	52	60	65	68	92	117	119	96
Male	328	693	1,262	1,429	1,542	1,654	1,750	1,864	2,044	2,394	2,728	2,940
Female	296	694	1,162	1,241	1,280	1,475	1,449	1,644	1,751	2,054	2,386	2,382
White	499	1,054	1,765	1,953	2,081	2,387	2,402	2,620	2,816	3,234	3,746	3,889
Black	109	314	618	659	661	668	711	793	860	1,085	1,215	1,261
Other race	16	19	41	58	80	74	86	95	119	129	153	172
†Hispanic												
†Non-Hispanic												
Diabetes	173	428	793	856	933	1,042	1,149	1,292	1,335	1,697	1,999	2,152
Hypertension	128	313	632	592	589	689	699	730	905	1,027	1,278	1,217
Glomerulonephritis	161	289	468	513	587	630	634	702	780	868	930	980
Cystic kidney	42	88	114	116	158	150	164	177	176	204	244	281
Other urologic	14	57	91	93	87	110	87	93	94	90	104	103
Other cause	94	166	298	367	383	422	389	432	404	489	529	563
Missing cause	12	46	28	133	85	86	77	82	101	73	30	26
All	624	1,387	2,424	2,670	2,822	3,129	3,199	3,508	3,795	4,448	5,114	5,322

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.22 (continued)

Incident patient counts: CAPD/CCPD patients, unknowns dropped*patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis*

	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	69	78	66	80	104	89	107	92	113	107	100	107
5-9	31	38	56	50	56	53	48	59	56	55	52	43
10-14	54	58	74	76	95	86	78	84	86	75	93	97
15-19	104	91	88	97	106	102	87	84	93	84	68	74
20-29	335	368	345	338	321	287	270	242	231	221	178	190
30-39	818	804	843	821	758	651	618	628	553	498	505	490
40-49	1,021	1,143	1,100	1,296	1,233	1,078	1,004	998	953	924	832	856
50-59	1,210	1,218	1,363	1,454	1,397	1,447	1,380	1,351	1,272	1,391	1,289	1,313
60-64	706	725	761	831	743	718	672	651	645	649	627	650
65-69	465	621	574	630	551	517	534	510	516	518	487	511
70-79	654	704	796	749	803	769	742	737	726	757	714	693
80+	133	147	170	164	193	202	172	194	196	238	223	233
Male	2,964	3,201	3,310	3,498	3,352	3,157	2,978	2,933	2,883	2,887	2,763	2,780
Female	2,636	2,794	2,926	3,088	3,008	2,842	2,734	2,697	2,557	2,630	2,405	2,477
White	4,040	4,232	4,397	4,587	4,532	4,348	4,076	4,094	3,908	3,899	3,608	3,587
Black	1,339	1,507	1,505	1,585	1,423	1,283	1,254	1,202	1,150	1,207	1,159	1,255
Other race	221	256	334	414	405	368	382	334	382	411	401	415
†Hispanic					698	595	597	629	700	597	639	629
†Non-Hispanic					5,662	5,404	5,115	5,001	4,740	4,920	4,529	4,628
Diabetes	2,332	2,445	2,602	2,916	2,927	2,706	2,595	2,574	2,452	2,442	2,321	2,310
Hypertension	1,253	1,406	1,423	1,300	1,115	1,143	1,091	1,072	1,059	1,081	1,062	1,128
Glomerulonephritis	1,021	1,042	1,131	1,184	1,172	1,078	1,000	921	940	897	787	819
Cystic kidney	281	319	330	331	321	320	284	318	280	317	276	310
Other urologic	125	129	112	171	145	164	136	148	156	156	159	129
Other cause	569	629	623	676	668	581	600	589	551	619	552	538
Missing cause	19	25	15	*	12	*	*	*	*	*	11	23
All	5,600	5,995	6,236	6,586	6,360	5,999	5,712	5,630	5,440	5,517	5,168	5,257

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.23

90-day survival probabilities: incident CAPD/CCPD patients

censored at transplant, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	*	100.0	100.0	100.0	98.3	100.0	100.0	98.4	100.0	100.0	94.7
5-9	*	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.7
10-14	*	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.6
15-19	*	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.9
20-29	100.0	99.2	99.5	99.5	99.6	99.2	99.6	98.6	100.0	99.4	99.2
30-39	99.1	98.6	98.8	99.3	99.0	98.9	98.2	98.9	98.5	98.8	99.1
40-49	100.0	99.0	99.2	98.9	98.7	98.8	98.8	98.8	99.5	99.6	99.2
50-59	98.9	98.1	98.3	98.5	98.8	97.9	98.9	98.8	98.5	98.7	99.1
60-64	98.6	99.5	98.7	98.6	98.1	95.5	96.8	97.3	97.7	99.3	98.4
65-69	96.4	97.6	94.6	94.8	94.6	97.1	97.5	96.0	96.8	96.3	97.6
70-79	96.1	95.3	92.7	93.4	94.9	95.5	94.4	95.9	94.7	96.2	95.7
80+	*	97.5	94.2	88.4	93.4	87.8	87.7	87.6	93.6	96.1	94.8
Male	99.4	98.4	97.2	97.7	98.1	97.3	97.6	97.9	98.2	98.6	98.3
Female	98.2	98.2	97.7	97.8	97.8	97.8	98.0	97.7	97.9	98.4	98.3
White	98.8	98.2	97.0	97.6	97.9	97.3	97.5	97.7	97.9	98.3	98.2
Black	99.1	98.5	98.7	98.3	98.3	98.6	98.7	97.9	98.3	99.0	98.6
Other race	100.0	100.0	100.0	95.5	98.8	96.4	97.8	100.0	99.2	98.6	98.2
†Hispanic											
†Non-Hispanic											
Diabetes	97.8	99.1	97.1	97.6	98.3	97.7	97.6	98.0	97.7	98.5	98.5
Hypertension	100.0	97.5	96.5	96.7	96.4	97.6	97.1	96.6	97.9	97.3	97.3
Glomerulonephritis	99.4	99.3	98.3	98.7	99.2	98.0	98.5	98.9	99.1	99.5	99.2
Other cause	98.6	97.5	98.1	98.0	98.0	97.0	98.2	97.5	97.7	98.8	98.4
All	98.8	98.3	97.4	97.7	98.0	97.5	97.8	97.8	98.1	98.5	98.3
ADJUSTED											
0-19	100.0	100.0	99.5	100.0	99.6	100.0	100.0	99.6	100.0	100.0	98.0
20-44	99.5	98.5	98.8	99.3	99.1	99.0	98.6	98.6	99.2	99.2	99.0
45-64	99.0	98.8	98.6	98.6	98.6	97.2	98.3	98.4	98.4	99.1	99.0
65-74	95.9	96.4	94.6	95.4	94.9	96.2	96.6	96.7	95.6	96.6	96.9
75+	100.0	97.9	91.9	89.6	95.0	94.2	91.9	92.0	95.7	95.9	95.8
Male	99.1	97.8	96.3	96.8	97.3	96.2	96.6	97.0	97.5	98.0	97.6
Female	96.9	97.3	96.6	96.6	96.6	96.6	96.9	96.6	96.8	97.6	97.5
White	97.7	97.2	95.6	96.4	96.7	95.9	96.2	96.6	97.0	97.7	97.5
Black	98.5	97.8	98.0	97.6	97.4	97.8	97.9	96.5	97.1	98.2	97.6
Other race	100.0	100.0	100.0	93.8	97.9	94.4	96.5	100.0	98.7	98.0	97.1
Diabetes	96.2	98.4	95.4	96.1	97.3	96.2	96.2	97.0	96.6	97.8	97.8
Hypertension	100.0	97.1	96.2	96.1	95.6	97.3	96.7	96.3	97.7	97.1	97.2
Glomerulonephritis	98.7	98.8	96.9	97.6	98.4	96.5	97.2	97.9	98.4	99.2	98.5
Other cause	97.3	96.3	97.3	97.0	96.9	95.3	97.1	96.1	96.4	98.1	97.3
All	98.1	97.6	96.4	96.7	97.0	96.4	96.7	96.8	97.2	97.8	97.6

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.23 (continued)

90-day survival probabilities: incident CAPD/CCPD patients*censored at transplant, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	98.8	98.6	100.0	98.7	97.7	99.1	96.9	97.3	97.0	98.3	100.0	99.1	99.1
5-9	100.0	100.0	100.0	100.0	100.0	98.4	100.0	100.0	98.5	100.0	98.3	100.0	100.0
10-14	100.0	100.0	98.4	98.8	98.8	100.0	99.0	100.0	100.0	100.0	100.0	100.0	100.0
15-19	100.0	100.0	100.0	100.0	100.0	99.1	100.0	100.0	100.0	98.0	98.9	100.0	98.8
20-29	99.4	98.9	99.7	99.7	100.0	99.4	100.0	99.7	98.8	100.0	99.6	100.0	100.0
30-39	99.0	98.9	99.2	99.1	99.4	99.6	99.3	99.8	99.2	99.6	99.8	99.2	99.6
40-49	99.5	99.2	98.8	99.4	99.3	99.1	99.0	99.5	99.3	99.5	99.7	99.6	99.9
50-59	98.5	99.0	98.9	98.9	99.1	99.0	99.5	98.8	99.4	99.0	99.2	99.2	99.2
60-64	98.3	98.6	98.8	98.4	98.4	98.8	98.8	98.7	99.1	98.8	99.0	99.1	99.7
65-69	98.3	97.8	99.1	98.5	98.0	97.3	98.9	98.0	98.1	98.9	99.3	99.4	98.9
70-79	97.1	97.1	96.2	98.2	97.4	96.9	97.7	97.3	97.1	97.1	97.5	97.6	97.4
80+	90.7	93.5	92.9	92.1	94.3	92.8	96.3	93.4	96.7	95.4	97.4	95.2	96.2
Male	98.7	98.4	98.4	98.8	98.7	98.5	98.9	98.5	98.8	98.7	99.0	98.7	99.1
Female	98.3	98.7	98.6	98.5	98.7	98.5	98.9	98.8	98.7	98.8	99.1	99.2	98.9
White	98.5	98.5	98.5	98.7	98.6	98.5	98.8	98.5	98.8	98.6	99.0	98.8	98.9
Black	98.4	98.4	98.7	98.5	98.8	98.5	99.2	98.9	98.9	99.2	99.3	99.3	99.4
Other race	99.5	99.6	98.9	99.2	98.9	98.4	99.2	99.0	98.3	98.5	99.1	99.5	99.5
†Hispanic						99.5	98.4	98.3	99.7	99.0	99.5	99.1	99.1
†Non-Hispanic						98.4	99.0	98.7	98.6	98.7	99.0	98.9	99.0
Diabetes	98.2	98.6	98.5	98.9	98.9	98.5	99.0	98.7	98.9	98.8	99.0	99.0	99.1
Hypertension	98.6	97.9	97.9	98.3	98.2	97.8	98.5	98.1	98.9	98.1	98.7	98.5	98.3
Glomerulonephritis	99.5	99.5	99.2	99.3	99.2	99.6	99.6	99.4	99.3	99.9	99.7	99.5	99.8
Other cause	98.2	98.2	98.7	98.2	98.4	98.1	98.4	98.4	98.1	98.2	99.0	98.7	99.0
All	98.5	98.5	98.5	98.7	98.7	98.5	98.9	98.6	98.8	98.7	99.0	98.9	99.0
ADJUSTED													
0-19	99.7	99.7	99.7	99.4	99.3	99.4	99.0	99.2	99.0	99.1	99.6	99.8	99.5
20-44	99.3	98.9	99.1	99.3	99.6	99.4	99.5	99.8	99.2	99.6	99.6	99.5	99.8
45-64	98.7	99.0	98.9	98.9	98.9	99.0	99.2	98.8	99.3	99.1	99.3	99.2	99.5
65-74	98.1	98.1	98.3	98.3	98.0	97.5	98.3	98.1	97.5	98.3	98.4	98.7	98.9
75+	94.7	94.8	94.2	96.2	95.8	94.7	97.5	95.3	97.5	96.2	97.7	96.7	95.9
Male	98.1	97.8	97.8	98.4	98.2	97.9	98.5	98.0	98.4	98.3	98.7	98.4	98.9
Female	97.5	98.0	98.0	97.9	98.1	97.8	98.5	98.2	98.2	98.3	98.7	98.9	98.6
White	97.9	97.9	97.9	98.3	98.1	98.0	98.4	98.0	98.4	98.3	98.7	98.5	98.6
Black	97.4	97.1	97.7	97.5	98.0	97.3	98.6	98.1	98.1	98.6	98.8	98.8	99.0
Other race	99.1	99.3	98.3	98.6	98.3	97.7	98.9	98.3	97.6	97.9	98.7	99.4	99.4
Diabetes	97.4	97.9	97.9	98.4	98.4	97.9	98.7	98.2	98.5	98.5	98.6	98.8	98.9
Hypertension	98.4	97.7	97.8	98.3	98.1	97.7	98.5	98.1	98.9	98.2	98.8	98.6	98.4
Glomerulonephritis	99.1	99.1	98.7	98.8	98.5	99.3	99.3	98.9	98.7	99.8	99.4	99.1	99.5
Other cause	97.0	97.1	97.8	97.0	97.3	96.9	97.3	97.2	96.9	97.1	98.3	97.9	98.3
All	97.8	97.9	97.9	98.2	98.1	97.9	98.5	98.1	98.3	98.3	98.7	98.6	98.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.24

One-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	*	100.0	85.5	85.8	81.7	82.5	93.2	96.3	80.5	90.4	80.6
5-9	*	100.0	90.0	100.0	84.7	83.3	100.0	100.0	100.0	100.0	96.8
10-14	*	100.0	98.0	100.0	96.2	98.1	97.6	100.0	94.5	94.9	96.5
15-19	*	100.0	91.0	93.3	93.8	92.6	96.3	94.9	100.0	97.1	100.0
20-29	95.8	90.9	90.6	88.5	91.1	91.8	94.8	89.0	92.4	91.1	90.0
30-39	81.5	87.6	84.4	88.4	86.7	86.0	84.0	87.4	88.4	88.7	90.3
40-49	85.4	83.5	83.7	85.1	84.8	85.0	83.5	87.5	87.4	87.5	89.5
50-59	80.0	81.2	80.3	79.9	81.2	78.3	79.5	82.4	83.0	82.8	85.5
60-64	78.3	73.6	75.3	73.9	72.0	76.8	76.3	74.6	78.0	77.8	78.7
65-69	67.9	68.9	67.8	71.8	67.0	68.4	68.2	67.8	74.4	74.0	75.6
70-79	51.0	64.6	63.2	60.2	63.2	71.0	64.6	65.2	65.1	66.9	64.6
80+	*	61.5	50.8	41.0	44.1	48.5	49.3	44.8	50.0	46.3	59.8
Male	79.1	78.8	79.3	78.1	78.7	79.5	79.6	80.8	80.3	80.5	82.3
Female	79.1	79.4	75.4	78.8	78.4	78.5	78.2	77.9	81.9	81.5	82.1
White	78.3	77.8	76.5	77.8	77.4	78.1	77.8	78.2	79.8	79.6	81.0
Black	81.1	82.2	80.1	79.7	81.8	81.9	81.8	82.3	83.5	83.8	84.9
Other race	89.7	94.7	76.7	85.1	81.3	81.2	86.9	87.1	90.5	88.7	88.2
†Hispanic											
†Non-Hispanic											
Diabetes	62.6	68.3	69.9	72.8	70.8	72.9	71.5	74.2	77.7	76.7	78.4
Hypertension	81.5	80.1	75.8	75.3	75.8	78.8	79.3	77.3	79.5	78.2	81.0
Glomerulonephritis	88.9	88.5	85.9	89.9	87.2	90.2	88.8	89.6	90.2	90.8	91.9
Other cause	83.8	82.3	82.3	79.9	83.1	78.9	81.8	81.4	80.1	83.3	82.6
All	79.1	79.1	77.4	78.5	78.6	79.0	79.0	79.4	81.1	81.0	82.2
ADJUSTED											
0-19	77.6	100.0	85.6	89.9	82.6	81.5	93.4	94.9	86.9	91.7	89.5
20-44	84.9	87.3	86.0	87.2	86.3	87.0	86.6	87.9	88.0	88.1	89.7
45-64	78.6	77.6	78.5	78.3	78.7	78.8	79.0	80.7	82.6	83.0	84.6
65-74	59.1	66.8	65.8	65.7	64.8	68.3	67.1	67.4	71.2	73.3	73.4
75+	50.7	55.8	53.4	50.0	53.6	62.9	56.1	55.7	56.2	54.3	58.5
Male	70.2	72.1	73.1	71.0	71.4	73.8	73.6	75.2	74.8	75.7	77.7
Female	68.5	72.1	69.3	71.7	71.0	71.6	71.3	72.2	76.0	76.4	78.0
White	66.6	69.1	69.2	69.8	69.0	71.3	70.5	72.1	73.8	74.8	76.6
Black	71.2	75.2	73.4	71.7	74.0	73.8	74.2	74.0	75.4	76.3	77.9
Other race	82.7	92.3	66.9	79.1	70.0	72.1	82.1	81.9	86.7	84.1	83.9
Diabetes	54.2	61.0	63.6	66.7	64.5	67.4	65.7	69.0	73.1	72.3	74.8
Hypertension	79.0	78.3	74.5	72.7	72.9	77.8	77.9	76.4	78.2	77.5	80.4
Glomerulonephritis	81.4	82.9	79.2	83.8	79.5	85.6	82.1	83.8	84.6	86.0	87.1
Other cause	75.7	78.0	78.2	74.6	78.0	72.6	75.6	75.7	73.5	77.4	76.2
All	69.5	72.0	71.1	71.3	71.1	72.8	72.5	73.8	75.4	76.0	77.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.24 (continued)

One-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	76.1	86.9	86.3	89.8	88.6	85.8	85.2	85.6	83.2	84.3	88.6	90.4	92.5
5-9	100.0	90.7	92.7	100.0	98.1	94.9	96.0	100.0	98.4	98.0	98.1	97.7	97.6
10-14	96.4	95.6	96.7	100.0	96.5	94.3	98.6	98.8	100.0	96.2	98.7	98.7	100.0
15-19	95.2	96.5	96.8	93.5	97.4	98.1	99.0	97.6	98.9	98.6	98.7	98.6	100.0
20-29	93.0	94.0	93.7	94.3	93.9	93.9	98.9	96.3	98.3	95.5	95.7	95.5	96.0
30-39	92.3	90.6	91.3	92.0	90.4	92.7	93.5	93.9	95.6	95.9	96.6	94.8	94.8
40-49	89.7	89.7	90.7	90.5	92.0	92.3	92.3	93.1	92.9	93.4	95.4	92.1	94.3
50-59	84.8	87.0	86.6	88.6	87.5	87.4	89.5	87.4	90.2	89.2	91.0	91.3	91.0
60-64	82.5	81.0	82.9	82.0	81.3	82.2	83.0	83.9	81.2	84.4	84.1	87.9	87.7
65-69	77.3	81.1	80.0	78.3	80.3	80.6	78.0	80.8	80.3	79.6	79.5	81.1	82.9
70-79	69.2	68.7	70.0	70.2	74.7	73.6	73.1	74.5	73.0	72.2	78.0	76.0	78.2
80+	61.3	60.4	57.7	58.9	65.6	60.7	57.0	60.0	60.2	61.8	63.2	58.5	65.4
Male	83.8	84.1	84.2	84.5	85.2	85.2	86.3	85.8	86.4	86.1	88.0	86.3	88.4
Female	84.1	84.6	84.9	84.9	85.8	85.8	85.3	86.3	86.1	86.0	86.9	87.8	87.8
White	82.6	83.5	83.5	83.7	84.5	84.0	84.2	84.2	84.8	84.3	85.8	85.1	86.8
Black	86.5	85.7	86.3	86.2	86.5	88.9	89.6	90.1	90.5	90.5	91.0	91.4	90.6
Other race	92.2	88.6	90.9	90.5	91.8	89.4	90.9	91.1	88.1	89.9	92.8	91.0	91.6
†Hispanic						89.6	88.6	90.8	91.3	90.4	92.2	88.6	90.3
†Non-Hispanic						84.9	85.5	85.4	85.6	85.4	86.9	86.7	87.8
Diabetes	80.4	80.9	82.1	81.5	82.2	82.1	81.6	82.6	83.2	82.8	85.1	83.3	85.7
Hypertension	83.5	83.7	82.6	82.4	85.9	85.7	85.3	84.3	84.4	84.8	85.9	86.8	86.2
Glomerulonephritis	90.1	91.7	93.1	93.3	93.1	92.8	93.6	94.9	95.4	95.3	93.7	96.1	95.7
Other cause	86.4	85.8	84.9	86.7	86.0	86.6	89.2	88.3	88.1	87.0	89.4	88.8	89.8
All	83.9	84.3	84.6	84.7	85.5	85.5	85.8	86.0	86.3	86.0	87.5	87.0	88.1
ADJUSTED													
0-19	82.4	88.4	87.5	91.6	90.8	88.6	90.7	90.2	90.4	88.2	92.2	93.0	94.9
20-44	91.3	90.4	90.9	91.5	91.2	92.8	94.1	94.3	95.0	95.0	96.1	94.5	94.5
45-64	85.9	86.6	87.1	87.8	87.6	87.8	89.0	88.2	89.3	89.4	90.5	90.9	91.2
65-74	75.3	77.4	78.9	76.5	78.6	79.7	78.6	81.1	79.1	78.9	81.8	79.7	82.8
75+	64.6	62.4	60.1	62.9	71.2	65.7	64.5	64.9	67.0	66.2	68.2	69.2	70.9
Male	79.7	80.3	80.7	81.3	82.3	82.5	84.2	83.6	84.5	84.3	86.5	84.5	86.8
Female	79.9	80.4	81.2	81.2	82.6	82.6	81.9	83.3	83.3	82.9	84.3	85.6	85.5
White	78.4	79.7	80.1	80.6	81.6	81.2	81.8	81.8	82.6	82.2	84.0	83.4	85.3
Black	80.5	79.3	80.1	80.1	81.5	84.2	85.2	86.3	86.7	86.6	87.5	88.3	87.2
Other race	88.6	84.2	87.9	86.3	89.4	86.9	88.3	87.8	85.3	86.3	91.1	89.0	89.6
Diabetes	76.7	77.2	79.1	78.5	79.3	79.4	79.4	80.4	81.1	80.8	83.4	81.6	84.2
Hypertension	82.2	83.2	81.9	82.0	85.3	85.5	85.3	84.4	84.7	84.9	86.4	87.3	86.6
Glomerulonephritis	84.9	86.8	89.3	89.6	89.5	89.0	89.9	91.7	92.6	92.8	90.4	94.1	93.0
Other cause	80.7	79.8	78.6	81.3	80.5	80.8	84.4	82.8	83.2	81.5	85.1	83.9	85.5
All	79.8	80.4	80.9	81.3	82.4	82.5	83.2	83.5	84.0	83.7	85.5	85.0	86.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.25

Two-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	*	95.5	80.5	75.9	78.3	75.6	90.1	91.7	71.6	90.4	69.9
5-9	*	100.0	90.0	91.7	77.0	83.3	84.4	100.0	100.0	100.0	86.9
10-14	*	78.8	98.0	100.0	89.5	98.1	93.3	100.0	94.5	91.9	87.2
15-19	*	100.0	88.0	89.8	87.0	87.7	90.2	92.3	97.0	95.1	97.9
20-29	80.8	78.4	81.1	81.7	76.6	80.1	87.2	78.6	86.2	83.0	81.5
30-39	66.4	76.7	74.4	80.5	74.9	73.2	71.1	76.1	79.1	78.4	79.5
40-49	72.7	70.1	68.5	70.1	69.6	72.8	70.0	75.1	75.4	74.1	80.0
50-59	65.0	67.1	64.3	64.3	65.9	61.4	61.7	62.5	66.5	67.4	69.2
60-64	66.7	52.5	52.8	54.8	51.9	55.8	55.4	57.7	60.5	59.3	57.6
65-69	39.6	54.9	47.3	51.3	51.2	47.8	42.8	46.4	52.9	52.4	56.0
70-79	46.9	42.1	43.1	37.9	37.7	47.2	38.2	43.1	42.4	42.2	40.9
80+	*	35.9	21.5	23.0	25.2	32.9	25.4	17.1	23.5	30.1	35.4
Male	64.9	64.0	63.5	61.8	61.7	60.0	61.0	63.4	63.9	63.6	64.6
Female	63.0	62.7	57.2	63.1	61.9	63.6	59.8	60.9	66.2	66.0	66.9
White	61.8	62.1	58.6	61.1	59.5	60.1	57.7	59.8	62.7	62.1	61.9
Black	71.4	67.0	65.4	65.5	67.5	67.2	67.6	69.2	71.3	70.3	74.1
Other race	79.2	68.0	63.2	68.8	68.8	63.6	67.6	61.2	67.7	75.4	83.0
†Hispanic											
†Non-Hispanic											
Diabetes	39.2	47.8	48.3	53.6	47.7	49.8	47.9	51.8	56.1	56.3	56.2
Hypertension	64.6	64.3	60.6	57.9	61.9	63.3	62.5	60.6	66.0	62.1	64.8
Glomerulonephritis	83.0	76.7	74.1	79.2	76.9	76.3	76.8	79.0	77.9	78.2	83.4
Other cause	70.7	68.5	66.1	65.8	67.2	64.9	64.4	67.2	66.6	71.6	71.1
All	64.0	63.3	60.5	62.5	61.8	61.8	60.4	62.2	65.0	64.7	65.7
ADJUSTED											
0-19	57.0	90.2	82.2	82.5	73.8	75.5	82.7	91.3	80.2	89.2	77.7
20-44	68.0	75.8	74.2	77.2	74.0	74.1	75.5	76.4	78.0	77.4	79.5
45-64	64.4	60.2	60.4	61.4	60.6	61.1	60.2	63.3	66.7	67.1	68.3
65-74	40.4	48.4	45.0	44.5	44.5	47.2	41.2	46.6	50.4	50.6	52.0
75+	29.2	33.4	30.7	28.4	30.7	39.4	30.9	29.8	29.3	33.4	35.4
Male	53.5	55.5	55.3	52.9	52.2	52.9	53.2	55.7	56.7	57.3	57.9
Female	48.5	52.6	49.9	54.0	52.2	54.9	50.5	53.8	57.8	58.7	61.2
White	46.8	51.0	49.5	51.2	49.1	51.7	48.7	52.1	55.0	55.8	56.1
Black	58.5	56.4	56.3	54.8	56.3	55.7	56.9	57.8	59.6	59.3	63.6
Other race	67.0	53.5	51.1	61.2	54.6	50.1	59.9	51.5	57.6	68.3	77.2
Diabetes	31.7	40.1	41.3	46.6	40.7	44.1	41.6	45.7	50.1	50.8	51.3
Hypertension	61.2	62.2	59.0	54.6	58.4	62.6	60.7	59.7	64.6	61.3	64.1
Glomerulonephritis	72.8	67.7	64.7	69.5	65.8	68.2	66.7	70.0	68.3	69.4	75.0
Other cause	59.0	62.4	60.4	59.1	59.8	56.9	55.8	59.3	58.0	63.6	62.7
All	51.3	53.9	52.5	53.4	52.1	53.9	52.0	54.7	57.3	57.9	59.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.25 (continued)

Two-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	76.1	84.4	84.5	83.5	78.4	81.3	77.1	81.4	81.6	74.3	83.3	79.2
5-9	100.0	90.7	92.7	91.1	93.4	94.9	96.0	95.2	95.4	98.0	91.0	86.2
10-14	96.4	85.7	93.0	100.0	93.6	89.8	92.1	97.0	100.0	94.0	94.8	97.1
15-19	95.2	94.8	87.0	91.4	93.5	91.2	95.6	89.5	96.8	93.4	95.1	98.6
20-29	84.3	87.8	88.0	88.1	89.5	87.8	91.8	92.1	93.3	92.8	88.9	90.0
30-39	81.9	80.2	82.1	81.4	84.2	84.4	84.7	85.6	88.7	90.6	88.8	90.7
40-49	75.0	79.1	78.3	78.2	80.6	82.4	82.2	82.8	82.5	84.3	87.1	84.8
50-59	67.3	71.3	72.7	73.2	72.4	73.2	74.7	73.2	76.8	76.6	77.1	80.4
60-64	61.4	61.0	66.3	64.7	62.8	63.6	67.1	64.9	65.9	69.9	69.5	73.4
65-69	54.5	59.0	60.9	61.6	61.4	61.2	56.0	62.7	59.8	60.6	66.2	63.4
70-79	48.5	47.6	48.2	48.1	51.1	50.8	52.1	52.5	51.0	48.8	58.5	53.6
80+	35.8	33.3	33.3	33.1	34.4	38.0	32.9	40.0	36.4	39.6	40.6	34.9
Male	65.4	67.3	69.5	68.6	69.7	69.6	70.6	70.3	71.7	72.3	73.3	73.8
Female	68.5	69.8	69.6	69.9	70.2	71.5	70.7	72.0	72.0	71.8	74.8	73.8
White	64.0	66.0	66.6	66.7	66.7	67.8	67.0	67.7	68.7	68.9	70.4	69.6
Black	72.8	73.6	74.9	72.9	76.0	76.7	79.4	78.5	79.8	79.4	81.6	83.0
Other race	78.4	77.1	81.5	82.3	78.7	76.3	79.3	81.0	79.2	80.4	84.6	82.5
†Hispanic						77.7	75.3	81.3	78.6	79.8	81.7	79.7
†Non-Hispanic						69.6	70.1	69.9	71.0	70.9	73.1	72.9
Diabetes	57.5	59.9	61.7	61.7	61.8	62.9	62.1	63.1	64.3	65.8	68.2	67.9
Hypertension	68.2	69.0	67.4	67.9	71.4	70.9	71.5	71.0	71.0	69.8	72.6	73.6
Glomerulonephritis	78.9	82.2	86.2	83.3	84.3	85.3	85.8	86.2	88.4	88.5	86.5	88.6
Other cause	74.7	74.9	75.5	75.4	75.5	75.9	77.3	78.6	78.1	76.0	79.4	77.4
All	66.8	68.5	69.5	69.2	69.9	70.5	70.6	71.1	71.8	72.1	74.0	73.8
ADJUSTED												
0-19	100.0	83.1	80.1	85.0	82.1	81.5	82.5	82.7	87.9	80.4	84.7	83.8
20-44	79.5	80.8	81.0	81.2	83.5	83.6	85.4	85.2	88.1	88.9	87.8	88.8
45-64	68.3	71.0	73.0	72.9	72.9	74.4	75.4	74.5	76.4	77.6	78.3	80.4
65-74	54.7	56.8	58.6	58.1	59.8	59.6	59.2	61.7	59.1	59.2	66.0	61.0
75+	40.4	38.0	39.0	38.6	40.8	43.1	39.9	44.8	43.8	42.5	48.1	45.4
Male	59.2	61.5	64.4	63.7	65.1	65.5	67.3	67.1	68.8	69.7	71.2	71.0
Female	62.4	63.6	63.8	64.2	65.2	66.7	65.4	67.4	67.4	67.0	70.7	70.2
White	58.3	60.6	61.9	62.3	62.6	64.1	63.7	64.6	65.6	66.2	68.0	67.4
Black	63.0	63.7	65.4	63.3	68.4	68.4	71.6	71.5	72.9	72.4	75.6	77.7
Other race	70.5	69.9	76.4	75.6	73.8	72.2	74.9	75.4	75.0	73.9	81.4	78.9
Diabetes	52.3	54.6	57.2	57.4	57.5	58.9	59.0	60.0	61.2	63.0	65.6	65.1
Hypertension	66.6	68.4	66.4	67.3	70.6	71.1	71.6	71.6	71.7	70.1	73.7	74.6
Glomerulonephritis	70.6	73.4	79.8	75.7	77.7	79.0	78.9	79.3	82.3	83.3	80.4	83.5
Other cause	66.2	66.3	67.0	67.2	67.5	67.2	69.2	70.2	70.7	67.8	72.5	69.2
All	60.6	62.5	64.1	64.0	65.2	66.0	66.5	67.3	68.2	68.5	71.0	70.7

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.26

Three-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to three years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	*	95.5	80.5	75.9	78.3	75.6	90.1	85.6	71.6	84.0	65.7	71.3
5-9	*	100.0	90.0	91.7	77.0	69.4	84.4	100.0	83.3	100.0	79.7	100.0
10-14	*	52.5	98.0	93.8	89.5	98.1	93.3	94.1	94.5	91.9	87.2	96.4
15-19	*	100.0	88.0	85.7	82.6	77.5	86.6	89.5	92.8	87.3	91.6	91.2
20-29	74.9	70.6	71.5	76.5	72.1	74.5	79.0	72.1	81.3	77.0	72.4	77.6
30-39	58.1	65.4	63.5	69.9	68.4	63.0	62.3	65.7	69.0	69.0	71.7	73.0
40-49	57.0	61.0	56.4	57.3	57.5	62.8	60.5	62.3	62.1	60.9	64.7	63.3
50-59	54.4	56.4	52.5	51.0	53.2	48.4	47.7	48.0	52.4	53.3	56.1	51.6
60-64	49.2	39.7	38.7	42.9	38.5	42.0	43.9	43.9	42.3	46.0	42.8	47.8
65-69	30.2	43.9	36.2	35.3	36.2	35.4	30.2	32.4	38.6	35.9	39.4	38.2
70-79	38.8	28.0	29.2	26.2	23.5	31.8	21.1	26.2	29.4	26.9	24.4	32.1
80+	*	15.4	10.8	13.1	19.4	12.5	16.6	10.5	13.7	13.8	22.8	23.6
Male	51.8	51.8	51.6	49.6	48.6	47.1	47.4	47.8	49.4	49.9	49.7	51.4
Female	53.6	51.6	44.8	50.6	51.1	50.8	49.0	49.3	53.7	52.3	53.6	54.9
White	49.4	49.2	46.2	47.0	47.5	46.5	44.4	44.9	47.5	47.1	46.7	48.9
Black	64.1	59.4	53.7	57.5	55.1	56.2	57.5	58.3	61.6	59.9	61.9	61.6
Other race	73.1	56.1	51.0	55.3	60.5	48.8	61.5	55.4	56.4	61.3	74.0	68.9
†Hispanic												
†Non-Hispanic												
Diabetes	26.3	33.8	33.1	36.4	33.5	35.1	35.4	36.2	39.0	39.6	39.4	41.0
Hypertension	56.7	51.5	48.6	48.4	48.9	52.0	50.7	47.0	52.4	48.8	51.5	55.1
Glomerulonephritis	72.8	69.6	64.9	70.7	67.5	62.9	65.2	68.1	68.0	68.1	72.0	69.3
Other cause	57.9	57.3	55.9	54.3	57.2	53.1	52.0	55.3	56.0	60.7	59.6	63.2
All	52.6	51.7	48.3	50.0	49.8	48.9	48.2	48.6	51.4	51.0	51.6	53.0
ADJUSTED												
0-19	57.0	85.0	82.2	77.1	71.7	67.5	80.5	85.4	75.3	81.9	70.9	78.1
20-44	58.7	65.2	63.5	68.2	66.0	64.9	66.4	65.8	67.2	67.7	69.5	70.9
45-64	49.7	48.6	47.5	47.9	47.2	48.0	47.8	49.5	51.7	53.3	53.9	53.8
65-74	31.2	35.3	31.9	31.0	30.4	33.6	27.4	30.7	36.2	33.7	35.0	38.8
75+	20.7	19.6	20.0	17.4	19.4	23.0	16.1	18.2	19.0	20.0	21.4	24.8
Male	39.9	43.2	43.1	40.7	39.0	40.6	39.7	40.1	42.2	43.6	42.8	45.2
Female	38.7	41.1	38.0	41.3	41.5	42.2	39.8	42.4	45.0	44.6	47.6	48.4
White	34.4	38.2	37.5	37.4	37.3	39.0	35.9	37.8	40.4	41.1	41.4	43.6
Black	49.7	47.9	43.9	46.1	43.0	43.7	45.7	45.6	48.2	47.7	49.6	50.4
Other race	59.4	39.7	39.1	48.6	45.4	34.9	53.6	45.3	45.9	53.4	66.6	59.6
Diabetes	20.8	27.4	27.4	30.6	27.9	30.9	29.9	31.0	33.8	34.7	35.0	36.4
Hypertension	53.3	49.5	47.5	45.2	45.6	51.7	48.9	46.9	51.3	48.5	51.3	53.7
Glomerulonephritis	59.9	59.9	54.8	59.4	55.2	54.1	53.7	57.6	56.8	57.5	60.9	59.8
Other cause	45.1	50.9	50.1	47.5	49.1	44.8	43.1	46.8	47.1	51.8	50.5	53.4
All	39.5	42.0	40.5	41.0	40.1	41.4	39.8	41.2	43.5	44.1	45.0	46.6

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.26 (continued)

Three-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to three years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	84.4	77.8	81.0	78.4	71.5	70.6	81.4	81.6	71.2	78.9
5-9	90.7	85.0	85.0	93.4	94.9	96.0	89.6	95.4	93.5	91.0
10-14	85.7	79.7	94.7	86.3	85.7	88.5	97.0	100.0	90.6	94.8
15-19	92.6	83.5	91.4	91.2	89.4	90.8	84.5	85.5	87.2	92.8
20-29	80.6	82.2	84.6	84.2	82.6	86.8	87.4	85.2	85.8	81.4
30-39	68.4	70.8	71.7	76.0	77.3	78.9	78.7	81.8	83.4	84.0
40-49	64.5	65.9	67.4	70.1	71.1	72.1	72.0	74.1	72.3	77.3
50-59	57.9	56.8	58.1	59.2	59.4	59.2	61.6	63.5	65.4	64.9
60-64	46.3	49.9	50.7	47.2	49.2	53.5	51.5	49.4	54.3	54.3
65-69	42.9	43.3	42.7	46.8	46.2	40.1	43.4	41.6	45.0	46.8
70-79	28.8	34.1	31.2	36.1	35.6	34.4	36.5	34.1	34.4	41.2
80+	20.1	18.6	15.4	15.8	20.3	17.9	20.0	20.4	24.6	26.1
Male	51.9	54.2	53.4	56.0	55.7	55.2	55.6	57.6	57.3	58.8
Female	56.4	55.8	56.7	57.7	59.3	59.0	60.3	58.8	61.5	62.5
White	49.7	50.5	50.6	52.4	53.2	52.3	53.9	54.1	55.0	56.2
Black	62.6	63.8	62.2	65.2	66.8	68.7	67.3	68.1	68.7	70.0
Other race	69.3	68.8	72.4	67.5	65.1	65.4	66.7	67.7	70.9	72.0
†Hispanic					64.2	65.4	68.1	66.6	69.2	71.1
†Non-Hispanic					56.5	56.0	56.7	57.1	57.8	59.4
Diabetes	43.5	43.8	44.1	45.5	46.4	46.2	47.0	48.0	51.0	52.5
Hypertension	53.3	53.9	53.7	58.5	58.6	57.4	60.1	57.3	58.3	60.0
Glomerulonephritis	74.0	74.1	73.9	75.9	76.3	76.2	75.7	80.3	80.3	74.9
Other cause	62.4	66.0	65.8	67.3	67.8	67.2	69.0	68.1	64.0	70.0
All	54.0	55.0	55.0	56.8	57.4	57.0	57.9	58.2	59.3	60.7
ADJUSTED										
0-19	81.7	70.3	80.8	77.7	75.6	76.3	79.2	82.4	74.3	81.8
20-44	69.2	69.7	72.4	75.5	75.7	78.9	77.1	80.1	79.0	80.6
45-64	57.1	58.1	58.9	59.5	61.2	61.7	62.9	63.8	65.8	66.2
65-74	39.9	42.2	40.4	45.4	44.6	41.8	44.2	41.8	44.5	48.7
75+	20.9	26.0	21.6	24.2	27.4	24.9	28.0	27.6	28.1	31.5
Male	46.0	49.0	48.3	51.2	51.4	51.6	52.4	54.7	54.6	56.8
Female	49.5	49.5	50.4	52.3	53.9	53.2	55.3	53.5	56.2	58.1
White	44.6	46.1	46.5	48.5	49.8	49.4	51.2	51.3	52.7	54.4
Black	51.0	52.7	51.2	56.1	56.8	58.6	58.5	59.1	59.6	62.1
Other race	60.8	62.7	64.1	61.4	60.2	59.9	59.4	62.5	62.7	67.6
Diabetes	38.6	39.7	40.1	41.5	42.8	43.4	44.2	45.0	48.2	50.0
Hypertension	52.9	53.4	53.5	57.7	59.0	57.9	61.4	58.7	58.9	61.8
Glomerulonephritis	63.0	64.9	64.0	67.1	68.0	66.6	65.7	71.4	72.8	66.0
Other cause	52.4	56.4	56.2	58.3	57.8	57.7	58.8	59.3	54.1	61.7
All	47.6	49.2	49.3	51.7	52.6	52.5	53.8	54.2	55.5	57.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.27

Five-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	
0-4	*	95.5	80.5	75.9	78.3	61.8	90.1	85.6	71.6	84.0	65.7	71.3	67.2	64.0	72.6	64.7	65.3	66.9	70.7	81.6	
5-9	*	100.0	90.0	91.7	77.0	52.1	70.3	100.0	83.3	81.8	79.7	100.0	90.7	85.0	79.0	65.4	94.9	96.0	80.7	95.4	
10-14	*	26.3	87.1	93.8	79.5	98.1	93.3	87.4	85.1	73.5	80.5	72.3	85.7	63.8	83.6	86.3	85.7	88.5	69.3	88.9	
15-19	*	100.0	78.2	85.7	67.6	64.0	76.7	85.0	83.9	78.7	77.8	81.3	88.9	83.5	81.1	88.0	82.2	87.8	77.9	78.4	
20-29		70.8	54.8	57.4	65.9	52.4	61.2	64.3	59.8	69.8	60.0	55.8	67.0	70.2	72.2	75.8	71.4	74.4	82.1	75.7	75.4
30-39		47.6	49.4	46.1	49.7	51.0	47.4	46.2	47.2	54.1	54.6	54.0	53.3	51.7	54.9	58.9	58.5	62.0	64.2	62.8	65.8
40-49		40.0	43.1	42.3	39.8	40.2	46.7	44.1	41.0	46.3	43.4	45.2	45.9	42.4	49.7	48.9	52.1	50.9	50.5	52.5	55.8
50-59		35.1	38.9	34.6	34.3	33.6	30.0	32.4	31.3	30.5	33.4	32.1	30.3	36.9	38.0	35.9	37.1	38.0	37.4	41.5	39.8
60-64		35.8	21.6	21.8	22.6	18.9	22.1	26.8	24.9	24.4	24.2	21.9	25.9	26.0	28.9	29.5	26.5	27.3	30.8	27.3	30.4
65-69		18.9	21.3	17.1	16.4	19.1	21.1	16.6	17.1	19.3	16.4	21.8	16.7	23.0	23.4	21.8	23.3	23.1	20.7	22.5	21.1
70-79		18.4	12.2	11.6	10.4	8.1	16.0	7.1	14.0	11.3	12.8	9.9	13.6	13.5	13.3	12.2	16.8	15.6	14.7	16.1	16.1
80+	*	2.6	3.1	0.0	7.8	1.6	9.1	1.3	4.9	6.5	7.1	6.6	6.9	4.5	6.9	4.9	5.4	6.3	5.4	8.7	
Male		35.9	31.2	31.6	30.3	29.0	30.9	31.3	30.6	30.3	31.5	29.7	30.7	32.2	34.9	33.5	34.1	34.0	34.5	36.9	
Female		39.1	35.8	29.7	33.1	33.3	31.6	33.3	31.9	35.7	33.5	34.5	37.0	36.8	37.0	37.3	39.7	39.5	39.9	39.8	
White		32.9	30.0	28.4	28.4	28.9	28.2	28.1	27.3	27.9	25.8	27.7	29.5	30.4	29.6	31.0	31.1	30.6	31.7	32.6	
Black		56.0	43.3	36.5	39.8	36.1	40.2	41.5	41.3	45.7	42.7	44.1	42.8	44.8	46.4	44.9	47.4	50.1	49.8	48.4	51.4
Other race		53.1	56.1	35.1	33.0	40.1	32.5	51.3	41.4	38.0	41.0	50.8	44.9	46.5	49.1	54.1	43.9	43.0	50.5	51.1	49.4
†Hispanic																	44.0	44.1	43.3	45.8	
†Non-Hispanic																	36.0	35.8	36.4	37.3	
Diabetes		16.3	18.4	16.4	18.4	16.9	18.0	18.1	17.0	20.4	19.1	17.6	19.3	21.4	23.7	24.5	23.1	24.5	24.7	24.8	26.0
Hypertension		41.9	31.6	32.7	34.1	31.3	35.6	35.6	32.4	34.5	31.7	34.0	35.3	36.5	36.9	34.3	40.0	39.4	37.5	37.5	38.9
Glomerulonephritis		53.3	48.4	46.8	47.1	46.4	46.0	49.2	52.9	48.7	52.9	53.6	51.2	58.0	54.4	53.2	58.8	56.8	58.8	60.2	62.6
Other cause		41.3	39.7	36.3	35.4	37.2	33.6	38.2	38.2	38.3	42.2	40.0	43.3	43.7	47.9	47.8	48.8	50.7	49.4	53.4	52.5
All		37.4	33.5	30.7	31.7	31.1	31.3	32.2	31.3	32.9	32.4	31.6	32.5	34.5	35.8	35.2	36.4	36.9	36.6	37.2	38.3
ADJUSTED																					
0-19		57.0	79.2	69.6	77.1	62.3	53.3	71.7	79.4	68.0	68.5	62.3	65.9	72.4	62.1	67.6	67.9	69.3	73.5	63.3	75.5
20-44		46.8	49.6	48.5	49.4	47.8	50.1	51.0	50.0	52.0	51.7	51.1	52.7	52.1	55.6	58.2	58.1	59.6	62.2	60.3	63.9
45-64		32.5	30.1	30.1	30.0	27.8	28.7	31.6	30.3	32.2	33.0	31.1	33.0	36.0	38.7	37.6	38.6	40.0	40.3	42.1	42.7
65-74		16.8	16.1	14.0	14.1	14.2	20.1	13.2	16.5	17.1	15.8	18.7	17.8	21.6	21.6	19.9	23.3	22.0	21.1	22.5	22.2
75+		8.7	6.0	7.5	4.1	7.4	7.8	6.1	8.2	6.1	9.7	6.8	8.7	7.2	7.9	7.8	9.2	11.2	9.8	11.5	12.0
Male		25.8	24.9	25.5	23.9	22.0	26.4	25.4	24.6	25.0	26.9	24.5	26.4	27.8	31.1	29.9	31.7	31.0	31.5	32.4	35.1
Female		25.8	26.6	24.7	25.8	25.9	25.4	25.7	27.1	28.6	27.4	29.3	29.3	31.4	31.7	31.7	33.1	35.3	34.8	36.1	35.0
White		20.8	21.8	22.5	21.8	21.6	23.6	22.1	22.9	23.5	24.4	23.1	24.8	26.7	28.3	27.5	29.1	29.9	29.8	31.1	31.7
Black		40.9	31.6	27.6	29.1	25.4	28.5	30.2	29.4	32.1	30.8	32.1	31.7	33.2	35.2	34.0	37.9	39.2	38.8	38.7	41.4
Other race		39.0	39.7	25.2	31.0	28.1	22.1	44.2	29.8	29.1	34.0	42.2	35.5	37.7	43.5	45.8	37.9	38.4	45.2	43.6	44.4
Diabetes		12.9	14.9	13.6	15.6	14.2	16.7	15.1	14.7	17.4	16.8	16.0	17.4	19.1	21.6	22.2	21.4	22.8	23.5	23.9	24.8
Hypertension		39.6	29.8	33.0	31.5	29.1	36.1	34.0	33.4	34.7	32.4	34.7	35.0	36.9	37.2	34.8	39.5	40.4	38.9	40.4	40.9
Glomerulonephritis		38.3	39.2	37.6	36.3	35.5	38.5	38.3	42.0	37.2	42.2	41.2	42.0	45.2	43.4	41.5	48.0	46.7	47.2	47.9	50.6
Other cause		29.1	34.1	31.5	29.6	29.9	26.8	30.4	30.6	30.3	34.1	31.8	33.5	34.3	38.5	37.6	39.5	39.7	39.4	42.1	43.2
All		26.0	25.6	25.0	24.7	23.8	26.0	25.5	25.8	26.7	27.2	26.7	27.7	29.5	31.4	30.8	32.3	33.1	33.1	34.2	35.1

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.28

Ten-year survival probabilities: incident CAPD/CCPD patients*censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	*	95.5	80.5	75.9	67.1	49.5	90.1	85.6	44.8	84.0	41.1	62.4	52.3	54.8	66.0
5-9	*	80.0	67.5	91.7	77.0	34.7	70.3	100.0	83.3	65.5	59.8	100.0	75.6	34.0	79.0
10-14	*	26.3	56.5	82.0	79.5	65.4	35.0	87.4	70.9	36.7	40.2	72.3	85.7	63.8	58.5
15-19	*	58.3	68.4	71.4	25.4	38.5	57.2	78.9	83.9	62.9	46.9	44.8	55.7	46.4	57.9
20-29	56.6	34.8	33.0	48.1	39.7	38.1	41.4	36.1	43.8	38.7	38.2	38.3	46.3	50.3	55.8
30-39	25.0	26.4	23.3	27.5	28.6	24.6	28.2	24.1	28.4	29.2	31.7	28.4	22.8	31.3	29.3
40-49	19.9	19.7	15.2	21.4	20.0	18.4	17.1	19.5	21.6	19.5	18.1	19.2	16.7	21.6	22.2
50-59	14.4	13.6	9.7	11.0	9.6	10.7	8.3	9.5	9.0	9.6	10.0	8.3	9.9	9.2	10.8
60-64	7.5	7.4	4.6	4.8	4.8	5.1	6.9	4.5	6.0	4.5	3.3	4.2	5.4	5.6	6.3
65-69	5.7	4.3	2.7	3.8	4.6	7.8	4.0	1.7	2.6	3.4	3.9	2.5	4.1	3.6	4.1
70-79	6.1	1.2	1.7	1.9	0.7	3.3	1.9	0.9	1.4	1.3	1.7	1.8	1.8	1.3	1.3
80+	*	2.6	.	.	3.9	0.8	0.8	0.9	1.4	.	0.6
Male	15.4	12.8	10.5	12.7	10.7	10.9	11.3	10.6	10.0	10.6	10.1	9.6	10.3	11.2	10.4
Female	18.3	13.6	9.7	13.6	14.3	12.6	12.5	11.7	14.8	13.2	12.1	12.2	12.2	12.7	14.8
White	14.9	11.9	9.6	11.3	10.6	9.9	9.8	8.7	7.8	8.3	8.0	7.5	8.3	8.7	8.8
Black	24.4	16.5	11.4	17.5	16.8	16.9	16.9	16.9	22.6	19.4	17.8	17.6	17.4	18.1	19.7
Other race	23.9	24.9	12.8	17.6	17.4	13.3	17.6	23.1	21.0	19.8	20.3	18.9	15.2	19.6	20.6
Diabetes	5.7	4.5	2.0	5.3	5.6	4.5	3.5	4.0	5.6	3.8	3.3	3.6	3.7	4.1	5.6
Hypertension	13.5	12.8	10.5	14.4	12.4	12.1	13.4	10.3	13.8	11.4	11.4	13.2	11.3	13.9	13.5
Glomerulonephritis	28.4	18.0	21.2	21.2	24.5	20.9	24.8	22.5	20.8	25.8	24.4	19.5	26.5	25.6	25.1
Other cause	21.0	18.2	13.6	16.4	13.2	14.8	15.3	16.6	14.9	17.4	17.5	17.8	18.8	18.8	19.2
All	16.8	13.2	10.2	13.1	12.5	11.7	11.9	11.2	12.3	11.8	11.0	10.8	11.2	11.9	12.5
ADJUSTED															
0-19	40.6	45.4	45.5	63.2	42.2	31.9	50.1	75.3	55.4	48.8	32.2	43.9	47.1	37.4	47.8
20-44	27.3	28.1	22.8	28.7	28.7	26.2	28.1	27.6	28.3	27.8	27.5	26.3	25.4	29.8	31.2
45-64	11.7	10.5	8.6	10.3	8.5	9.0	9.1	9.2	10.7	10.0	9.0	9.6	10.5	11.6	12.3
65-74	4.7	2.6	2.7	3.3	3.2	6.3	3.7	2.4	2.4	3.3	3.6	3.3	3.7	3.5	3.6
75+	4.4	1.6	0.6	0.9	2.0	3.0	0.9	1.3	0.8	0.3	0.6	0.5	1.4	0.3	1.2
Male	11.3	10.6	9.0	10.2	7.9	10.7	9.7	8.7	8.3	9.0	8.4	8.7	9.4	10.5	10.1
Female	11.2	10.4	8.8	10.7	12.0	11.1	9.9	11.0	12.3	11.1	11.3	11.0	11.2	11.6	13.2
White	9.4	9.3	8.4	9.1	8.4	10.2	8.6	8.6	7.9	8.2	8.4	8.1	9.3	9.7	10.1
Black	14.5	10.3	8.0	11.6	10.9	10.9	10.3	10.4	13.7	12.0	11.1	11.3	11.1	11.8	13.2
Other race	15.7	15.1	10.4	21.2	11.5	8.2	15.9	12.4	13.5	16.4	15.3	13.9	11.1	19.4	17.8
Diabetes	4.8	4.1	2.3	5.2	5.5	6.0	3.7	4.3	5.3	3.9	3.8	3.9	4.4	4.8	6.0
Hypertension	17.4	13.3	13.4	14.7	11.9	15.5	13.8	13.3	15.1	13.3	12.8	14.0	13.1	15.1	15.6
Glomerulonephritis	17.2	15.3	16.0	15.0	17.9	17.9	17.8	15.9	13.6	19.3	16.9	15.8	18.8	18.0	16.8
Other cause	13.4	15.4	11.3	13.1	9.9	11.5	11.9	12.2	10.6	12.9	13.5	12.5	13.8	14.1	12.6
All	11.3	10.4	8.9	10.4	9.8	11.0	9.8	9.8	10.1	10.0	9.7	9.7	10.3	11.0	11.6

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

*Values for cells with ten or fewer patients are suppressed.

." Zero values in this cell.

Table I.29

90-day patient survival probabilities: first transplants, deceased donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	92.9	92.0	94.4	94.1	95.7	95.0	97.8	94.5	98.0	97.9	92.3
5-9	97.0	98.2	98.1	100.0	97.9	100.0	100.0	100.0	100.0	98.5	91.5
10-14	96.7	98.7	100.0	98.3	99.2	97.7	97.6	96.7	97.7	97.8	97.3
15-19	98.0	96.9	97.6	96.7	97.3	97.5	98.1	97.9	98.3	96.6	96.7
20-29	95.1	97.2	97.1	97.4	97.2	98.0	96.9	97.7	97.4	97.2	98.6
30-39	93.1	94.0	94.8	95.6	97.0	96.7	96.3	97.0	96.9	97.0	96.8
40-49	92.2	92.5	95.0	94.1	95.7	95.1	95.4	94.8	96.3	95.7	96.0
50-59	89.9	90.3	89.9	93.0	93.2	90.6	92.3	93.0	93.4	94.1	95.0
60-64	100.0	95.5	90.9	91.5	90.8	94.6	92.1	94.3	91.0	94.6	94.2
65+	*	*	*	*	95.5	93.1	84.8	82.5	89.6	91.9	93.1
Male	94.1	94.5	95.3	95.7	96.0	95.7	95.2	95.3	95.5	95.6	96.2
Female	92.8	94.4	95.0	95.2	96.6	96.1	96.4	96.5	96.6	96.7	96.3
White	93.8	94.7	95.1	95.4	96.3	96.0	95.4	95.6	95.8	95.8	96.0
Black	92.4	93.8	95.6	95.7	95.9	95.8	96.2	96.1	96.2	96.7	97.2
Other race	97.4	93.9	94.1	96.4	96.7	93.3	97.5	96.9	96.2	96.6	95.6
†Hispanic											
†Non-Hispanic											
Diabetes	91.3	92.9	94.1	93.6	96.0	95.3	93.4	94.3	94.5	95.4	95.3
Hypertension	97.3	94.5	95.5	97.2	96.6	94.5	95.9	95.7	96.8	96.3	96.8
Glomerulonephritis	96.6	96.5	97.0	96.9	97.0	97.5	97.0	96.9	95.9	96.5	97.1
Other cause	91.3	93.6	94.1	94.6	95.5	95.3	95.8	95.7	96.4	95.9	96.0
All	93.6	94.5	95.2	95.5	96.2	95.8	95.6	95.7	95.9	96.0	96.3
ADJUSTED											
0-19	96.0	96.1	97.5	97.2	97.8	98.8	98.8	96.5	97.7	96.7	92.9
20-44	92.6	93.7	94.9	95.1	96.4	96.6	96.2	96.2	96.6	96.5	97.0
45-64	87.9	89.8	90.8	92.2	92.6	91.0	92.0	93.4	93.7	94.1	94.3
65+	*	*	*	*	92.7	93.3	86.2	86.2	87.3	89.0	94.0
Male	84.2	85.3	87.4	88.7	89.8	89.5	88.7	89.3	90.3	90.5	92.1
Female	80.5	84.3	86.9	87.8	91.3	90.4	91.4	91.9	92.4	92.7	92.1
White											
Black	83.3	86.0	89.7	90.6	90.8	91.2	92.2	92.3	92.8	93.6	94.6
Other race	93.2	82.7	82.6	87.9	91.4	82.7	93.1	91.6	90.7	92.4	90.5
Diabetes	83.1	86.1	88.6	87.9	92.3	91.4	88.0	90.1	90.5	92.0	92.0
Hypertension	94.8	89.4	91.6	94.9	94.2	90.6	93.0	92.7	95.0	94.2	95.1
Glomerulonephritis	91.0	90.5	92.2	91.8	92.5	94.0	93.0	93.1	91.4	92.6	94.0
Other cause	81.6	85.9	86.6	87.9	90.0	89.8	91.1	91.2	93.0	92.0	92.1
All	82.9	85.1	87.3	88.4	90.4	89.9	89.7	90.4	91.2	91.4	92.1

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.29 (continued)

90-day patient survival probabilities: first transplants, deceased donors*by age, gender, race/ethnicity, primary diagnosis*

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	97.6	95.9	93.3	97.5	97.7	96.4	96.4	100.0	96.6	97.4	100.0	98.2	100.0
5-9	100.0	100.0	98.2	96.4	96.4	98.5	98.3	96.4	98.1	98.0	100.0	100.0	100.0
10-14	99.0	98.9	100.0	99.4	99.2	97.2	99.1	100.0	100.0	99.1	97.6	100.0	99.4
15-19	99.6	99.1	98.2	99.6	99.1	99.0	97.8	99.5	98.8	99.5	100.0	99.4	98.9
20-29	98.8	98.1	98.9	99.0	98.9	99.2	99.0	98.9	99.2	98.7	98.8	97.9	99.2
30-39	98.2	97.9	98.4	98.0	98.0	98.1	97.8	98.2	98.0	98.4	98.8	98.5	98.5
40-49	97.0	97.0	97.2	97.5	97.4	96.7	97.1	97.7	97.5	97.5	97.6	97.3	98.1
50-59	95.5	95.7	95.5	95.9	96.0	96.3	95.8	96.6	96.1	95.9	96.5	96.5	96.8
60-64	95.8	93.2	95.4	96.5	93.3	95.2	96.0	97.0	95.0	94.6	95.7	96.1	95.7
65+	92.6	93.3	92.5	96.0	94.2	95.2	93.9	95.7	94.1	94.9	94.5	94.9	95.8
Male	97.1	96.9	97.0	97.3	97.1	97.0	97.2	97.8	97.2	96.9	97.2	97.2	97.3
Female	97.4	96.9	97.4	97.8	97.3	97.4	96.7	97.4	97.1	97.4	97.6	97.3	98.0
White	97.3	96.6	97.2	97.2	96.7	97.2	96.8	97.5	97.2	97.1	97.5	97.2	97.5
Black	97.0	97.4	96.9	98.0	98.1	96.7	97.1	97.8	97.3	96.7	97.2	97.3	97.6
Other race	97.4	97.8	98.6	98.6	97.8	98.4	98.3	98.5	96.8	98.4	97.3	97.4	97.9
†Hispanic						99.0	97.4	98.5	97.8	97.5	97.6	98.0	97.9
†Non-Hispanic						96.9	97.0	97.5	97.1	97.1	97.4	97.1	97.5
Diabetes	96.2	95.3	96.7	96.3	96.2	96.7	96.5	96.9	96.1	96.8	96.7	96.5	96.8
Hypertension	97.6	96.8	97.2	97.8	96.8	97.1	97.0	98.1	97.5	95.9	96.9	96.7	97.7
Glomerulonephritis	98.4	97.8	98.2	98.6	98.0	97.9	97.9	98.2	98.4	98.3	98.8	98.4	98.5
Other cause	96.9	97.6	96.8	97.4	97.8	97.0	96.9	97.6	97.2	97.4	97.6	97.6	97.8
All	97.3	96.9	97.2	97.5	97.2	97.1	97.0	97.6	97.2	97.1	97.4	97.2	97.6
ADJUSTED													
0-19	99.0	98.0	97.3	98.6	98.8	97.8	98.1	99.0	98.5	98.6	98.7	99.1	99.3
20-44	98.0	97.4	98.4	98.2	98.1	98.2	98.1	98.4	98.1	98.2	98.6	98.4	98.6
45-64	95.7	95.7	95.6	96.4	96.1	96.1	96.0	96.9	96.4	96.5	96.9	96.6	97.1
65+	92.1	92.4	93.2	94.9	92.5	93.9	93.5	95.4	94.1	93.9	94.3	94.9	95.6
Male	94.1	93.7	94.2	94.8	94.6	94.5	95.1	96.2	95.3	95.0	95.6	95.7	96.0
Female	94.7	93.8	95.0	95.9	94.9	95.3	94.1	95.4	94.9	95.7	96.1	95.7	96.8
White													
Black	94.3	95.0	94.5	96.4	96.6	94.3	95.3	96.3	95.6	94.8	95.7	95.9	96.4
Other race	94.3	95.1	97.1	97.2	95.3	97.0	96.9	97.3	94.8	97.4	95.6	95.8	96.9
Diabetes	93.7	92.4	94.7	94.3	94.1	95.0	94.8	95.5	94.5	95.6	95.5	95.4	95.9
Hypertension	96.2	95.2	95.9	96.8	95.4	96.0	95.9	97.5	96.6	94.6	96.0	95.9	97.1
Glomerulonephritis	96.6	95.5	96.3	97.3	96.2	96.2	96.1	96.8	97.1	97.0	97.9	97.3	97.6
Other cause	94.1	95.4	93.9	95.2	95.9	94.6	94.5	95.8	95.1	95.6	95.9	96.1	96.5
All	94.4	93.8	94.5	95.2	94.7	94.9	94.7	95.9	95.2	95.3	95.8	95.7	96.3

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.30

One-year patient survival probabilities: first transplants, deceased donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	71.4	88.0	94.4	91.2	91.3	91.7	97.8	90.9	84.3	95.8	84.6	90.2
5-9	97.0	98.2	98.1	100.0	97.9	98.4	96.3	98.5	100.0	95.5	91.5	98.0
10-14	91.3	96.1	100.0	94.9	98.3	95.3	97.6	95.9	96.9	94.4	92.7	98.0
15-19	95.9	93.8	95.7	96.3	94.9	96.7	95.5	95.0	98.3	93.6	96.0	98.3
20-29	90.6	93.5	93.9	94.5	94.2	96.1	93.7	95.3	94.4	95.6	96.7	97.1
30-39	86.2	88.7	90.6	90.0	92.8	93.4	92.4	93.3	93.8	94.5	94.0	95.6
40-49	83.5	83.9	88.5	87.1	88.6	90.0	89.6	89.2	92.1	91.4	91.6	94.2
50-59	81.9	79.6	77.7	83.5	85.9	82.8	84.7	86.1	87.5	89.4	90.1	91.4
60-64	75.0	72.7	81.8	78.7	84.6	88.2	86.5	86.5	84.1	88.3	88.1	90.1
65+	*	*	*	*	63.6	72.4	69.7	80.7	83.0	87.4	83.1	85.1
Male	87.3	88.4	90.0	91.2	90.9	91.2	90.5	90.7	91.3	92.0	92.0	93.9
Female	86.6	88.6	90.3	88.5	92.0	92.9	91.7	92.4	92.9	93.5	93.2	94.7
White	87.2	89.1	89.9	89.9	91.3	92.1	90.8	91.2	91.7	92.2	91.9	94.1
Black	86.3	86.6	91.7	90.7	91.3	91.1	91.3	91.6	92.7	93.5	94.3	94.4
Other race	89.7	87.8	82.4	93.6	91.7	90.8	92.4	93.2	91.0	94.3	92.4	95.1
†Hispanic												
†Non-Hispanic												
Diabetes	82.2	83.5	85.8	84.4	88.6	90.9	86.7	88.4	89.1	91.2	90.4	91.2
Hypertension	91.8	91.0	91.6	91.1	91.9	89.1	92.4	92.1	93.5	93.2	92.6	95.3
Glomerulonephritis	92.6	92.9	94.1	93.8	93.1	95.0	93.6	93.9	93.0	94.1	94.7	95.7
Other cause	83.4	86.3	88.0	89.4	91.0	90.9	90.9	90.7	92.0	91.9	92.1	94.9
All	87.1	88.5	90.1	90.2	91.3	91.8	91.0	91.3	91.9	92.6	92.5	94.3
ADJUSTED												
0-19	90.5	93.3	97.0	94.5	95.6	96.7	97.2	93.4	94.6	93.4	90.1	96.0
20-44	85.4	87.4	89.6	89.7	91.4	93.5	92.0	92.1	92.9	93.7	93.8	95.3
45-64	76.3	77.7	80.9	82.2	84.6	83.2	83.9	86.2	88.0	88.6	89.1	91.9
65+	*	*	*	*	61.0	71.4	77.6	79.8	77.0	82.6	83.5	84.0
Male	68.7	71.1	74.9	77.9	78.1	79.4	78.8	79.8	81.9	83.2	83.9	87.8
Female	66.6	70.4	76.0	72.8	80.6	83.1	81.0	83.1	84.8	86.1	85.8	89.3
White	66.8	71.2	74.3	74.5	78.6	80.7	78.8	80.1	82.2	83.3	83.5	88.2
Black	71.6	71.5	81.4	80.4	81.2	82.0	82.7	84.1	86.4	87.5	89.0	89.5
Other race	75.5	68.4	56.3	79.7	79.5	76.9	80.3	82.5	79.1	87.5	84.1	89.4
Diabetes	67.5	69.8	74.0	72.3	78.9	83.6	76.6	80.4	81.7	84.9	84.1	85.8
Hypertension	84.7	83.1	84.8	84.3	86.5	81.8	87.3	86.8	89.8	89.4	88.8	92.8
Glomerulonephritis	81.1	81.3	85.3	84.4	83.4	88.0	85.4	86.6	85.7	87.7	89.4	91.4
Other cause	67.2	71.5	74.3	77.5	80.7	80.8	81.5	81.5	84.8	84.6	84.9	90.2
All	68.1	71.1	75.4	76.1	79.1	80.9	79.7	81.2	83.1	84.4	84.7	88.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.30 (continued)

One-year patient survival probabilities: first transplants, deceased donors

by age, gender, race/ethnicity, primary diagnosis

UNADJUSTED	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	93.9	91.1	92.5	95.5	96.4	94.5	100.0	93.1	97.4	95.6	94.6	98.1
5-9	100.0	96.4	94.6	92.7	98.5	98.3	96.4	96.3	95.9	100.0	98.4	100.0
10-14	98.9	99.0	95.5	99.2	96.3	98.3	99.0	98.6	99.1	97.6	100.0	96.9
15-19	98.1	96.5	97.2	97.9	98.4	96.1	97.3	97.9	99.1	99.4	98.9	98.4
20-29	96.1	97.1	97.3	97.6	97.6	97.3	97.8	97.6	97.4	96.8	96.5	98.3
30-39	95.3	95.8	94.9	96.0	96.1	96.0	96.5	96.6	96.4	97.6	96.8	96.3
40-49	93.8	94.1	93.9	94.2	93.8	94.5	95.2	94.4	94.4	95.2	94.7	95.2
50-59	90.2	91.3	91.5	91.8	92.2	91.0	92.5	92.7	90.5	92.3	93.0	92.7
60-64	88.7	87.7	90.3	87.2	89.8	90.6	89.2	88.6	89.1	90.9	90.6	90.2
65+	88.8	82.5	88.2	87.4	90.4	85.8	88.9	87.4	88.7	86.6	89.2	90.1
Male	93.4	93.6	93.5	93.8	94.1	93.9	94.4	94.1	93.2	94.2	94.0	93.9
Female	94.0	94.0	94.4	94.5	94.4	93.7	94.6	94.2	94.2	94.6	94.8	95.0
White	93.2	93.4	93.4	93.3	94.1	93.7	94.3	94.1	93.7	94.6	94.3	94.2
Black	94.3	94.2	94.5	95.6	94.4	93.6	94.6	94.1	93.1	93.9	94.3	94.0
Other race	96.4	96.2	95.7	95.9	94.9	96.0	96.0	94.2	95.2	94.0	94.7	96.3
†Hispanic					96.3	95.5	96.1	94.8	94.6	95.4	96.3	95.2
†Non-Hispanic					94.0	93.6	94.3	94.0	93.5	94.2	94.0	94.2
Diabetes	91.1	91.7	91.9	92.1	92.5	92.4	92.8	92.4	91.8	92.9	92.5	92.6
Hypertension	93.1	93.7	94.4	93.9	95.0	92.9	94.6	93.3	91.8	93.0	94.1	93.9
Glomerulonephritis	95.8	96.3	96.0	95.9	95.6	95.7	96.1	96.4	96.3	97.1	96.4	96.3
Other cause	94.4	93.7	93.4	94.6	94.3	94.5	95.1	94.7	94.7	94.9	95.2	95.3
All	93.6	93.8	93.8	94.0	94.2	93.8	94.5	94.1	93.6	94.4	94.3	94.3
ADJUSTED												
0-19	97.5	95.0	94.3	97.6	97.8	96.7	98.0	96.6	98.6	97.8	97.8	97.5
20-44	94.5	95.7	95.3	96.0	96.0	96.2	96.7	96.5	96.2	96.9	96.8	96.9
45-64	90.9	91.1	91.7	91.8	92.3	91.9	92.8	92.4	91.7	93.2	93.1	93.2
65+	87.2	83.2	86.8	85.2	87.1	85.4	88.0	87.1	87.6	87.5	88.8	89.7
Male	87.1	87.8	87.8	88.7	89.5	89.5	90.6	90.2	89.2	90.8	90.7	90.9
Female	88.1	88.5	89.5	89.7	90.1	89.0	90.8	90.0	90.5	91.3	91.9	92.3
White	86.8	87.5	87.8	87.9	89.6	89.2	90.5	90.1	90.1	91.5	91.3	91.5
Black	89.4	89.9	90.2	92.3	90.5	89.6	91.3	90.6	89.0	90.6	91.4	91.1
Other race	92.1	92.0	91.8	91.4	90.7	92.6	92.9	90.7	92.2	90.3	91.6	94.5
Diabetes	85.9	86.9	87.6	88.1	89.0	89.1	89.9	89.5	89.0	90.6	90.2	90.6
Hypertension	89.7	90.9	91.8	91.2	93.0	90.4	92.9	91.1	89.4	91.2	92.5	92.3
Glomerulonephritis	91.7	92.6	92.4	92.4	92.0	92.1	92.9	93.5	93.5	95.0	94.0	94.1
Other cause	89.5	88.4	88.1	90.2	90.0	90.4	91.5	90.8	91.3	91.6	92.0	92.6
All	87.5	88.2	88.5	89.2	89.8	89.3	90.7	90.2	89.8	91.1	91.2	91.5

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.31

Two-year patient survival probabilities: first transplants, deceased donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	64.3	80.0	94.4	91.2	91.3	90.0	93.3	90.9	82.4	93.7	84.6	87.8
5-9	97.0	92.9	94.3	100.0	97.9	96.7	94.4	98.5	98.5	95.5	89.8	98.0
10-14	89.1	93.5	97.9	90.6	98.3	93.8	95.2	95.1	96.1	93.3	91.8	98.0
15-19	93.9	93.3	93.8	93.8	93.4	93.3	92.1	93.8	97.0	92.1	94.5	97.4
20-29	86.1	90.3	89.4	91.5	90.7	93.8	91.3	92.4	92.2	93.9	94.5	95.1
30-39	80.8	83.0	85.5	85.3	88.4	88.5	88.6	88.8	90.1	91.5	91.8	93.2
40-49	77.2	78.3	82.5	80.1	83.0	86.2	84.4	84.2	87.9	87.6	88.1	91.4
50-59	74.0	73.5	72.1	74.1	78.8	77.6	79.5	79.9	83.3	84.0	86.1	88.2
60-64	65.0	72.7	78.8	68.1	80.0	81.7	78.6	77.2	77.6	82.5	85.1	84.3
65+	*	*	*	*	54.5	55.2	63.6	75.4	80.2	81.1	76.9	80.6
Male	81.6	83.5	85.8	85.4	86.0	86.9	86.1	85.6	87.4	88.5	89.1	91.1
Female	82.2	84.7	84.5	84.4	88.4	89.4	88.2	89.1	89.8	90.1	90.3	92.1
White	81.9	84.8	85.1	85.0	87.1	88.4	86.8	86.9	88.3	88.9	89.2	91.4
Black	81.8	80.6	86.5	84.6	86.1	86.2	87.0	86.4	88.5	89.3	90.7	91.5
Other race	79.5	85.4	81.2	88.2	87.6	87.5	88.6	90.6	88.5	92.0	90.2	93.5
†Hispanic												
†Non-Hispanic												
Diabetes	72.0	75.6	76.9	76.8	80.2	84.3	81.0	81.1	83.3	86.3	85.5	86.7
Hypertension	87.6	86.0	88.0	85.5	86.8	84.3	88.3	87.7	89.8	88.9	89.5	92.2
Glomerulonephritis	90.0	89.9	91.4	89.8	90.8	92.7	90.9	91.2	90.8	91.9	93.0	94.3
Other cause	77.3	81.8	82.8	84.4	86.9	87.4	86.7	86.8	88.9	89.0	89.9	92.7
All	81.8	83.9	85.3	85.0	86.9	87.8	86.9	87.0	88.4	89.1	89.6	91.5
ADJUSTED												
0-19	88.9	89.5	95.1	91.8	95.6	93.9	93.2	93.0	93.0	91.8	88.9	95.0
20-44	78.9	81.9	83.7	84.5	86.1	89.1	88.0	87.8	89.6	90.7	91.0	92.9
45-64	68.2	70.9	74.2	72.8	78.0	77.9	77.8	79.3	82.6	83.2	85.0	87.9
65+	*	*	*	*	50.8	56.3	67.4	70.8	71.1	76.3	78.1	78.0
Male	57.7	61.2	66.1	65.8	68.0	70.5	70.2	70.2	74.6	76.6	78.5	82.5
Female	57.9	62.2	63.9	64.6	72.7	75.8	73.9	76.6	78.7	79.6	80.3	84.2
White	56.4	62.2	64.2	64.3	69.6	72.7	70.7	71.8	75.6	77.0	78.5	82.9
Black	63.7	60.9	71.2	69.2	71.3	73.1	74.9	75.0	78.9	80.1	82.4	84.2
Other race	56.3	63.3	54.1	65.6	70.8	69.6	71.9	76.5	74.1	82.9	79.8	85.9
Diabetes	52.3	57.6	60.0	60.7	65.3	72.7	67.6	69.3	72.8	77.0	76.6	78.9
Hypertension	77.6	74.7	78.7	75.3	78.4	74.4	80.8	79.8	84.2	83.1	84.3	88.2
Glomerulonephritis	75.4	74.4	79.1	75.4	78.4	82.8	79.9	81.0	81.4	83.4	86.0	88.5
Other cause	57.4	63.6	64.8	68.3	73.0	74.1	73.9	74.6	79.3	79.3	80.9	86.3
All	58.0	61.8	65.5	65.5	69.9	72.6	71.7	72.7	76.3	77.8	79.3	83.2

Reference cohort is 1996 incident ESRD patients.
 Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.
 Patient age is determined as of the date of transplant.
 U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.
 †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.
 *Values for cells with ten or fewer patients are suppressed.

Table I.31 (continued)

Two-year patient survival probabilities: first transplants, deceased donors

by age, gender, race/ethnicity, primary diagnosis

UNADJUSTED	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	91.8	86.7	90.0	95.5	92.7	92.7	100.0	93.1	94.7	95.6	91.1
5-9	100.0	96.4	94.6	90.9	95.5	98.3	96.4	96.3	95.9	98.4	95.2
10-14	95.7	98.0	92.9	98.3	94.4	97.4	98.0	98.6	98.1	95.2	100.0
15-19	96.8	94.2	96.4	97.9	96.9	94.9	96.3	96.7	98.1	98.9	97.7
20-29	94.2	95.6	96.7	96.3	96.1	95.9	96.6	96.4	95.9	95.2	95.7
30-39	92.3	93.6	92.0	94.1	93.9	93.6	94.7	94.5	93.7	94.9	94.5
40-49	90.5	90.0	90.4	92.0	90.7	92.1	92.4	92.3	92.2	91.7	91.9
50-59	86.1	87.2	86.9	87.7	88.2	87.6	88.8	89.0	87.0	87.7	88.6
60-64	82.7	83.5	85.2	83.2	85.3	86.0	84.5	83.8	83.5	85.7	85.1
65+	83.4	75.4	82.0	81.0	84.8	79.8	82.3	83.2	82.5	81.7	84.3
Male	90.2	90.3	89.9	90.9	91.2	91.0	91.4	91.4	90.2	90.6	90.5
Female	90.6	90.9	91.6	92.3	91.1	91.1	92.1	91.8	91.2	91.2	92.0
White	90.0	90.1	90.1	90.8	90.9	90.9	91.8	91.7	91.1	91.0	90.9
Black	90.8	90.9	91.2	92.7	91.3	91.1	91.0	90.9	89.1	90.2	91.4
Other race	93.3	94.8	93.5	94.3	93.7	92.9	93.7	92.0	92.3	92.0	91.6
†Hispanic					93.6	92.7	94.8	93.2	92.8	92.4	93.5
†Non-Hispanic					90.9	90.9	91.3	91.3	90.3	90.6	90.7
Diabetes	85.9	87.3	87.9	88.5	88.4	88.2	89.0	88.9	88.0	87.9	87.7
Hypertension	89.5	89.7	91.1	90.7	91.4	90.1	91.8	90.2	87.7	89.5	91.0
Glomerulonephritis	93.9	94.1	93.7	94.1	93.2	93.7	94.3	94.7	94.2	94.6	94.4
Other cause	91.8	91.4	90.2	92.8	92.3	92.7	92.6	92.8	92.6	92.2	92.8
All	90.3	90.6	90.6	91.5	91.2	91.1	91.7	91.5	90.6	90.8	91.1
ADJUSTED											
0-19	95.5	92.8	91.8	96.8	94.8	95.7	97.5	96.3	96.8	96.1	96.1
20-44	91.5	93.3	93.0	94.2	94.0	94.1	94.8	94.3	94.0	94.3	94.9
45-64	86.7	86.5	87.1	88.3	88.2	88.6	89.2	89.5	88.5	88.7	89.2
65+	80.3	77.1	80.3	78.9	81.3	78.7	81.9	81.1	80.7	82.3	82.9
Male	81.3	82.0	81.7	83.8	84.6	84.8	85.8	85.8	84.5	85.4	85.6
Female	81.8	82.9	84.6	85.8	84.6	84.7	86.6	86.1	85.9	86.0	87.5
White	81.0	81.6	82.0	83.6	84.2	84.5	86.4	86.3	86.1	86.0	86.3
Black	83.0	84.2	84.7	87.2	85.5	85.7	85.6	85.7	83.0	85.1	87.0
Other race	85.7	89.3	87.9	88.1	88.7	87.1	88.8	87.2	87.8	87.0	86.6
Diabetes	78.1	80.4	81.7	82.8	83.1	83.2	84.5	84.8	84.1	84.1	84.1
Hypertension	84.6	85.1	87.2	86.7	88.1	86.7	89.1	87.1	84.3	86.8	88.8
Glomerulonephritis	88.1	88.4	88.1	89.3	87.9	88.6	89.8	90.5	89.9	90.8	90.7
Other cause	84.9	84.3	82.5	87.2	86.6	87.5	87.4	87.6	88.0	87.3	88.3
All	81.5	82.4	82.9	84.7	84.7	84.8	86.2	86.0	85.1	85.7	86.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.32

Three-year patient survival probabilities: first transplants, deceased donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	64.3	76.0	91.7	91.2	89.1	88.3	88.9	89.1	78.4	93.7	82.7	87.8
5-9	97.0	91.1	94.3	97.6	93.6	93.4	94.4	98.5	98.5	93.9	89.8	94.1
10-14	88.0	92.2	92.6	89.7	97.5	89.1	92.1	95.1	96.1	91.0	91.8	95.0
15-19	93.4	89.2	91.3	92.9	91.4	92.1	89.8	93.8	94.8	90.6	92.3	95.7
20-29	83.2	88.3	86.1	88.5	88.1	90.5	88.9	90.6	90.0	91.8	92.5	92.7
30-39	76.3	79.2	80.1	80.9	83.7	84.7	84.4	85.2	86.6	89.3	89.1	90.8
40-49	71.3	74.1	77.1	73.6	78.4	80.2	78.5	79.9	84.2	83.7	84.4	88.3
50-59	67.9	68.1	65.6	66.8	71.4	71.9	74.8	73.6	78.4	79.6	82.0	83.0
60-64	55.0	68.2	72.7	63.8	72.3	68.8	71.4	71.5	73.1	77.4	79.0	79.6
65+	*	*	*	*	54.5	48.3	54.5	66.7	71.7	72.1	70.0	74.3
Male	78.1	79.9	80.1	80.2	81.4	82.1	81.2	81.6	83.4	85.3	85.5	87.4
Female	76.8	81.2	81.4	81.1	84.7	85.3	85.2	86.0	86.9	87.0	87.6	89.3
White	77.5	81.1	80.6	80.7	82.5	84.3	82.7	83.5	85.0	85.9	85.6	88.3
Black	78.5	77.4	80.4	79.3	82.7	80.7	81.6	81.7	83.9	85.6	88.0	87.6
Other race	74.4	82.9	81.2	83.6	84.3	82.5	88.0	89.1	85.8	90.1	88.9	89.6
†Hispanic												
†Non-Hispanic												
Diabetes	68.2	71.6	69.0	69.7	73.2	77.6	75.2	76.2	78.1	81.7	80.3	83.1
Hypertension	82.5	82.5	83.3	80.5	83.5	80.0	83.8	82.6	85.5	84.7	86.2	89.0
Glomerulonephritis	86.7	87.3	88.1	86.5	87.6	89.9	87.6	88.0	88.5	90.0	90.8	91.1
Other cause	72.7	77.7	78.3	80.3	82.7	82.6	82.9	84.2	85.7	86.4	87.2	89.4
All	77.6	80.4	80.6	80.5	82.6	83.3	82.6	83.3	84.8	86.0	86.3	88.2
ADJUSTED												
0-19	87.8	86.3	92.2	90.9	93.0	90.0	89.7	92.6	91.1	90.6	87.7	93.1
20-44	74.1	78.0	78.2	79.5	81.1	84.5	83.4	84.3	85.9	87.9	88.2	90.3
45-64	61.9	65.5	67.3	65.4	72.1	71.2	72.4	73.3	77.8	78.7	80.1	82.9
65+	*	*	*	*	47.6	45.6	59.0	65.4	63.8	67.2	70.6	71.0
Male	51.8	54.8	55.7	56.4	59.5	61.7	61.5	63.2	67.7	70.8	72.1	75.8
Female	48.7	55.6	58.3	58.6	65.6	67.8	68.2	70.8	73.3	73.9	75.3	79.1
White	48.9	55.3	55.9	56.5	60.9	64.5	63.4	65.5	69.6	71.5	72.1	77.3
Black	58.3	55.9	60.4	60.3	65.2	63.8	65.9	67.4	71.5	73.6	77.7	77.5
Other race	48.5	58.6	54.1	55.5	64.4	59.4	70.5	73.1	68.7	79.1	77.4	78.2
Diabetes	47.2	52.0	49.1	50.9	55.1	62.5	59.2	62.3	65.3	70.2	69.0	73.6
Hypertension	69.3	69.2	71.2	67.6	73.6	68.1	74.0	72.1	77.8	76.9	79.5	83.4
Glomerulonephritis	68.3	68.7	71.9	68.5	71.8	76.9	73.4	74.9	77.2	79.7	82.0	82.4
Other cause	50.8	57.0	57.4	61.4	65.7	65.5	67.3	70.2	73.9	74.9	76.2	80.6
All	50.8	55.4	56.8	57.4	61.9	64.1	64.1	66.1	69.9	72.1	73.4	77.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.32 (continued)

Three-year patient survival probabilities: first transplants, deceased donors*by age, gender, race/ethnicity, primary diagnosis*

UNADJUSTED	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	91.8	86.7	90.0	93.2	92.7	89.1	97.7	91.4	92.1	95.6
5-9	100.0	96.4	94.6	90.9	92.4	98.3	96.4	96.3	95.9	98.4
10-14	92.4	97.0	92.9	97.5	94.4	97.4	98.0	97.1	96.3	95.2
15-19	94.9	92.5	96.0	97.0	94.8	93.3	96.3	96.3	97.6	97.8
20-29	93.0	93.4	94.6	94.8	94.3	94.2	95.6	95.2	94.5	93.8
30-39	89.7	90.6	89.9	91.6	92.1	91.7	93.1	92.0	91.4	92.5
40-49	87.0	86.5	87.4	89.3	87.4	89.1	89.0	89.5	90.0	88.9
50-59	81.6	83.3	82.9	82.9	84.0	83.2	84.1	84.9	83.6	83.5
60-64	79.1	76.3	80.1	78.1	79.9	80.3	79.2	77.4	78.6	80.7
65+	74.9	69.4	74.6	73.2	78.8	71.7	76.1	76.8	77.4	75.7
Male	87.0	86.8	86.9	87.7	88.0	87.8	87.9	88.2	87.7	87.1
Female	87.5	87.6	88.7	89.3	88.0	87.9	89.3	88.5	88.0	88.3
White	86.9	86.7	87.2	87.6	87.9	87.7	88.4	88.5	88.5	88.0
Black	87.0	87.4	87.7	89.0	87.8	87.5	88.1	87.6	85.7	86.2
Other race	91.3	92.1	91.3	93.2	90.0	90.3	90.8	89.6	90.7	90.3
†Hispanic					91.5	90.6	92.3	90.0	91.6	89.5
†Non-Hispanic					87.7	87.5	88.0	88.1	87.3	87.3
Diabetes	80.8	82.2	84.5	84.7	84.2	83.7	84.4	84.3	84.0	84.0
Hypertension	86.1	86.8	87.8	86.8	87.6	87.3	88.5	87.4	84.5	85.6
Glomerulonephritis	92.1	91.7	90.9	91.9	91.0	91.3	91.5	92.3	92.6	92.5
Other cause	89.3	88.4	87.8	90.1	90.0	89.9	90.7	90.2	90.5	89.5
All	87.2	87.1	87.6	88.3	88.0	87.8	88.5	88.3	87.8	87.6
ADJUSTED										
0-19	93.5	91.9	91.8	95.6	93.0	94.3	97.0	95.1	95.4	95.6
20-44	89.0	90.5	90.5	91.8	91.8	92.0	93.0	92.4	91.9	92.3
45-64	82.1	81.8	83.4	84.1	84.0	84.4	84.9	85.5	85.2	84.7
65+	72.8	70.4	73.0	71.9	74.8	71.1	75.1	73.4	75.6	76.8
Male	75.6	76.0	76.7	78.4	79.5	79.5	80.3	80.9	80.9	80.3
Female	76.3	77.2	79.6	80.7	79.4	79.5	82.1	80.8	80.9	81.8
White	75.8	75.6	77.3	78.5	79.5	79.5	81.2	81.2	82.2	81.6
Black	76.5	78.6	79.0	81.2	79.9	80.1	81.2	80.6	77.9	79.3
Other race	81.8	84.1	84.2	85.9	82.4	82.6	83.8	83.5	85.4	84.5
Diabetes	70.7	73.0	76.9	77.4	77.3	77.1	78.5	78.7	79.1	79.2
Hypertension	79.8	81.1	82.6	81.4	83.0	82.9	84.8	83.5	80.2	82.1
Glomerulonephritis	84.6	83.9	83.0	85.3	84.1	84.4	85.0	86.4	87.3	87.4
Other cause	80.7	79.3	78.6	82.5	82.7	82.8	84.4	83.5	84.7	83.1
All	76.0	76.6	77.9	79.4	79.5	79.6	81.1	81.0	80.9	81.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.33

Five-year patient survival probabilities: first transplants, deceased donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	64.3	72.0	88.9	88.2	84.8	86.7	86.7	87.3	78.4	91.7	82.7	87.8	89.8	82.2	90.0	90.9	92.7	87.3	93.2	87.9
5-9	97.0	87.5	81.1	97.6	89.4	90.2	92.6	95.5	92.5	89.4	89.8	92.2	98.1	92.9	92.9	89.1	87.9	98.3	94.6	96.3
10-14	84.8	87.0	87.4	86.3	93.3	85.9	84.9	91.8	93.8	88.8	90.9	91.0	91.3	94.1	91.6	95.9	93.5	95.7	94.0	96.4
15-19	90.8	82.6	87.5	90.5	89.1	84.2	86.8	91.3	89.6	88.8	90.5	92.8	93.1	89.8	92.8	93.6	91.6	88.2	94.1	94.2
20-29	77.7	81.9	80.9	81.4	82.5	84.9	82.4	85.5	85.4	86.1	87.8	89.0	88.2	88.6	91.1	90.6	88.9	90.5	92.4	91.8
30-39	68.1	69.6	73.6	72.8	72.9	77.0	75.9	76.5	80.1	83.1	83.6	83.7	83.2	84.3	84.0	85.8	87.2	86.8	89.1	87.3
40-49	60.9	65.7	65.6	63.2	69.3	68.5	66.9	68.9	74.9	76.3	76.7	80.2	77.7	80.1	79.3	81.4	79.7	82.5	82.7	83.4
50-59	52.3	57.7	53.1	55.0	59.7	61.7	61.9	62.1	66.9	69.1	71.7	71.6	70.6	72.0	73.4	73.7	74.5	73.0	75.1	74.8
60-64	20.0	45.5	57.6	53.2	50.8	54.8	50.0	58.5	58.6	66.1	68.0	64.5	68.1	61.5	64.2	65.2	69.3	69.5	67.0	65.5
65+	*	*	*	*	40.9	27.6	39.4	50.9	61.3	63.1	53.8	57.7	58.3	54.4	61.8	55.5	62.7	58.4	64.8	61.8
Male	69.6	71.0	71.5	72.1	72.0	73.4	71.0	72.4	75.0	77.5	78.1	78.6	78.8	78.6	79.2	80.0	80.4	80.8	81.2	80.7
Female	68.7	74.0	74.6	72.8	77.0	77.4	77.2	78.2	79.4	80.9	81.1	82.6	79.5	80.6	81.7	81.9	80.8	80.5	82.9	82.0
White	69.6	73.1	73.2	73.0	74.2	76.0	73.5	75.1	76.9	78.6	78.7	80.5	78.9	79.2	80.3	80.2	80.7	80.8	82.0	81.2
Black	69.1	67.5	70.8	69.0	72.6	71.3	71.1	71.6	75.3	78.2	80.2	79.1	78.1	78.3	79.0	80.7	79.4	79.3	80.5	80.3
Other race	64.1	79.3	74.1	80.9	76.0	77.5	82.9	82.8	81.6	85.9	83.5	80.8	85.8	88.3	83.9	88.3	84.4	85.8	87.0	85.0
†Hispanic																	86.3	84.3	86.8	84.2
†Non-Hispanic																	79.9	80.3	81.2	80.8
Diabetes	53.0	62.5	58.4	57.6	59.6	63.2	61.7	63.0	66.5	71.2	70.2	72.7	69.0	71.6	73.3	75.0	73.7	73.5	75.4	74.8
Hypertension	77.0	73.8	73.8	72.1	73.7	72.4	74.0	71.9	76.4	77.2	78.7	80.0	77.6	77.9	79.6	77.9	79.0	80.8	80.7	79.2
Glomerulonephritis	82.0	80.8	81.6	81.0	81.6	83.7	79.9	81.7	81.6	84.8	85.1	84.3	85.6	86.0	85.4	85.6	85.8	85.8	87.0	86.6
Other cause	62.8	68.6	71.0	71.7	74.6	75.3	75.0	77.7	79.7	80.3	81.7	83.2	83.3	82.9	83.2	84.6	84.9	84.3	86.1	85.4
All	69.3	72.1	72.7	72.3	73.9	74.9	73.3	74.6	76.7	78.8	79.3	80.2	79.1	79.4	80.1	80.7	80.5	80.7	81.9	81.2
ADJUSTED																				
0-19	85.7	80.0	84.6	87.4	89.2	84.2	85.5	90.0	86.3	86.6	85.7	89.2	91.0	88.4	89.8	92.9	90.1	92.4	92.2	93.3
20-44	65.7	68.6	71.1	70.9	71.8	75.8	74.6	75.8	78.4	81.3	82.4	83.8	82.3	84.6	84.6	86.3	86.3	86.8	88.9	87.6
45-64	46.6	54.0	52.9	52.7	59.0	58.9	58.1	60.7	66.4	68.2	69.7	71.2	70.6	71.0	73.3	73.8	74.2	75.2	76.1	76.6
65+	*	*	*	*	34.7	29.2	38.3	47.0	49.5	56.6	55.1	55.2	56.6	54.3	58.3	56.7	60.6	57.7	63.5	58.7
Male	39.4	41.6	42.5	43.8	45.1	47.8	46.2	49.1	54.7	58.1	60.2	61.5	62.5	63.1	64.7	66.4	67.7	69.0	70.4	69.7
Female	37.2	44.0	47.3	45.5	52.4	54.2	54.8	57.7	60.6	63.4	64.3	67.7	63.4	65.9	68.3	68.8	68.4	68.4	72.3	71.0
White	37.4	42.6	44.2	44.3	47.4	50.5	48.9	52.1	56.5	59.4	60.9	64.4	63.0	63.8	66.4	66.9	68.4	69.0	71.6	70.3
Black	44.6	42.0	45.9	45.2	49.6	50.0	50.3	52.5	58.5	62.0	64.9	63.9	62.6	64.7	65.7	68.2	67.4	68.2	70.0	70.0
Other race	35.6	52.1	42.6	50.0	50.5	50.5	60.4	60.6	61.3	71.3	67.7	62.5	71.2	77.0	71.8	76.6	73.4	75.2	77.5	76.7
Diabetes	30.0	40.6	36.4	36.6	38.2	43.5	42.0	45.4	50.2	55.4	55.4	59.2	55.1	58.7	61.8	64.4	63.4	63.9	66.8	66.6
Hypertension	61.1	56.5	57.4	55.9	60.0	57.7	60.4	57.2	65.2	66.6	69.3	70.8	68.5	69.3	71.7	69.6	71.8	74.7	75.0	73.1
Glomerulonephritis	59.2	56.3	59.5	58.2	60.5	64.8	59.6	63.6	65.1	70.3	71.8	70.4	73.2	73.8	73.6	74.8	75.6	75.4	77.4	76.9
Other cause	38.3	44.1	46.6	48.2	52.9	54.0	55.0	59.8	64.3	65.2	67.2	70.3	70.7	70.3	71.2	73.6	74.6	74.1	77.1	75.9
All	38.8	42.7	44.4	44.7	47.9	50.3	49.4	52.4	57.0	60.3	61.9	64.0	62.9	64.3	66.2	67.5	68.1	68.9	71.2	70.3

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.34

Ten-year patient survival probabilities: first transplants, deceased donors*by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	57.1	68.0	80.6	85.3	78.3	83.3	86.7	83.6	72.5	89.6	78.8	82.9	85.7	71.1	87.5
5-9	87.9	80.4	69.8	88.1	74.5	85.2	87.0	85.1	83.6	83.3	78.0	88.2	96.2	85.7	83.9
10-14	80.4	76.6	75.8	76.9	81.5	76.6	73.8	82.8	82.0	80.9	84.5	78.0	87.0	84.2	81.9
15-19	78.6	71.8	79.3	82.6	81.6	72.1	78.1	82.6	82.7	80.9	81.8	83.8	84.3	80.5	83.5
20-29	63.6	68.5	67.9	69.3	68.4	72.4	68.3	72.5	72.5	73.5	74.6	76.0	72.7	76.3	79.1
30-39	49.8	50.0	55.4	55.9	55.5	58.6	56.7	58.3	63.3	64.1	64.5	64.7	65.5	67.3	66.7
40-49	39.7	41.6	44.3	42.7	45.0	45.8	45.2	48.1	52.1	53.9	55.3	55.5	55.3	58.6	59.0
50-59	30.3	30.5	29.1	31.0	32.8	29.9	33.0	37.0	40.1	42.4	43.7	43.7	41.9	46.4	44.4
60-64	10.0	9.1	30.3	21.3	16.9	29.0	23.0	29.5	25.5	34.2	32.3	33.2	32.2	30.9	33.0
65+	*	*	*	*	18.2	6.9	9.1	29.8	28.3	30.6	20.0	22.9	23.8	21.0	25.7
Male	50.7	52.0	52.7	54.2	52.4	54.3	51.4	53.8	54.6	56.9	57.0	56.6	56.3	58.3	57.6
Female	54.6	56.2	60.0	58.3	59.6	58.3	58.4	60.0	60.4	61.9	60.9	61.6	59.2	61.0	62.3
White	54.4	56.2	56.2	57.5	55.8	57.5	54.7	57.1	57.6	59.4	58.4	58.6	57.3	59.5	59.6
Black	45.0	43.7	51.3	47.8	51.5	50.0	49.2	51.3	53.0	55.3	57.1	57.0	55.2	55.6	57.3
Other race	47.4	54.9	68.2	71.8	65.3	62.5	72.2	66.1	66.0	68.3	68.4	65.5	70.4	74.9	68.2
Diabetes	32.6	37.5	38.1	33.9	35.9	38.4	35.8	39.0	40.4	44.1	43.6	43.1	41.3	45.9	44.9
Hypertension	57.4	51.9	54.7	52.6	51.9	49.9	48.6	51.1	52.0	54.4	54.8	56.4	53.5	55.7	57.1
Glomerulonephritis	67.3	65.8	65.7	66.8	64.9	68.0	66.3	66.1	66.1	68.9	69.1	67.8	67.0	69.7	69.3
Other cause	45.6	50.5	54.5	57.5	58.0	58.4	58.2	61.8	62.9	64.0	63.5	65.1	66.5	66.8	68.2
All	52.2	53.5	55.4	55.7	55.1	55.8	53.9	56.1	56.9	58.9	58.6	58.5	57.5	59.3	59.4
ADJUSTED															
0-19	76.8	68.1	72.9	77.9	78.6	74.2	76.7	78.6	77.7	77.8	77.7	80.4	84.8	77.0	79.4
20-44	46.4	49.3	53.6	53.5	53.5	57.4	55.9	57.6	60.8	62.9	63.8	64.2	63.8	67.5	67.9
45-64	25.8	28.0	28.2	29.7	31.1	30.6	31.1	36.3	38.4	40.8	41.4	42.7	41.3	45.1	46.0
65+	*	*	*	*	13.0	7.9	14.1	19.8	18.1	24.0	21.2	20.6	21.5	20.4	23.1
Male	20.3	21.7	22.4	23.9	23.8	25.7	24.7	27.8	30.3	32.3	33.6	33.6	34.1	37.1	37.1
Female	22.5	23.8	29.1	28.3	30.1	30.1	31.0	33.8	35.5	37.7	37.0	38.9	36.8	39.8	42.2
White	21.9	24.0	24.7	26.2	26.0	27.9	27.1	30.2	32.3	34.8	34.9	35.9	35.6	38.4	39.7
Black	19.6	18.6	24.5	22.6	25.5	25.5	25.6	29.0	31.5	33.0	34.7	35.3	33.5	36.0	37.2
Other race	20.8	23.1	34.7	35.2	36.2	29.9	42.6	36.0	38.6	43.6	44.6	40.2	46.4	55.5	49.5
Diabetes	13.6	17.4	17.8	15.9	16.9	19.2	17.6	21.8	23.2	25.7	26.4	26.7	25.3	29.9	29.8
Hypertension	36.6	31.3	34.8	33.5	34.7	32.1	31.7	33.4	36.7	39.3	40.9	42.2	40.1	42.9	44.7
Glomerulonephritis	36.9	34.5	36.3	36.9	36.2	40.6	39.9	40.7	42.6	45.8	47.3	45.7	45.4	49.0	49.5
Other cause	21.5	24.6	27.6	31.0	32.2	32.7	33.9	38.6	41.6	43.3	42.2	44.8	47.1	47.6	49.7
All	21.2	22.6	24.8	25.6	26.1	27.4	27.0	30.0	32.3	34.4	35.0	35.7	35.2	38.2	39.1

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.35

90-day patient survival probabilities: first transplants, living donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	*	100.0	95.2	100.0	95.1	100.0	100.0	100.0	92.5	100.0	92.2	95.7
5-9	100.0	100.0	100.0	96.7	100.0	100.0	97.6	100.0	97.2	98.2	92.9	98.7
10-14	100.0	100.0	98.5	98.8	99.0	100.0	97.0	100.0	100.0	99.0	93.2	98.0
15-19	97.6	97.6	100.0	98.8	99.3	98.2	99.4	99.4	100.0	100.0	95.2	98.8
20-29	99.3	98.7	98.9	98.3	98.1	98.7	98.8	99.4	98.9	98.3	99.2	99.8
30-39	97.3	97.4	98.4	97.0	98.7	98.3	99.0	98.7	98.6	99.6	97.8	98.8
40-49	98.5	96.3	94.9	97.3	97.6	97.0	98.6	98.6	98.4	99.7	97.7	99.1
50-59	94.4	91.8	98.4	95.8	95.7	96.6	98.1	98.5	96.2	97.6	96.2	98.2
60-64	*	*	*	90.9	100.0	100.0	95.0	98.4	95.2	97.2	96.8	91.5
65+	*	*	*	*	*	*	90.0	100.0	*	*	95.0	94.1
Male	98.2	97.9	98.1	97.4	98.8	98.5	98.3	99.0	98.4	98.8	97.4	98.6
Female	98.6	97.0	97.9	98.0	97.0	97.5	98.9	99.0	98.5	99.1	97.0	98.8
White	98.1	97.8	97.9	97.4	98.4	98.2	98.5	99.1	98.1	98.9	97.2	98.6
Black	100.0	95.9	98.6	98.3	95.9	98.3	98.9	98.9	100.0	98.6	96.7	98.6
Other race	100.0	95.0	98.0	100.0	100.0	94.9	97.2	97.6	100.0	100.0	98.7	100.0
†Hispanic												
†Non-Hispanic												
Diabetes	98.1	96.6	95.3	95.0	97.2	95.2	98.0	97.6	98.6	99.5	97.6	97.6
Hypertension	98.8	98.1	98.2	97.3	98.6	98.5	98.8	100.0	96.6	99.0	94.7	99.6
Glomerulonephritis	99.0	98.4	98.9	99.5	98.2	99.1	98.7	98.9	98.8	99.0	98.0	99.6
Other cause	97.9	96.9	98.5	97.2	98.3	98.8	98.5	99.4	98.6	98.5	96.8	98.3
All	98.4	97.5	98.0	97.6	98.1	98.1	98.5	99.0	98.4	98.9	97.2	98.7
ADJUSTED												
0-19	97.9	99.2	98.7	98.8	98.0	99.5	98.0	99.5	97.5	99.1	89.9	96.7
20-44	97.7	96.3	97.4	96.7	97.9	97.9	98.7	98.7	98.3	98.6	98.1	99.0
45-64	96.3	94.0	96.2	95.3	95.8	95.9	97.1	98.4	96.9	98.3	95.9	97.9
65+	100.0	100.0	*	100.0	100.0	100.0	91.8	97.0	100.0	84.4	90.5	89.6
Male	92.9	91.7	93.1	90.9	95.8	95.5	94.7	96.9	94.5	96.0	91.3	95.5
Female	94.7	90.2	93.2	93.6	90.9	92.9	96.9	97.2	95.3	97.2	91.6	96.7
White	92.5	91.7	92.8	90.9	94.6	94.6	95.6	97.3	93.8	96.5	91.3	95.8
Black	100.0	89.5	95.8	95.6	89.1	95.9	97.2	97.3	100.0	96.0	90.8	96.6
Other race	100.0	86.7	94.2	100.0	100.0	88.1	92.4	93.9	100.0	100.0	97.1	100.0
Diabetes	95.9	93.0	90.2	89.6	94.1	91.0	96.0	95.5	97.1	98.9	95.3	95.5
Hypertension	97.0	95.7	95.9	95.0	97.1	97.1	97.6	100.0	93.0	97.8	89.5	99.2
Glomerulonephritis	96.4	94.8	96.2	98.2	94.6	97.4	96.7	97.1	96.0	96.8	93.8	98.6
Other cause	93.5	90.4	95.6	91.9	95.2	96.8	96.3	98.6	95.4	95.5	91.0	94.8
All	93.7	90.9	93.2	92.0	93.7	94.4	95.6	97.0	94.8	96.5	91.3	96.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.35 (continued)

90-day patient survival probabilities: first transplants, living donors

by age, gender, race/ethnicity, primary diagnosis

UNADJUSTED	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	95.2	98.9	95.7	95.8	98.7	100.0	100.0	100.0	98.6	99.1	98.9	100.0
5-9	100.0	100.0	100.0	96.1	98.6	100.0	98.5	100.0	100.0	98.7	100.0	98.7
10-14	98.1	100.0	100.0	100.0	99.2	100.0	99.2	98.6	100.0	99.3	100.0	100.0
15-19	98.1	100.0	100.0	99.5	99.5	99.5	99.4	100.0	100.0	100.0	100.0	100.0
20-29	99.4	99.0	99.8	99.3	99.8	99.5	100.0	99.9	99.9	99.7	99.4	99.7
30-39	99.2	98.8	99.1	99.2	99.2	99.5	98.9	99.3	99.4	99.3	99.4	99.7
40-49	99.4	99.8	99.5	99.1	98.7	98.9	99.1	99.2	98.9	99.4	99.5	99.5
50-59	98.3	97.9	98.7	97.6	97.0	97.5	98.8	98.0	98.6	98.1	98.5	98.8
60-64	93.8	100.0	96.7	96.2	98.7	98.0	97.4	98.1	98.2	98.2	98.0	98.6
65+	100.0	97.6	100.0	95.9	96.8	97.4	96.1	98.2	96.6	97.9	98.1	98.1
Male	98.9	99.2	99.2	98.4	98.6	99.0	98.9	98.9	98.9	99.0	98.9	99.3
Female	98.6	99.0	99.4	98.9	98.9	98.7	99.1	99.2	99.1	99.0	99.3	99.3
White	98.9	99.2	99.3	98.5	98.6	98.9	98.9	99.0	99.0	99.0	99.1	99.3
Black	98.1	98.7	99.0	99.2	98.9	98.9	99.3	99.0	98.5	98.9	98.6	99.3
Other race	98.9	99.0	100.0	99.4	100.0	99.4	98.9	99.5	99.3	99.4	99.7	99.4
†Hispanic					98.3	99.1	99.0	98.9	99.3	99.1	99.6	99.5
†Non-Hispanic					98.8	98.9	98.9	99.0	98.9	99.0	99.0	99.2
Diabetes	98.3	98.7	98.3	97.5	98.1	97.5	97.9	98.9	98.1	98.2	98.4	98.0
Hypertension	98.8	99.4	99.5	98.6	99.1	98.9	99.2	98.6	98.4	98.8	99.2	99.4
Glomerulonephritis	99.2	99.4	99.4	99.5	99.3	99.6	99.7	99.0	99.3	99.5	99.4	99.6
Other cause	98.7	98.9	99.7	98.6	98.5	99.0	98.9	99.3	99.5	99.2	99.2	99.8
All	98.8	99.1	99.3	98.6	98.8	98.9	99.0	99.0	99.0	99.0	99.1	99.3
ADJUSTED												
0-19	96.9	99.6	99.2	97.5	98.6	99.6	98.9	99.3	99.6	99.1	99.7	99.7
20-44	99.1	98.7	99.3	98.9	99.2	99.3	98.9	99.3	99.3	99.3	99.1	99.7
45-64	98.1	98.7	98.5	97.8	97.7	97.7	98.6	98.2	98.5	98.5	98.7	98.9
65+	92.7	97.9	100.0	96.0	95.6	96.0	95.9	98.1	95.8	97.5	97.7	97.4
Male	96.5	97.5	97.6	95.7	96.4	97.4	97.3	97.5	97.5	97.8	97.6	98.5
Female	96.4	97.3	98.5	97.4	97.5	97.0	97.9	98.1	98.1	98.0	98.7	98.5
White	96.6	97.5	98.0	95.9	96.6	97.1	97.3	97.6	97.9	97.8	98.2	98.5
Black	95.7	97.1	97.6	98.3	97.8	97.7	98.6	98.1	97.2	98.1	97.4	98.7
Other race	97.3	97.5	100.0	98.6	100.0	98.9	98.0	99.0	98.7	99.0	99.4	98.9
Diabetes	96.9	97.7	97.1	95.9	97.1	96.2	96.8	98.4	97.3	97.6	97.9	97.3
Hypertension	97.6	99.0	99.1	97.6	98.5	98.2	98.8	97.8	97.6	98.1	98.8	99.1
Glomerulonephritis	97.6	98.1	98.3	98.6	98.2	99.1	99.1	97.7	98.5	98.9	98.7	99.2
Other cause	96.4	97.1	99.1	96.4	96.3	97.6	97.6	98.3	98.8	98.3	98.3	99.5
All	96.4	97.4	98.0	96.4	96.9	97.2	97.5	97.7	97.8	97.9	98.1	98.5

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.36

One-year patient survival probabilities: first transplants, living donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	*	100.0	90.5	93.3	92.7	100.0	91.8	98.5	88.7	96.4	88.2	95.7
5-9	96.2	100.0	97.1	93.3	97.9	98.1	97.6	100.0	97.2	98.2	92.9	98.7
10-14	100.0	100.0	98.5	97.6	98.1	98.8	97.0	100.0	97.1	98.0	90.9	97.0
15-19	96.4	96.0	97.5	96.3	98.6	98.2	98.9	97.7	97.4	98.5	94.0	97.0
20-29	97.0	96.5	96.3	97.3	96.2	97.4	97.6	97.9	98.1	96.4	98.4	99.2
30-39	94.2	94.6	94.5	94.8	97.4	95.6	97.3	96.2	96.8	98.9	97.4	98.4
40-49	92.6	90.8	91.1	93.0	95.1	95.1	96.6	95.9	96.0	97.6	96.5	97.4
50-59	88.9	87.7	92.6	92.3	93.3	95.3	95.9	96.9	93.1	93.5	93.0	94.5
60-64	*	*	*	90.9	100.0	100.0	93.3	93.4	90.5	97.2	90.3	87.2
65+	*	*	*	*	*	*	86.7	100.0	*	*	90.0	94.1
Male	94.3	94.8	94.8	94.8	97.0	96.9	96.4	96.7	96.6	96.9	96.0	97.3
Female	96.6	94.7	94.4	95.9	95.4	95.7	97.6	97.3	96.3	97.7	95.8	97.7
White	95.3	94.9	95.1	95.3	96.7	96.4	96.8	96.8	96.1	97.1	95.7	97.5
Black	95.0	94.3	94.3	94.8	94.2	97.3	98.0	97.8	98.1	97.1	96.7	96.9
Other race	95.0	92.5	86.3	96.4	98.4	93.6	94.4	97.6	98.3	100.0	98.7	100.0
†Hispanic												
†Non-Hispanic												
Diabetes	90.4	91.2	88.5	89.6	93.0	90.5	94.2	94.1	95.6	98.4	95.5	95.2
Hypertension	96.3	95.3	95.3	96.3	98.1	98.2	97.3	98.7	95.5	97.0	94.2	97.7
Glomerulonephritis	98.0	97.7	97.5	98.4	97.6	98.0	98.1	97.4	97.9	96.6	97.0	98.8
Other cause	94.2	93.3	94.6	94.6	96.3	97.9	97.2	97.7	95.9	97.2	95.6	97.7
All	95.3	94.8	94.7	95.3	96.4	96.4	96.8	97.0	96.5	97.2	95.9	97.5
ADJUSTED												
0-19	95.8	97.5	96.0	94.1	96.4	98.4	95.6	98.1	93.6	97.2	87.3	95.5
20-44	93.2	92.4	92.6	94.0	95.5	95.3	96.8	95.7	96.8	96.6	97.0	98.0
45-64	89.0	87.4	90.6	91.1	93.1	93.9	94.7	95.7	92.6	95.3	93.3	94.8
65+	62.0	100.0	*	100.0	100.0	94.3	86.4	97.0	76.9	84.4	85.8	89.6
Male	79.2	81.0	82.8	82.6	89.9	90.7	89.4	90.4	88.4	89.7	87.1	91.6
Female	87.9	83.3	82.5	87.6	86.2	88.1	93.2	92.8	89.0	93.3	88.4	93.8
White	82.4	81.6	83.8	84.1	89.1	89.3	90.7	90.7	87.6	90.8	86.9	92.3
Black	85.1	85.5	84.0	87.2	85.0	93.5	95.1	94.7	94.6	92.2	90.8	92.5
Other race	86.9	80.5	65.5	89.8	95.1	85.3	85.4	93.9	95.1	100.0	97.1	100.0
Diabetes	80.6	82.6	77.5	79.2	86.0	82.5	88.7	88.9	91.0	96.8	91.2	91.2
Hypertension	91.2	89.5	89.3	93.0	96.1	96.3	94.6	97.5	90.7	93.4	88.5	95.3
Glomerulonephritis	93.0	92.3	92.0	94.7	92.7	94.0	95.0	92.8	93.2	89.7	90.6	96.4
Other cause	83.0	80.4	85.3	84.9	89.6	94.7	93.0	94.4	87.4	91.7	87.8	93.2
All	82.7	81.9	82.7	84.6	88.4	89.6	90.9	91.4	88.6	91.2	87.6	92.5

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.37

Two-year patient survival probabilities: first transplants, living donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	*	100.0	85.7	90.0	92.7	100.0	91.8	97.1	84.9	96.4	88.2	95.7
5-9	96.2	100.0	97.1	90.0	97.9	98.1	92.9	97.5	97.2	98.2	92.9	98.7
10-14	91.8	98.0	98.5	96.5	97.1	98.8	95.0	97.8	95.1	98.0	89.8	97.0
15-19	94.0	94.4	96.8	95.7	97.1	97.6	98.3	97.1	96.7	98.5	94.0	96.4
20-29	95.7	94.3	94.9	95.8	95.1	96.6	96.1	96.0	96.8	94.3	97.9	98.2
30-39	93.3	90.1	92.3	91.6	95.7	93.0	95.7	94.3	95.3	97.4	96.2	96.3
40-49	88.1	88.3	88.6	89.9	92.7	93.7	94.8	92.1	95.2	95.2	93.9	95.0
50-59	88.9	86.3	88.5	89.4	90.9	93.1	93.9	93.8	88.5	91.2	89.7	92.7
60-64	*	*	*	90.9	95.2	100.0	91.7	91.8	85.7	97.2	90.3	85.1
65+	*	*	*	*	*	*	86.7	100.0	*	*	85.0	88.2
Male	92.9	91.9	92.7	92.5	95.6	95.2	94.7	94.5	94.7	95.1	95.0	95.9
Female	93.6	92.4	93.1	93.7	93.6	94.3	96.1	94.7	95.1	96.5	94.1	96.0
White	93.4	92.2	93.3	93.2	95.1	95.1	95.2	94.4	94.8	95.5	94.4	95.9
Black	93.1	91.9	92.4	91.7	93.0	94.7	96.6	95.3	95.2	95.2	94.7	95.2
Other race	85.0	90.0	84.3	94.5	95.3	91.0	92.5	96.0	94.8	100.0	98.7	100.0
†Hispanic												
†Non-Hispanic												
Diabetes	86.5	83.0	84.2	83.9	89.9	88.0	91.2	89.2	92.3	94.6	93.4	91.3
Hypertension	95.0	94.3	93.6	94.7	95.8	96.7	95.7	95.8	93.9	97.0	92.6	97.0
Glomerulonephritis	96.0	97.2	96.6	97.5	96.5	96.9	96.9	96.6	96.8	95.3	96.0	97.6
Other cause	92.4	90.2	93.0	92.5	95.3	96.4	96.1	95.6	94.9	96.3	94.5	97.2
All	93.2	92.1	92.8	93.0	94.8	94.9	95.2	94.6	94.8	95.7	94.6	95.9
ADJUSTED												
0-19	90.7	96.6	95.4	91.8	95.9	97.8	93.7	95.8	91.1	89.2	86.9	90.4
20-44	91.3	87.2	89.9	90.7	93.5	93.5	94.7	93.5	95.2	94.2	95.9	95.8
45-64	83.1	86.0	87.3	88.2	89.3	91.3	92.5	90.8	88.7	92.6	89.2	92.3
65+	62.0	100.0	*	100.0	100.0	77.7	86.4	94.1	76.9	84.4	81.1	84.5
Male	74.9	72.2	76.5	76.0	85.3	86.1	84.8	84.5	82.7	84.1	84.2	87.4
Female	78.1	76.9	78.9	81.5	81.4	84.4	89.3	86.2	85.7	89.9	84.1	89.4
White	76.3	73.4	78.5	77.8	84.3	85.6	86.3	84.4	83.6	86.1	83.4	87.8
Black	79.8	79.9	79.1	80.2	81.9	87.4	91.6	89.1	87.1	87.3	85.9	88.5
Other race	65.5	74.8	61.8	85.2	86.0	80.0	81.0	90.0	85.8	100.0	97.1	100.0
Diabetes	73.6	68.4	69.9	69.1	80.0	78.3	83.3	80.2	84.6	89.5	87.2	84.2
Hypertension	88.4	87.5	85.5	90.1	91.4	93.4	91.8	92.1	87.4	93.4	85.5	93.7
Glomerulonephritis	86.5	90.7	89.0	91.8	89.5	91.2	91.8	90.7	90.0	85.9	87.9	92.9
Other cause	78.1	72.5	81.5	79.7	87.0	90.9	90.3	89.5	84.3	88.9	85.0	91.7
All	76.1	74.0	77.4	78.2	83.6	85.4	86.6	85.1	83.8	86.6	84.0	88.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.37 (continued)

Two-year patient survival probabilities: first transplants, living donors

by age, gender, race/ethnicity, primary diagnosis

UNADJUSTED	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	95.2	97.8	91.3	94.4	94.9	95.7	97.4	96.7	97.1	97.3	95.8
5-9	100.0	94.8	98.3	96.1	98.6	98.1	98.5	98.6	98.5	98.7	98.9
10-14	95.4	97.3	100.0	98.3	97.5	100.0	99.2	98.6	100.0	97.2	98.4
15-19	95.0	99.5	97.9	97.9	99.5	97.7	98.3	98.6	97.8	99.6	99.2
20-29	97.8	97.9	98.8	97.6	98.7	98.3	98.2	98.7	97.9	97.8	97.9
30-39	97.0	96.1	97.7	96.7	96.5	97.7	97.2	97.8	97.3	97.4	97.5
40-49	96.4	97.0	94.5	96.2	96.2	96.1	95.8	96.2	95.9	96.9	96.7
50-59	93.7	92.2	93.3	91.8	92.5	93.7	95.2	94.9	93.2	93.8	94.4
60-64	82.5	91.8	89.0	86.9	91.8	94.4	93.5	93.3	93.8	92.3	92.7
65+	92.9	85.4	90.7	86.5	92.6	90.4	86.9	90.5	88.9	90.0	89.9
Male	96.2	96.3	95.9	95.0	96.2	96.7	96.1	96.0	95.2	96.0	95.7
Female	95.6	96.1	96.8	96.0	95.9	95.8	96.4	97.3	96.2	95.8	95.9
White	96.2	96.5	96.6	95.1	96.1	96.2	96.4	96.5	95.7	95.9	95.8
Black	93.9	94.5	95.1	96.7	95.1	96.1	94.9	95.8	94.7	95.5	95.2
Other race	96.7	97.0	96.2	96.1	100.0	98.8	96.8	98.2	96.0	97.6	97.4
†Hispanic					96.6	97.6	97.3	97.4	96.0	96.4	96.4
†Non-Hispanic					96.0	96.1	96.1	96.4	95.5	95.8	95.7
Diabetes	92.8	93.3	94.7	91.9	93.7	92.8	92.5	94.4	91.9	93.2	93.3
Hypertension	96.1	95.0	95.4	95.4	94.9	96.2	96.4	96.3	94.2	95.4	95.2
Glomerulonephritis	97.5	98.2	97.4	96.9	97.9	98.4	98.5	97.0	97.4	97.6	97.0
Other cause	96.3	96.7	96.7	96.2	96.4	96.6	96.6	97.3	97.0	96.6	96.9
All	95.9	96.2	96.3	95.4	96.1	96.3	96.2	96.5	95.6	95.9	95.8
ADJUSTED											
0-19	93.9	96.7	96.7	95.4	96.8	97.2	97.5	97.4	97.9	97.8	97.8
20-44	96.3	96.4	97.1	96.1	96.5	97.0	96.6	96.8	96.6	96.6	96.7
45-64	93.2	92.8	91.8	92.0	93.3	93.4	94.1	94.5	93.2	93.9	94.2
65+	76.1	83.3	90.0	83.9	89.4	89.7	87.2	91.5	87.6	90.1	89.3
Male	88.5	89.4	88.6	87.0	90.5	91.7	90.8	90.9	89.7	91.5	91.4
Female	88.7	89.9	92.0	90.5	90.7	90.3	91.9	93.9	91.9	91.6	92.2
White	89.0	90.0	90.6	87.6	90.3	90.6	91.5	92.1	90.8	91.3	91.8
Black	86.8	87.6	88.9	92.8	89.8	92.1	90.1	91.9	90.3	92.0	91.4
Other race	92.1	92.8	92.3	91.5	100.0	97.7	94.1	96.1	92.1	96.2	95.4
Diabetes	87.2	88.3	91.0	87.2	90.3	89.1	88.8	92.1	88.7	90.8	91.1
Hypertension	92.4	91.0	91.4	92.1	91.6	93.8	94.2	94.2	91.3	93.2	93.2
Glomerulonephritis	93.1	94.8	92.7	92.0	94.7	96.0	96.1	93.0	94.1	94.6	93.7
Other cause	90.1	91.1	91.4	90.5	91.3	91.9	92.3	93.9	93.7	92.7	93.6
All	88.5	89.5	90.1	88.4	90.5	91.0	91.2	92.1	90.6	91.5	91.7

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.38

Three-year patient survival probabilities: first transplants, living donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	*	100.0	85.7	76.7	90.2	100.0	89.8	95.6	84.9	94.6	88.2
5-9	96.2	92.0	94.1	90.0	97.9	98.1	90.5	97.5	97.2	98.2	92.9
10-14	89.8	94.1	97.0	96.5	96.2	98.8	95.0	97.8	95.1	98.0	89.8
15-19	94.0	93.6	96.8	94.5	95.7	96.4	97.7	95.4	96.1	97.8	93.4
20-29	94.7	91.5	92.5	93.1	94.0	95.7	94.8	93.9	95.8	94.0	97.3
30-39	90.6	86.3	89.3	88.6	93.2	91.2	94.4	93.1	93.0	96.3	94.0
40-49	83.0	81.6	85.2	87.9	87.8	90.3	93.8	91.3	94.8	92.4	90.8
50-59	80.6	80.8	82.0	85.2	87.2	91.0	91.7	91.4	85.5	86.5	88.6
60-64	*	*	*	90.9	90.5	100.0	90.0	86.9	85.7	94.4	90.3
65+	*	*	*	*	*	*	83.3	88.0	*	*	80.0
Male	90.2	87.9	89.9	89.8	93.5	93.1	93.3	92.7	93.3	93.9	93.1
Female	91.6	88.9	90.5	91.2	90.6	93.1	94.9	93.3	94.0	94.7	93.1
White	90.9	88.4	90.8	90.4	92.8	93.4	93.9	92.7	93.8	94.1	92.9
Black	92.1	87.0	87.6	89.6	89.7	92.3	94.9	93.9	92.4	93.8	92.8
Other race	80.0	90.0	84.3	94.5	93.8	89.7	91.6	94.4	93.1	100.0	98.7
†Hispanic											
†Non-Hispanic											
Diabetes	82.7	75.5	77.9	78.1	85.4	83.6	88.7	86.4	89.0	92.4	90.3
Hypertension	92.5	93.4	89.5	92.0	93.9	95.2	95.1	94.2	92.2	94.4	91.1
Glomerulonephritis	93.4	95.1	95.6	95.9	94.4	95.9	95.9	95.1	96.1	94.6	95.3
Other cause	90.5	85.5	90.7	90.4	93.5	95.4	94.9	94.4	94.5	95.0	93.3
All	90.8	88.3	90.1	90.4	92.4	93.1	93.9	92.9	93.6	94.3	93.1
ADJUSTED											
0-19	89.7	92.6	94.1	89.0	94.0	96.8	92.3	94.5	90.7	96.7	86.9
20-44	88.6	82.7	86.2	86.8	91.3	91.6	93.2	91.6	93.4	92.8	93.8
45-64	73.7	76.8	81.8	85.3	82.5	87.7	90.3	88.4	86.5	88.4	86.7
65+	28.4	100.0	*	100.0	100.0	77.7	83.7	85.4	76.9	84.4	76.6
Male	67.0	61.7	69.2	68.9	79.3	80.6	81.1	79.8	78.7	80.8	78.8
Female	72.5	68.3	72.1	75.1	73.8	81.5	86.3	83.0	82.8	85.2	81.7
White	68.8	63.3	71.8	70.3	77.8	81.2	83.0	80.2	80.7	82.0	79.4
Black	77.2	69.7	68.0	75.6	74.3	82.3	87.7	86.1	80.1	83.7	81.1
Other race	56.3	74.8	61.8	85.2	81.9	77.4	78.9	86.4	81.5	100.0	97.1
Diabetes	66.9	57.0	59.8	59.8	72.1	71.3	78.8	75.6	78.5	85.5	81.7
Hypertension	83.0	85.5	77.0	85.5	87.7	90.6	90.6	89.1	84.1	88.2	82.6
Glomerulonephritis	78.4	84.5	86.2	86.9	83.7	88.4	89.3	87.1	87.9	84.1	85.7
Other cause	73.5	61.9	76.0	74.8	82.3	88.5	87.7	86.9	83.3	85.3	82.0
All	69.0	64.2	70.3	71.4	77.0	80.9	83.2	81.1	80.3	82.6	79.9

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

Table I.38 (continued)

Three-year patient survival probabilities: first transplants, living donors

by age, gender, race/ethnicity, primary diagnosis

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	95.7	93.5	95.7	91.3	94.4	94.9	95.7	97.4	96.7	95.7	97.3
5-9	98.7	98.6	94.8	98.3	94.7	97.2	98.1	98.5	98.6	97.0	97.3
10-14	97.0	93.5	97.3	100.0	98.3	97.5	100.0	98.5	97.9	100.0	96.6
15-19	95.2	92.5	98.9	96.9	97.9	98.6	96.4	98.3	97.7	97.4	98.4
20-29	97.2	96.6	96.2	97.5	96.2	96.7	97.5	97.2	97.3	97.7	97.0
30-39	94.2	95.7	94.1	96.4	96.0	95.7	96.5	95.6	96.8	96.7	96.0
40-49	92.7	94.5	95.3	93.2	94.6	94.5	94.3	94.4	94.7	94.3	95.2
50-59	90.0	91.3	86.8	88.2	89.0	90.8	91.5	93.2	91.8	90.6	92.0
60-64	83.0	78.8	85.9	80.2	83.1	88.1	91.4	90.0	84.6	90.9	87.9
65+	88.2	85.7	78.0	81.4	82.4	88.4	85.1	82.4	87.5	84.4	87.5
Male	94.1	94.4	93.8	94.0	93.6	94.6	95.1	94.4	93.9	93.5	94.3
Female	94.6	93.7	94.1	94.4	94.5	94.3	94.1	95.0	95.1	94.8	94.1
White	94.4	94.7	94.0	94.5	93.6	94.4	94.7	94.8	94.5	93.9	94.3
Black	92.5	90.1	93.0	93.1	95.0	93.7	94.6	93.6	93.1	93.8	93.2
Other race	98.8	94.6	94.9	92.5	96.1	99.3	96.4	95.7	97.2	95.7	96.4
†Hispanic						95.1	96.6	95.9	96.0	95.1	95.5
†Non-Hispanic						94.4	94.5	94.4	94.2	93.9	94.0
Diabetes	87.1	89.8	89.1	90.7	89.0	90.8	89.2	89.6	90.7	89.4	90.5
Hypertension	95.1	94.2	92.0	92.7	93.8	92.7	93.9	94.3	94.0	92.1	94.5
Glomerulonephritis	96.9	95.9	96.9	96.0	95.9	96.7	97.7	97.7	95.8	96.4	96.0
Other cause	96.5	94.9	94.9	95.4	95.2	95.7	95.6	95.4	95.5	95.7	95.2
All	94.3	94.1	93.9	94.2	94.0	94.5	94.7	94.6	94.4	94.0	94.2
ADJUSTED											
0-19	94.7	91.7	95.6	95.9	95.1	95.8	96.5	97.1	96.7	96.9	97.2
20-44	93.9	94.3	94.0	95.4	94.8	94.8	95.3	94.8	95.3	95.7	94.7
45-64	88.8	90.3	88.1	87.3	89.1	90.9	90.9	91.9	90.7	90.6	91.3
65+	84.5	69.3	77.1	80.1	78.8	85.0	84.2	82.1	86.8	82.8	87.6
Male	82.3	83.6	82.5	83.7	83.5	86.8	87.9	87.0	86.5	86.3	88.0
Female	85.9	84.3	85.2	86.4	87.1	87.3	86.7	88.9	89.3	89.0	88.4
White	83.7	85.0	83.5	85.4	83.9	86.5	86.9	87.9	87.7	87.1	88.0
Black	82.4	79.2	84.4	84.6	89.2	87.1	89.2	87.5	86.9	88.8	88.0
Other race	97.1	86.9	88.1	84.8	91.5	98.6	93.3	92.1	94.2	91.4	94.3
Diabetes	77.3	82.2	81.3	84.6	82.8	85.9	83.9	84.6	87.0	85.3	87.2
Hypertension	89.9	89.0	85.8	86.6	89.5	88.0	90.1	91.0	90.7	88.2	91.8
Glomerulonephritis	90.7	88.6	91.3	88.9	89.4	91.8	94.2	94.2	90.3	92.0	91.2
Other cause	89.8	86.8	86.6	88.1	88.0	89.5	89.6	89.7	90.0	91.0	89.9
All	83.7	83.8	83.6	84.8	84.9	86.9	87.3	87.7	87.6	87.4	88.1

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.39

Five-year patient survival probabilities: first transplants, living donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	*	93.3	71.4	70.0	90.2	100.0	85.7	88.2	83.0	94.6	88.2	95.7	91.9	94.6	91.3	91.7	93.7	93.5	97.4	96.7
5-9	96.2	92.0	85.3	90.0	97.9	96.2	90.5	97.5	91.7	98.2	91.1	96.1	98.6	93.1	98.3	94.7	97.2	98.1	98.5	98.6
10-14	85.7	90.2	97.0	92.9	94.3	97.6	93.1	97.8	94.1	97.0	86.4	94.1	92.6	95.6	99.0	96.7	95.8	97.4	97.7	96.4
15-19	91.6	90.4	95.5	92.6	93.6	92.8	94.4	94.3	92.8	97.0	92.2	94.5	91.3	95.7	95.9	96.3	96.6	91.4	96.6	95.3
20-29	92.4	88.7	89.0	87.6	90.9	91.2	89.7	90.2	93.2	91.7	95.5	96.1	94.7	94.3	95.0	92.6	94.3	94.8	94.6	95.2
30-39	83.9	78.0	83.9	84.4	88.7	86.2	90.4	88.9	86.9	92.1	90.5	90.6	92.6	90.8	91.7	93.0	92.4	91.8	92.3	94.2
40-49	75.6	74.8	77.6	81.7	82.3	84.2	88.7	87.6	87.3	86.3	86.2	86.8	87.9	89.3	88.4	90.0	89.2	90.6	90.1	91.2
50-59	66.7	72.6	72.1	78.9	79.3	83.3	86.6	84.6	81.7	78.2	79.5	82.2	86.7	78.1	81.7	82.7	84.3	84.2	84.9	86.5
60-64	*	*	*	72.7	90.5	83.9	86.7	78.7	61.9	75.0	74.2	76.6	68.8	74.1	65.9	74.6	83.6	79.8	79.6	73.8
65+	*	*	*	*	*	*	70.0	80.0	*	*	70.0	82.4	78.6	65.9	69.8	74.3	78.9	74.6	66.0	76.8
Male	84.9	81.3	84.9	84.3	89.3	87.5	88.8	88.4	89.3	90.3	89.9	90.7	91.1	89.5	89.4	89.7	90.7	90.1	89.2	90.0
Female	87.4	85.0	85.2	87.3	86.7	88.7	90.3	89.4	88.4	90.1	88.7	90.8	89.6	89.5	90.5	90.2	90.1	89.2	90.4	91.1
White	86.0	82.9	85.7	85.4	88.8	88.3	89.3	88.8	90.0	90.3	88.9	91.1	91.1	89.9	90.4	89.3	90.5	89.7	89.9	90.7
Black	87.1	81.3	82.4	84.8	84.8	87.0	90.0	88.0	83.8	87.6	90.9	87.7	86.3	87.7	87.8	91.5	89.6	88.7	88.0	88.6
Other race	75.0	85.0	80.4	90.9	92.2	84.6	89.7	91.1	82.8	98.4	94.9	93.8	91.3	88.9	88.7	92.9	93.6	93.3	92.0	93.5
†Hispanic																	91.9	92.9	92.9	92.8
†Non-Hispanic																	90.3	89.3	89.2	90.1
Diabetes	72.1	66.7	69.2	68.5	76.3	74.3	81.0	78.7	81.3	85.4	84.4	80.2	82.3	80.6	82.2	82.1	83.7	80.9	80.3	82.3
Hypertension	86.3	86.8	85.4	87.2	91.0	91.9	92.4	91.6	82.7	88.4	84.7	89.4	90.3	87.5	86.8	88.0	87.9	88.1	88.4	89.6
Glomerulonephritis	90.4	90.2	91.6	92.3	90.7	91.1	92.1	92.5	94.1	92.5	93.0	94.2	93.5	94.3	93.9	94.1	93.0	94.0	94.5	93.4
Other cause	86.1	80.8	85.9	86.6	91.3	91.8	91.0	90.6	90.8	91.6	90.3	95.2	92.5	91.5	92.3	91.5	93.7	91.6	92.1	93.1
All	85.9	82.8	85.0	85.5	88.3	88.0	89.4	88.8	89.0	90.3	89.4	90.7	90.5	89.5	89.8	89.9	90.5	89.7	89.7	90.5
ADJUSTED																				
0-19	85.7	89.4	90.2	85.1	91.5	93.6	88.5	91.8	87.3	95.8	84.3	93.1	90.0	92.8	95.1	93.7	93.4	92.0	96.8	95.4
20-44	81.5	74.9	79.8	80.3	86.5	85.4	87.5	86.4	87.6	88.2	90.1	90.2	90.5	90.2	90.5	89.8	90.5	89.9	90.5	91.8
45-64	64.7	66.5	71.6	77.0	73.8	79.2	83.9	82.5	77.6	78.6	77.5	80.4	83.1	78.8	79.6	82.7	84.5	83.4	83.6	84.5
65+	28.4	100.0	*	100.0	82.9	61.6	72.9	74.1	76.9	84.4	67.5	79.4	58.2	60.8	68.4	69.7	76.3	73.3	66.9	75.6
Male	54.1	47.7	57.6	56.5	68.3	67.5	70.6	70.0	68.1	71.3	70.7	73.6	75.3	72.3	72.7	74.7	78.0	76.7	76.3	78.6
Female	61.9	59.8	60.2	66.0	64.9	71.1	75.5	74.3	69.4	73.9	71.4	76.8	75.3	74.9	77.9	77.9	78.8	76.6	79.3	81.1
White	56.7	51.2	59.7	58.8	67.7	69.1	72.1	71.3	70.8	72.2	69.8	75.3	76.0	73.5	75.6	74.5	77.9	76.1	77.5	79.8
Black	65.6	59.4	57.5	66.2	63.7	71.4	77.4	74.2	61.6	69.4	76.6	72.6	72.1	74.0	74.0	82.3	79.3	78.2	77.4	79.0
Other race	48.2	64.6	55.1	76.5	78.0	67.7	74.8	79.4	59.1	96.4	88.7	86.0	79.0	75.4	77.8	84.6	87.7	88.0	85.6	86.9
Diabetes	50.7	45.1	47.6	46.2	57.3	57.4	66.2	63.7	65.4	73.3	71.6	66.4	70.5	68.1	71.6	72.7	75.7	72.3	72.0	75.7
Hypertension	70.5	72.9	69.2	77.5	82.3	84.4	85.7	84.5	66.9	76.5	71.5	79.2	81.8	78.4	76.7	80.3	80.5	81.3	82.1	84.1
Glomerulonephritis	70.1	71.2	75.1	76.9	74.3	76.2	80.3	80.7	82.4	78.7	79.4	83.3	82.7	84.2	83.6	85.1	83.0	85.4	86.4	85.1
Other cause	63.4	52.7	65.6	66.5	77.0	80.3	79.0	78.6	73.5	76.4	74.8	86.1	80.9	78.4	80.8	79.6	85.0	81.1	82.7	84.7
All	57.0	52.3	58.6	60.2	66.9	68.8	72.5	71.7	68.5	72.3	70.7	74.8	75.0	73.2	74.8	75.9	78.2	76.5	77.4	79.5

Reference cohort is 1996 incident ESRD patients.
 Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.
 Patient age is determined as of the date of transplant.
 U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.
 †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.
 *Values for cells with ten or fewer patients are suppressed.

Table I.40

Ten-year patient survival probabilities: first transplants, living donors

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	*	80.0	66.7	66.7	85.4	91.4	85.7	85.3	77.4	92.9	86.3	91.4	85.5	90.3	89.1
5-9	84.6	92.0	73.5	83.3	93.7	94.3	83.3	85.0	88.9	96.4	87.5	92.2	94.3	91.4	91.4
10-14	77.6	80.4	89.4	83.5	85.7	95.1	85.1	90.1	89.2	88.0	80.7	88.1	87.0	85.8	93.8
15-19	81.9	88.0	87.9	89.0	84.3	86.7	84.7	84.6	90.2	91.0	84.9	87.9	80.6	88.2	87.2
20-29	86.4	80.2	79.3	77.5	80.9	81.3	80.2	79.7	87.9	84.0	87.7	87.6	84.0	85.4	87.8
30-39	69.5	65.8	69.1	72.0	73.7	71.0	77.0	75.1	72.9	80.1	79.4	77.5	80.3	78.8	80.3
40-49	57.8	54.6	60.3	65.0	64.2	66.6	68.8	66.3	65.1	71.5	68.0	69.7	71.5	71.3	69.0
50-59	38.9	52.1	42.6	62.0	63.4	57.9	58.0	64.0	58.0	53.5	50.8	54.3	59.1	54.8	55.1
60-64	*	*	*	45.5	61.9	58.1	65.0	44.3	47.6	41.7	35.5	53.2	38.8	44.7	46.2
65+	*	*	*	*	*	*	30.0	52.0	*	*	50.0	64.7	50.0	24.4	34.9
Male	73.7	69.4	70.5	72.4	75.1	72.4	72.2	72.5	77.5	77.9	77.2	78.4	76.6	75.5	75.2
Female	75.1	74.7	73.3	75.9	75.6	76.2	77.1	74.9	77.2	79.3	75.9	76.7	74.8	75.6	76.1
White	74.9	72.8	71.4	74.3	76.1	74.8	73.9	73.9	78.3	78.4	77.0	78.6	76.4	76.6	76.4
Black	71.3	63.4	71.9	69.6	68.3	68.3	72.4	69.8	71.4	75.6	71.3	71.0	71.3	69.3	71.0
Other race	65.0	67.5	72.5	78.2	84.4	75.6	83.2	76.6	75.9	90.3	84.6	81.3	78.3	76.8	79.7
Diabetes	53.8	45.6	48.2	47.7	50.9	50.7	55.1	55.4	60.2	65.4	61.9	56.3	57.0	56.0	58.1
Hypertension	70.0	76.4	67.8	73.9	79.7	72.1	74.2	71.8	69.8	75.8	70.5	74.1	72.7	72.3	70.2
Glomerulonephritis	81.8	80.6	81.9	81.8	80.2	82.1	82.1	80.1	84.9	83.7	82.9	83.4	81.4	83.2	82.9
Other cause	74.7	71.0	73.5	78.6	81.4	81.0	78.7	78.8	83.3	82.2	81.6	88.0	82.8	81.8	82.5
All	74.2	71.5	71.5	73.8	75.3	73.9	74.1	73.4	77.4	78.5	76.6	77.7	75.8	75.5	75.6
ADJUSTED															
0-19	71.5	82.4	79.1	76.5	82.8	88.4	80.8	80.9	81.7	88.9	77.6	85.3	81.7	84.4	86.3
20-44	67.8	60.6	64.5	66.1	69.0	69.6	71.0	70.7	73.9	75.5	77.8	75.1	74.5	75.4	76.5
45-64	40.1	45.0	45.2	56.3	55.2	54.4	57.9	56.1	53.7	53.5	46.7	56.5	55.5	54.4	54.2
65+	.	100.0	*	43.2	49.6	24.8	33.1	36.9	28.6	37.6	41.8	54.4	39.3	23.5	36.1
Male	34.9	30.3	34.1	37.0	41.2	41.6	41.7	42.1	44.2	45.9	45.4	48.3	46.9	45.8	46.4
Female	39.0	41.8	40.0	44.9	44.9	48.1	51.0	48.6	48.2	52.4	47.8	50.3	48.3	49.4	52.2
White	36.7	34.8	36.0	39.5	43.6	44.7	44.7	44.9	47.1	48.3	47.0	49.9	47.4	48.1	49.4
Black	38.4	34.8	40.4	42.7	37.8	41.9	47.7	44.9	41.0	47.2	40.8	45.1	48.5	44.5	46.2
Other race	34.7	37.6	43.8	50.6	60.6	52.1	61.9	53.6	48.0	78.7	67.9	61.6	53.6	54.7	62.1
Diabetes	29.3	23.7	24.8	24.0	27.3	30.0	33.3	34.6	36.6	44.3	40.0	36.1	38.1	36.6	40.8
Hypertension	45.2	55.8	41.5	57.6	63.0	53.0	57.0	53.8	47.5	55.5	50.1	54.7	53.9	55.5	51.8
Glomerulonephritis	50.6	50.8	53.6	53.3	52.6	57.0	59.8	55.8	60.5	58.4	55.6	58.7	56.7	59.7	59.4
Other cause	43.0	37.3	44.4	51.8	56.5	59.1	55.8	56.7	57.0	55.7	57.0	68.4	60.4	58.0	60.2
All	36.3	34.4	36.2	40.0	42.5	43.9	45.1	44.6	45.7	48.4	46.2	48.9	47.2	47.0	48.6

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted probabilities for one of the four variables are adjusted for the remaining three.

Patient age is determined as of the date of transplant.

U.S. & territories only; patients of unknown age or gender, or of age >110, are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with ten or fewer patients are suppressed.

." Zero values in this cell.

i patient survival

